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Abstract 
 
The selective hydroxylation of aromatic compounds is one of the most challenging 
chemical reactions. As an alternative to traditional chemical catalysis, biocatalysis 
emerged during the past decades. Hence, in the present work, a number of 
biocatalysts was investigated with regard to the realization of a novel synthesis route 
to the valuable aromatic compound vanillin, starting from the simple low-cost 
aromatic substrate 3-methylanisole via the intermediate products 3-methoxybenzyl 
alcohol or 4-methylguaiacol and via vanillyl alcohol, as an example of consecutive 
enzyme-catalyzed oxidation reactions accomplished in a multi-enzymatic three-step 
cascade reaction. 
For this reason a preselected set of enzymes, namely the m-hydroxybenzoate 
hydroxylase MobA from Comamonas testosteroni GZ39 and the cytochrome P450 
monooxygenases CYP116B3 from Rhodococcus ruber DSM 44319 and CYP102A1 
from Bacillus megaterium ATCC 14581, was investigated towards the selective 
hydroxylation of the substrate 3-methylanisole. Beside the wild type enzymes, a 
variant of MobA, which was created by rational protein design, and an existing 
focused minimal mutant library of CYP102A1 were applied in initial biotransformation 
reactions, combined with an efficient cofactor recycling system. Though the wild type 
enzymes of CYP116B3 and CYP102A1 displayed only a basic level of activity 
towards 3-methylanisole, highly increased activity was detected for many of the 
CYP102A1 variants with a maximum of 59% total conversion for the double mutant 
F87V/A328L. With 3-methoxybenzyl alcohol and 4-methylguaiacol both intermediate 
compounds of the intended cascade synthesis were generated, though 4-methoxy-
2-methylphenol was the main product in most of the reactions. However, none of the 
so far investigated variants accepted any of the intermediate compounds as 
substrate.  
As CYP116B3 was a good candidate for further protein engineering approaches, as 
a basic level of activity towards the substrate of interest was already present in the 
wild type enzyme, a focused mutant library of 20 single mutant variants of CYP116B3 
was created based on literature, sequence and structure information in order to 
improve the enzymes activity and selectivity towards conversion of the substrate 
3-methylanisole and in order to find variants for the conversion of 3-methoxybenzyl 
alcohol and/or 4-methylguaiacol. Therefore a homology model of the 
Abstract 
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monooxygenase domain of CYP116B3 was generated. Though, compared to the 
wild type, variants with up to almost six time increased activity towards the model 
substrate 7-ethoxycoumarin were found, total activity towards 3-methylanisole was 
still much lower compared to the best CYP102A1 variants. In addition, none of the 
variants displayed appropriate conversion of the intermediate compounds 
3-methoxybenzyl alcohol and 4-methylguaiacol. Moreover, additional mutation in the 
literature known amino acid position 437 of CYP102A1 variant F87V/A328L revealed 
no benefit towards conversion of any of the substrates, too. 
Molecular dynamics simulations of a CYP102A1 variant with 4-methylguaiacol as 
substrate revealed the bottleneck in the conversion of this compound. 
4-Methylguaiacol was shown to be stabilized at the entrance of the substrate access 
channel by the polar amino acid residues R47 and Y51. Replacement of these 
residues by the hydrophobic residues leucine and phenylalanine, respectively, 
resulted in successful conversion of 4-methylguaiacol to vanillyl alcohol, the 
precursor of vanillin in the intended cascade synthesis. Though, as the yield of 
vanillyl alcohol synthesized from 4-methylguaiacol with CYP102A1 variants was 
rather low, a vanillyl alcohol oxidase from Penicillium simplicissimum and rationally 
designed variants thereof, described in literature, were investigated. As a result, not 
only vanillyl alcohol but also 4-methylguaiacol was converted in high yield to vanillin.  
Finally, a combination of the best 4-methylguaiacol producing variant, CYP102A1 
variant A328L, with the best 4-methylguaiacol converting variant, VAO variant F454Y, 
in one reaction system both in vitro and in vivo yielded vanillin from 3-methylanisole 
with a maximal product formation of 2.0% and 1.1% vanillin, respectively.  
We demonstrated as a proof-of-principle the establishment of the proposed multi-
enzymatic three-step cascade reaction pathway. Though further optimizations 
concerning increase of enzyme activity and improvement of enzyme selectivity are 
required, the above mentioned exemplary synthesis of vanillin illustrates the 
capability of biocatalysis. 
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Zusammenfassung 
 
Die selektive Hydroxylierung aromatischer Verbindungen ist eine der 
herausforderndsten chemischen Reaktionen. Als eine Alternative zur traditionellen 
chemischen Katalyse hat sich die Biokatalyse während der vergangenen Jahrzehnte 
entwickelt. In der hier vorliegenden Arbeit wurden verschiedene Biokatalysatoren 
hinsichtlich der Verwirklichung einer neuen Syntheseroute zu der wertvollen 
aromatischen Verbindung Vanillin untersucht. Dies sollte, ausgehend von dem 
einfachen und preiswerten Substrat 3-Methylanisol, über die Zwischenprodukte 
3-Methoxybenyzlalkohol oder 4-Methylguaiacol und über Vanillylalkohol, als Beispiel 
für aufeinanderfolgende enzymkatalysierte Oxidationsreaktionen in einer 
multienzymatischen dreistufigen Kaskadenreaktion bewerkstelligt werden. 
Aus diesem Grund wurde eine Auswahl an Enzymen, und zwar die 
m-Hydroxybenzoathydroxylase MobA aus Comamonas testosteroni GZ39 und die 
Cytochrom P450 Monooxygenasen CYP116B3 aus Rhodococcus ruber DSM 44319 
und CYP102A1 aus Bacillus megaterium ATCC 14581, hinsichtlich der selektiven 
Hydroxylierung des Substrates 3-Methylanisol untersucht. Neben den Wildtyp-
Enzymen wurde eine Variante von MobA, die durch rationales Proteindesign erstellt 
wurde, und eine bestehende fokusierte Minimalmutantenbibliothek von CYP102A1 
kombiniert mit einem effizienten Cofaktor-Regenerierungssystem in anfänglichen 
Biotransformationsreaktionen angewendet. Obwohl die Wildtyp-Enzyme von 
CYP116B3 und CYP102A1 nur eine geringe Grundaktivität gegenüber 
3-Methylanisol zeigten, wurde für viele der CYP102A1-Varianten eine sehr viel 
höhere Aktivität gemessen, mit einem Maximum von 59% Gesamtumsetzung für die 
Doppelmutante F87V/A328L. Mit 3-Methoxybenzylalkohol und 4-Methylguaiacol 
wurden beide Zwischenprodukte der angestrebten Kaskadensynthese hergestellt. 
Allerdings war 4-Methoxy-2-methylphenol das Hauptprodukt in den meisten der 
Reaktionen. Indes akzeptierte keine der bis hierhin untersuchten Varianten 
irgendeines der Zwischenprodukte als Substrat. 
Da CYP116B3, aufgrund seiner bereits im Wildtyp-Enzym vorhandenen 
grundsätzlichen Aktivität gegenüber dem Substrat, ein guter Kandidat für weitere 
Protein Engineering Ansätze war, wurde basierend auf Literatur-, Sequenz- und 
Strukturinformationen eine fokusierte Mutantenbibliothek von CYP116B3 erstellt. 
Dies geschah mit der Absicht die Enzymaktivität und -selektivität hinsichtlich der 
Zusammenfassung 
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Umsetzung des Substrates 3-Methylanisol zu verbessern, und mit dem Ziel Varianten 
für die Umsetzung von 3-Methoxybenzylalkohol und/oder 4-Methylguaiacol zu finden. 
Deshalb wurde ein Homologiemodell der Monooxygenase-Domäne von CYP116B3 
erstellt. Obwohl Varianten gefunden wurden, die im Vergleich zum Wildtyp eine bis 
nahezu sechsfach höhere Aktivität gegenüber dem Modellsubstrat 7-Ethoxycumarin 
gezeigt haben, war die Gesamtaktivität gegenüber 3-Methylanisol immer noch viel 
niedriger verglichen mit der besten CYP102A1-Variante. Außerdem zeigte keine der 
Varianten eine angemessene Umsetzung der Zwischenprodukte 3-Methoxy-
benzylalkohol und 4-Methylguaiacol. Auch zusätzliche Mutationen an der 
literaturbekannten Aminosäureposition 437 der CYP102A1-Variante F87V/A328L 
zeigten keinen Nutzen hinsichtlich der Umsetzung eines der Substrate. 
Molekulardynamiksimulationen einer CYP102A1-Variante mit 4-Methylguaiacol als 
Substrat enthüllten den Engpass bei der Umsetzung dieser Verbindung. Es wurde 
gezeigt, dass 4-Methylguaiacol am Eingang des Substratzugangskanals durch die 
polaren Aminosäurereste R47 und Y51 stabilisiert wurde. Ein entsprechender 
Austausch dieser Aminosäuren durch die hydrophoben Aminosäuren Leucin und 
Phenylalanin hatte die erfolgreiche Umsetzung von 4-Methylguaiacol zu 
Vanillylalkohol zur Folge, welches die Vorstufe von Vanillin in der geplanten 
Kaskadensynthese war. Da die Ausbeute an Vanillylalkohol, welcher durch 
CYP102A1-Varianten aus 4-Methylguaiacol erhalten wurde, eher gering war, wurde 
eine Vanillylalkoholoxidase aus Penicillium simplicissimum untersucht, ebenso wie 
Varianten davon, die durch rationales Proteindesign hergestellt wurden und in der 
Literatur beschrieben sind. Als Ergebnis wurde nicht nur Vanillylalkohol, sondern 
auch 4-Methylguaiacol in hohem Maße zu Vanillin umgesetzt. 
Schließlich hat eine Kombination der besten 4-Methylguaiacol produzierenden 
Variante, CYP102A1-Variante A328L, zusammen mit der besten 4-Methylguaiacol 
umsetzenden Variante, VAO-Variante F454Y, in einem Reaktionssystem sowohl in 
vitro als auch in vivo Vanillin aus 3-Methylanisol erzeugt, mit einer entsprechenden 
maximalen Produktbildung von 2,0% beziehungsweise 1,1% Vanillin. 
Somit konnte die angestrebte multienzymatische dreistufige Kaskadenreaktion als 
grundsätzliches Konzept erfolgreich etabliert werden. Trotz dessen, dass weitere 
Optimierungen hinsichtlich der Erhöhung der Enzymaktivität und der Verbesserung 
der Enzymselektivität erforderlich sind, verdeutlicht die oben erwähnte exemplarische 
Synthese von Vanillin das Leistungsvermögen der Biokatalyse. 
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1   Introduction 
 
1.1   Biocatalysis 
 
While for many years enzymes as “green” biocatalysts were not of interest for 
industrial applications, identification of the first three-dimensional enzyme structure 
by X-ray analysis, giving important insight into how biocatalysts work, was a 
breakthrough for biocatalysis in the late 1950s. Emerging genetic engineering 
technologies in the 1980s were a further key step towards application of biocatalysts 
in industrial biotechnology. In 2012 Bornscheuer and co-workers described three 
waves of biocatalysis. The first wave started more than one century ago when 
scientists recognized that components of living cells could be applied to useful 
chemical transformations. The limited stability of the biocatalyst was the main 
challenge to be overcome by enzyme immobilization. The second wave took place in 
the 1980s and 1990s, when initial protein engineering technologies could be 
employed for extension of the substrate range of enzymes allowing the synthesis of 
unusual synthetic intermediates. Hence, biocatalysis could be applied in the 
synthesis of pharmaceutical compounds and fine chemicals. However, in addition to 
the stability, the optimization of the biocatalyst for non-natural substrates was another 
challenge. The third wave of biocatalysis, which takes place at the present, started in 
the mid and late 1990s by the development of directed evolution methods. Today, a 
better knowledge of proteins and an increased number of available directed evolution 
methods allows making major changes in enzyme properties by enzyme engineering, 
supported by advances in bioinformatics.1 Hence, within the last couple of years, 
both in laboratory and in industrial scale, biocatalysis could be established as a 
practical and environmentally friendly alternative to traditional metallocatalysis and 
organocatalysis in chemical synthesis due to scientific and technological 
advances.1, 2 Currently, there are many examples for biocatalysis applied in industrial 
production processes, for example the production of the antimalarial drug precursor 
artemisinic acid in engineered yeast3 or the production of the valuable aromatic flavor 
compound vanillin in a microbiological process.4 
Major advantages of biocatalysis compared to chemocatalysis are the high 
selectivity, activity and environmental friendliness of enzymatic biocatalysts.5 Their 
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high selectivities simplify reaction work-ups and provide product in higher yields. 
Moreover, biocatalytic processes are safe as they typically run at ambient 
temperature, atmospheric pressure and neutral pH.1 Due to the high regio- and 
enantioselectivity, biocatalysts are applied in the synthesis of fine chemicals, 
including pharmaceuticals, agrochemicals, and their intermediates.5 With biocatalysts 
the number of production steps, waste generation and thus fabrication costs could be 
reduced in some industrial processes, for example the synthesis of cortisone with the 
whole-cell biocatalyst Rhizopus arrhizus.6, 7 The enzymatic production of the bulk 
chemical acrylamide is another example for biocatalysis applied in industry, taking 
advantage of the low E factor (kgwaste/kgproduct) and ambient reaction conditions.
8 
 
1.2   Aromatic hydroxylation 
 
Some of the major aims in chemistry are the improvement of atoms economies, of 
chemical steps and of process operations in chemical syntheses.9 Thereby, one of 
the most sought-after reactions both in laboratory and on an industrial scale is the 
catalytic aerobic C-H oxidation.10 Here, the activation of an inert C-H bond, the 
functionalization of the activated organic fragment in a way that allows catalyst 
turnover, and the realization of these steps with controlled and high chemo-, regio-, 
and stereoselectivities under environmentally friendly and safe conditions, are some 
of the main challenges.11-13 Especially the activation of the thermodynamically strong 
and kinetically inert C-H bonds in hydrocarbons is difficult to achieve.14, 15 This 
chemical inertness originates from the fact that the constituent atoms of alkanes are 
held together by strong and localized C–C and C–H bonds. Therefore the molecules 
have neither empty orbitals of low energy nor filled orbitals of high energy that could 
participate in a chemical reaction.16 Though with the usage of transition metal 
complexes and the development of various methods for catalytic functionalization the 
activation of C-H bonds has been shown with many substrates, particularly arenes,17 
the achievement of suitable selectivities, especially with functionally complex 
compounds, still remains challenging.9 
Concerning the intended oxidation of C-H bonds in aromatic compounds, there are 
basically three ways described: i) heterogeneous catalysis with e.g. Pd, Re or Cu 
catalysts, ii) homogeneous catalysis with catalysts like a catecholate-Fe complex, 
and iii) biocatalysis employing enzymes as catalysts.10 
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In this context, a variety of enzymatic mechanisms exist in nature that can 
accomplish C-H bond functionalization in aqueous solution at ambient temperature 
and pressure.18 Basically, all of these enzymatic mechanisms involve the action of 
cofactors (in many cases metals) in the active site of the enzyme. The positioning of 
these cofactors plays an important role in controlling the substrate scope of the 
enzyme and the selectivity of the reaction. Two large classes of reactivities can be 
distinguished by involvement of functionalization of either aromatic or aliphatic C-H 
bonds. A unique feature of aromatic substrates is that the activation of their C-H 
bonds can happen via reaction of their π-electrons.19 
Enzymes can catalyze a variety of C-X bond formations (X = C, O, N, S, halogen, 
etc.). Thereby, the reactivities of the catalytic enzymes depend on the type of the 
employed cofactor. According to Lewis and co-workers,9 enzymes can be grouped 
depending on the employed cofactors into flavoproteins (cofactor: flavin 
mononucleotide (FMN), flavin adenine dinucleotide (FAD)), Ado● enzymes (cofactor: 
5’-deoxyadenosyl radical (Ado●)), mononuclear non-heme metalloenzymes, 
metalloenzymes with carboxylate-bridged diiron centers, binuclear copper 
monooxygenases, and heme enzymes (cofactor: heme). Concerning the challenging 
hydroxylation of aromatic substrates, the metalloenzymes with carboxylate-bridged 
diiron centers, the binuclear copper monooxygenases, the flavoproteins and the 
heme enzymes are of special interest. 
 
Belonging to the group of metalloenzymes with carboxylate-bridged diiron centers, 
bacterial multicomponent monooxygenases (BMMs) use residue-ligated iron centers 
for hydroxylation of unactivated C-H bonds.20 Amongst others, phenol hydroxylases 
and alkene/arene monooxygenases were identified to belong to the BMMs.21 Toluene 
monooxygenases (TMO) from Pseudomonas mendocina and Ralstonia pickettii, 
belonging to the class of alkene/arene monooxygenases, are well known for their 
ability to hydroxylate toluene to p-cresol with high regioselectivity and thus a 
preference for aromatic ring hydroxylation,22 whereas xylene monooxygenases 
(XMO) preferentially perform benzylic hydroxylations (Figure 1.1).23 
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Figure 1.1: Oxidation of toluene catalyzed by toluene monooxygenase (TMO) (aromatic hydroxylation) 
and xylene monooxygenase (XMO) (benzylic hydroxylation). Graphic adapted from Lewis et al. 2011.
9
 
 
Flavoproteins are interesting enzymes, as the flavin cofactors are known for their 
ability to hydroxylate the C-H bonds of electron-rich (hetero)arenes.24, 25 A key step in 
the hydroxylation of C-H bonds of a variety of compounds is that one of the oxygen 
atoms of the dioxygen is inserted into the C-H bond of the substrate 
(monooxygenation), while the second oxygen atom is reduced to water.26 In addition 
to C-H bond hydroxylations, flavoprotein monooxygenases (FPMOs) catalyze many 
other oxidation reactions like epoxidations, Baeyer-Villiger oxidations, and amine 
oxidations.24 Two subclasses of FPMOs, defined by differences in sequence and 
structure (e.g. number of domains, type of employed cofactors), have aromatic 
hydroxylase activity.27 As an example, the p-hydroxybenzoate 3-hydroxylase is one 
of the most investigated enzymes of the FPMO family.28 Other examples of FPMOs 
are known to catalyze the hydroxylation of phenol (e.g. the phenol 
2-monooxygenase) or halogenated phenol derivatives.29 However, due to their 
electrophilic aromatic substitution-based mechanism, FPMOs have a rather small 
substrate scope, limited to electron-rich aromatic substrates.9 
 
The group of the heme enzymes might be the most prominent group of enzymes 
known to catalyze the functionalization of C-H bonds.30 This functionalization can 
proceed via complex formation of the heme cofactor either with peroxides or with 
dioxygen, depending on the respective proximal ligand and active site residues of the 
enzyme.31 The reactive intermediate, known as compound I,32 reacts with the 
substrates in different ways, characteristic for the different heme enzyme subfamilies 
(peroxidases, haloperoxidases, and cytochrome P450 monooxygenases (CYPs, 
P450s)). For example, P450-catalyzed hydroxylation of sp2 and sp3 C-H bonds can 
TMO 
p-cresol toluene benzylalcohol 
XMO 
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take place by direct oxo transfer, electrophilic aromatic substitution, or H atom 
abstraction.33 
 
For each of the different enzyme groups described above, there are examples for 
applications of these enzymes in various syntheses, some of them are already 
applied in industrial processes,9 for example in the production of fine chemicals.34-36 
However, though these enzymes are often active on a range of substrates with high 
chemo-, regio- and stereoselectivity, there are also some challenges like insufficient 
activity, recombinant enzyme expression and purification, cofactor supply, organic 
solvent and oxygen tolerance, stability and substrate scope that have to be overcome 
and improved towards a broader practical application of the biocatalysts on an 
industrial scale.37-41 Another advantage of biocatalysts compared to chemocatalysts 
is that, in many cases, enzymes can be evolved in the lab (improved activity, altered 
regioselectivity, …) by means of protein engineering (directed evolution, rational 
protein design) and metabolic engineering of production hosts allows the combination 
of enzymes from different organisms.9, 42-45 
 
1.3   Flavoproteins 
 
Flavoproteins or flavoenzymes are oxidoreductases that catalyze a variety of 
chemical reactions, having respectively diverse biological functions.46 According to 
their name, flavoproteins contain flavin nucleotides, either flavin mononucleotide 
(FMN) or flavin adenine dinucleotide (FAD), as a cofactor. The FMN is derived from 
riboflavin via phosphorylation and the FAD is derived from FMN by adenylation.27 
Only a few flavoproteins contain a covalently bound FMN or FAD, whereas the 
majority of flavoproteins contain a non-covalently bound flavin as a prosthetic 
group.47 Because of their ability to catalyze not only one-electron but also two-
electron transfer reactions, flavoproteins play a central role in aerobic metabolism.48 
Moreover, due to their broad reaction spectrum, their high regio- and 
stereoselectivity, and their ability to catalyze oxidation reactions under 
environmentally friendly and mild conditions, flavoproteins are important enzymes for 
the mineralization of phenolic compounds. Hence, they are interesting enzymes for 
the biocatalytic production of valuable compounds in the pharmaceutical, fine 
chemical and food industries.46, 49 
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Flavoproteins comprise two different groups of enzymes, the flavoprotein 
monooxygenases (FPMOs) and the flavoprotein oxidases (FPOs). FPMOs can be 
distinguished from FPOs by their mode of reaction. While FPMOs incorporate one 
oxygen atom into a substrate by previous activation and cleavage of molecular 
oxygen using electrons from NAD(P)H, flavoprotein oxidases react with their 
substrates using only molecular oxygen without employment of external cofactors.49 
 
1.3.1   Flavoprotein monooxygenases 
 
Flavoprotein monooxygenases (FPMOs) are a very diverse enzyme family, known for 
their ability not only to catalyze regioselective C-H bond hydroxylations but also a 
variety of other oxygenation reactions like epoxidations, Baeyer-Villiger oxidations, 
and enantioselective sulfoxidations (Figure 1.2).24 Hence, they play a role in 
biological processes like drug detoxification, biodegradation of aromatic compounds, 
and biosynthesis of antibiotics and siderophores, to mention only a few.50 As their 
name already says, FPMOs catalyze monooxygenation reactions by introduction of a 
single oxygen atom of molecular oxygen into the substrate, while the second oxygen 
atom is concomitantly reduced to water.46 Most FPMOs are external FPMOs 
(EC 1.14.13), as they consume NAD(P)H as reduced coenzyme during reduction of 
their flavin cofactor.24 Internal FPMOs (EC. 1.13.12), where the flavin is reduced by 
the substrate itself, are very rare and will therefore not be further mentioned, 
subsequently.  
 
 
Figure 1.2: A selection of reactions catalyzed by flavoprotein monooxygenases. Graphic adapted from 
van Berkel et al. 2006.
24
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Based on available sequential and structural information, external FPMOs can be 
classified into six subclasses (A-F):24, 46 
 
Subclass A: These FPMOs are encoded by a single gene and contain a tightly bound 
FAD cofactor. They are dependent on NAD(P)H as coenzyme, and typically react 
with aromatic compounds containing an activating hydroxyl or amino group as 
substrates, whereat NAD(P)+ is released immediately after flavin reduction. 
Structurally they are composed of one dinucleotide binding domain (Rossmann fold) 
which binds the cofactor FAD. Subclass A FPMO members usually are very 
regioselective and display a narrow substrate specificity with a subtle coenzyme, 
oxygen and substrate recognition mechanism.24, 46 They are reported to be involved 
in the microbial degradation of aromatic compounds by hydroxylation of the aromatic 
ring in o- or p-position.49 The electrophilic attack on the aromatic ring of the substrate 
takes place by the C(4a)-hydroperoxyflavin as oxygenating flavin species. A specialty 
of this subclass of FPMOs is that the isoalloxazine ring of the FAD prosthetic group 
can move during catalysis between different positions. Hence, there is an open, a 
closed (in) and an out conformation possible. Further details concerning these 
conformational changes are given by Ballou and co-workers50 and will not be 
explained in detail here. One of the most prominent members of subclass A is the 
p-hydroxybenzoate 3-hydroxylase (also called PHBH, 4-hydroxybenzoate 
3-monooxygenase, or 4-hydroxybenzoate 3-hydroxylase).28 Another interesting 
member, whose crystal structure was dissolved in 2006,51 is the 3-hydroxybenzoate 
4-hydroxylase from Comamonas testosteroni. This enzyme was reported to have a 
large tunnel that connects the substrate-binding pocket to the protein surface, thus 
enabling substrate and oxygen transport. This special feature is not present in 
homologous enzymes like the 4-hydroxybenzoate 3-hydroxylase, though the protein 
fold of the catalytic domains as well as the active-site architecture are similar.51 
 
Subclass B: Members of this subclass of FPMOs are, as the subclass A enzymes, 
encoded by a single gene and contain a tightly bound FAD cofactor. As a difference, 
they are specific for NADPH as coenzyme and the NADPH/NADP+ is kept bound 
during catalysis. Moreover, these enzymes are composed of two dinucleotide binding 
domains (Rossmann fold) enabling the binding of cofactor FAD and coenzyme 
NADPH.24, 46 Subclass B can be further differentiated into three subfamilies: flavin-
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containing monooxygenases, microbial N-hydroxylating monooxygenases, and 
Baeyer-Villiger monooxygenases (Type I BVMOs).52 
 
In contrast to the subclasses A and B that are single-component enzymes as they 
consist of a single polypeptide chain encoded by a single gene, the sublasses C-F 
comprise FPMOs that are multi-component enzymes, thus generally consisting of two 
different polypeptide chains with different functions: a reductase component for the 
flavin reduction and an oxygenase component for oxidation of the substrate with 
molecular oxygen. They employ flavin as a coenzyme rather than a cofactor.24 With 
respect to the coenzyme use and specificity as well as concerning sequence 
homology, there is a large variety between the subclasses C-F.24, 53 Further 
information about the subclasses C-F is given by van Berkel and co-workers.24 
Concerning the catalytic reaction mechanism (Figure 1.3), in general FPMO-
catalyzed reactions can be described by three steps: First, the flavin is reduced by 
NAD(P)H; Second, the reduced flavin reacts with molecular oxygen to provide the 
reactive intermediate, the C(4a)-(hydro)peroxyflavin (peroxyflavin for electrophilic 
substrates and hydroperoxyflavin for nucleophilic substrates); Third, the substrate is 
bound, oriented and activated for its oxygenation by the C(4a)-(hydro)peroxyflavin.
50 
However, in detail, the differentiation between single-component and two-component 
systems goes along with a different kind of reaction mechanism during substrate 
oxygenation. For the single-component FPMOs, the isoalloxazine ring of the flavin is 
“flexible” (movement of several angstroms), allowing protein rearrangements as 
mentioned before (see Subclass A), thus yielding in a way multiple active sites.50 For 
the two-component enyzmes, this is not possible. Here, first a transfer of the reducing 
equivalents from NAD(P)H to a reductase-bound flavin takes place, followed by a 
transfer of the reduced flavin to the oxygenase component. Then the peroxygenated 
flavin is formed by reaction with molecular oxygen, finally initiating the 
monooxygenation reaction of the substrate.24 More detailed information on the 
catalytic reaction mechanism of single-component and two-component systems is 
given by Ballou et al..50 
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Figure 1.3: General catalytic mechanism of oxygenation reactions catalyzed by external flavoprotein 
monooxygenases. Graphic adapted from van Berkel et al. 2006.
24
 
 
1.3.2   Flavoprotein oxidases 
 
Flavoprotein oxidases (FPOs) are interesting enzymes for biocatalytical applications, 
as they are not dependent on expensive external cofactors by simply using molecular 
oxygen as a cheap and clean oxidant.49 They can introduce side-chain modifications 
in p-substituted phenols and many of them display activity with amines or (unnatural) 
amino acids. Hence, due to this substrate spectrum and due to their high regio- and 
enantioselectivity they are interesting enzymes for the production of flavors, 
fragrances and pure enantiomers in chiral organic syntheses.49, 54 
FPO-catalyzed substrate conversion consists of two half-reactions. These are the 
reduction of the flavin cofactor by the substrate and the following re-oxidation of the 
reduced flavin by molecular oxygen.55 The molecular oxygen is concomitantly 
reduced to hydrogen peroxide.46 Hence, the flavin cofactor is necessary for substrate 
oxidation, though it is not directly involved in the monooxygenation reaction. The 
oxygen atom used for substrate oxidation originates from water.24 
One of the most investigated and best characterized flavoprotein oxidases is the 
vanillyl-alcohol oxidase (VAO, EC 1.1.3.38).56  
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1.3.3   m-Hydroxybenzoate hydroxylase MobA from Comamonas testosteroni 
 
The m-hydroxybenzoate hydroxylase (MHBH) (3-hydroxybenzoate 4-monooxy-
genase (EC 1.14.13.23))24, 51 from Comamonas testosteroni is a single-component 
FPMO encoded by a single gene,51 classified as a member of subclass A of the 
flavoprotein monooxygenases.24 It was reported to be an FAD-dependent 
monooxygenase, catalyzing the conversion of 3-hydroxybenzoate 
(m-hydroxybenzoate) to 3,4-dihydroxybenzoate (protocatechuate), requiring 
equimolar amounts of NADPH and molecular oxygen (Figure 1.4 A). The optimal pH 
in Tris-HCl buffer is 7.3 and the relative molecular weight, determined by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), is 71.0 kDa. 
Generally, the enzyme displays a strict substrate specificity under experimental 
conditions. Nevertheless, a few other substrates, like 2,5-dihydroxybenzoate 
(gentisate) and 2,3-dihydroxybenzoate, were converted with relative activities of 
17.0% and 31.7%, respectively, compared to the activity with 3-hydroxybenzoate.57 
In 1998 MHBH was crystallized and further characterized concerning its absorption 
profiles and its reaction with several inhibitors.58 Hiromoto and co-workers did 
investigations on the primary structure of MHBH, determined its crystal structure in 
the Michaelis complex form with its substrate and analyzed the Xe-derivative 
structure.51 They determined the nucleotide sequence of the MHBH-gene, named 
mobA, comprising 1917 nucleotides which encode a protein consisting of 639 amino 
acids with a calculated molecular mass of 70.0 kDa. Highest similarity of the deduced 
amino acid sequence was found to the sequence of a phenol hydroxylase from 
Trichosporon cutaneum with 35% identity. From the determination of the crystal 
structure the enzyme, subsequently called MobA, was shown to form a 
physiologically active homodimer with crystallographic 2-fold symmetry. Each subunit 
of the homodimer consists of three α/β domains. The catalytic domains I and II 
comprise a substrate binding pocket (active site) whereas the C-terminal domain III is 
involved in oligomerization. Structural similarities between MobA, PHBH, and the 
phenol hydroxylase, concerning the protein fold of the catalytic domains and the 
active-site architecture, including the FAD and substrate-binding site, strengthen the 
assumption, that members of the class of flavoprotein aromatic hydroxylases share a 
similar mechanism of catalytic substrate hydroxylation.59 In MobA the substrate-
binding pocket is located at the bottom of a large tunnel in the protein interior that 
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connects this pocket to the surface. The two entrances of the tunnel are open to the 
solvent region and separated on the protein surface by hydrophobic amino acid 
residues. However, in the protein interior they are building a common large space. 
This tunnel enables the substrate transport in MobA. Both the environment of the 
tunnel interior, characterized by distinctly divided hydrophilic and hydrophobic 
regions, and the size of the tunnel entrance are assumed to play an important role in 
enzymatic substrate selection by amphiphilic nature and molecular size of the 
substrate. In addition, results of the Xe-derivative structure analysis of the protein 
indicate the existence of a highly hydrophobic pocket, a putative oxygen-binding site, 
in direct proximity to the substrate-binding site. Moreover, the tunnel is suggested to 
be involved in oxygen transport.51 
Previous mentioned investigations with the MHBH from C. testosteroni have been 
carried out with the strain KH122-3s.51, 57, 58 In 2008 Chang and Zylstra examined the 
substrate range of the MHBH MobA from the C. testosteroni strain GZ39, which is 
98% identical to MobA from C. testosteroni KH122-3s.60 As implied by the results of 
Hiromoto and co-workers it might be difficult to modify the substrate specificity of 
MobA by rational protein engineering of the substrate-binding pocket, a directed 
evolution approach was performed by error-prone PCR (polymerase chain reaction) 
mediated in vitro mutagenesis of MobA followed by in vivo screening for mutants with 
an altered substrate specificity. In this way numerous mutants were found, one of 
these, the MobA variant with the single V257A substitution, was identified to be able 
to transform phenol to catechol (Figure 1.4 B). This was the first example of a 
monooxygenase known for its conversion of phenolic acid substrates that can 
successfully hydroxylate phenol. Moreover, some other substituted phenols were 
also reported to be converted with enhanced efficiency by the MobA variant 
V257A.60  
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Figure 1.4: Reactions catalyzed by the wild type (wt) of the MHBH MobA (A) and by its variant V257A 
(A and B). Graphic adapted from Chang and Zylstra 2008.
60
 
 
1.3.4   Vanillyl-alcohol oxidase (VAO) from Penicillium simplicissimum 
 
The vanillyl-alcohol oxidase (VAO) flavoprotein family comprises a group of 
oxidoreductases sharing a conserved FAD-binding domain61 and favouring the 
covalent binding of the cofactor FAD to this domain. This covalent linkage of the 
flavin cofactor to the apoprotein, taking place via a dual covalent binding of the 
isoalloxazine ring of the flavin,62 is an autocatalytic process depending on the primary 
folding of the polypeptide chain.47, 63 
Members of the VAO flavoprotein family are involved in a variety of metabolic 
processes in nature. A few of these members were summarized by Leferink and 
co-workers, arranged according to their distinct FAD-binding mode into following 
groups: histidyl-FAD enzymes, cysteinyl-histidyl FAD enzymes, other covalent 
linkages, and non-covalent flavoenzymes.64 
 
The vanillyl-alcohol oxidase (VAO, EC 1.1.3.38) from Penicillium simplicissimum56, 65 
is one of the most investigated and best characterized flavoprotein oxidases. This 
enzyme is a stable homooctamer of 520 kDa.65 Stability of this octamer is suggested 
to derive from dimer-dimer interactions created by a specific loop region.64 Each 
subunit contains a FAD cofactor which is covalently linked to the N3 atom of a 
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histidine (His422) of the apoprotein via the C8α-position of the isoalloxazine ring of 
the flavin.65, 66 The standard reaction catalyzed by VAO is the conversion of vanillyl 
alcohol to vanillin in the presence of molecular oxygen,67, 68 which is necessary for 
flavin re-oxidation.24 In addition, VAO is active with a variety of specifically phenolic 
compounds67-69 and it is known for its ability to enantioselectively hydroxylate various 
alkylphenols.70, 71 However, with 4-alkylphenols having an aliphatic side-chain longer 
than seven carbon atoms, no catalytic activity was observed68 due to the limited size 
of the VAO active site.66 Some VAO-mediated reactions, which are oxidations, 
deaminations, demethylations, dehydrogenations and hydroxylations, are even of 
interest for industrial applications like the synthesis of natural vanillin, 
4-hydroxybenzaldehyde, coniferyl alcohol and enantiomeric pure phenol 
derivatives.72 
The VAO protein is structurally different compared to the flavoprotein aromatic 
hydroxylases,61 resulting in a differing catalytic reaction mechanism compared to 
FPMOs. This mechanism has been studied intensively by stopped flow kinetic 
studies with 4-(methoxymethyl)phenol as a substrate. As a first step of the reaction 
cycle a hydride is transferred from the Cα-atom of the substrate to the N5-atom of the 
flavin. This results in the formation of a binary complex between reduced enzyme and 
the p-quinone methide product intermediate. Next, the reduced flavin is re-oxidized 
by molecular oxygen with the concomitant formation of hydrogen peroxide. Finally, 
the p-quinone methide intermediate reacts with water in the active site of the enzyme 
yielding the final products (Figure 1.5).73  
 
 
Figure 1.5: Catalytic reaction cycle of the flavoprotein oxidase VAO with the exemplary substrate 
4-methylguaiacol (creosol). Graphic adapted from van den Heuvel et al. 2004.
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There are several amino acid residues in the VAO protein that are known to play 
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necessary for the covalent binding of the cofactor FAD, is one of these amino acids. 
Moreover, the presence of an activating nucleophile in the FAD domain, which is 
His61, was reported to be necessary for the covalent binding of the cofactor FAD to 
this His422 of the apoprotein.74 Another key residue, which was shown to be crucial 
for efficient redox catalysis, is Asp170. The bulkiness of the side-chain of this amino 
acid is suggested to regulate the efficiency of the hydroxylation of 4-alkylphenols.71 In 
various studies, other amino residues of VAO were addressed by means of rational 
protein design/site-directed mutagenesis yielding different effects like inversion of the 
stereospecificity of a VAO-catalyzed reaction75 or an increased catalytic efficiency 
(kcat/KM) towards the production of vanillin from the precursor creosol (2-methoxy-
4-methylphenol, 4-methylguaiacol).69 
 
1.4   Cytochrome P450 monooxygenases 
 
1.4.1   Nomenclature and functions 
 
Cytochrome P450 monooxygenases (CYPs, P450s) (EC 1.14.x.x) comprise one of 
the largest superfamilies of soluble and membrane-bound heme-thiolate proteins. 
These enzymes can be found in all domains of life including plants, animals, 
mammals, fungi, and bacteria.76 The terminology P450 describes the spectral 
properties of the b-type heme-containing reddish pigmented enzmyes (P = pigment) 
which show a typical absorption maximum at 450 nm in their reduced carbon 
monoxide bound form.77 Classification of the P450s according to their origin and 
sequence identity was introduced to simplify the identification of the increasing 
number of P450s.78-82 According to the “Cytochrome P450 Homepage” 
(http://drnelson.uthsc.edu/ CytochromeP450.html),81 there are more than 20.000 
P450 sequences classified (updated in July 2013). These sequences are available in 
several databases such as the “Cytochrome P450 Engineering Database” (CYPED), 
which is part of the BioCatNet, an internet database that integrates information on 
sequence, structure and function of P450s.83 However, there are many more 
sequences known which have not been classified yet as a result of the increasing 
speed of identification of new P450 sequences.84 As an example, in November 2015 
the CYPED database contained more than 52.000 P450 sequences.83 
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Cytochrome P450 monooxygenases catalyze a variety of different reactions including 
aliphatic and aromatic hydroxylations, epoxidations, peroxidations, sulfoxidations, 
aromatizations, cleavage of carbon-carbon bonds, dealkylations (N-, O-, and S-), 
deaminations, dehalogenations, desulfurations, oxidative phenolic coupling, N-oxide 
reductions and other complex reactions.30, 39, 85-90 Moreover, their spectrum of 
reactions has been expanded to non-natural reactions by protein engineering and 
evolution.91-95 P450s play central roles in living organisms in the metabolism of drugs 
and are involved in the biosynthesis of numerous important compounds like 
antibiotics and antifungals, hormones, steroids and many more.86, 96-99 In addition to 
the above mentioned versatility of P450s they are known for their ability to catalyze 
regio- and stereoselective oxygenations of organic compounds.100 Hence they are of 
great interest for a potential industrial usage in the biotechnology sector as, 
compared to chemical syntheses, they provide a “greener” route to the production of 
various high value compounds.39, 101, 102 
 
1.4.2   Catalytic reaction mechanism 
 
The most prominent reactions catalyzed by P450s are monooxygenase reactions. 
Here a single oxygen atom from molecular oxygen is introduced into the substrate 
compound while the other oxygen atom is reduced to water88 (Scheme 1.1).  
 
 
Scheme 1.1: General monooxygenase reaction catalyzed by P450s. 
 
For most P450-catalyzed reactions an interaction of the enzyme with one or more 
redox partners is required, which deliver the redox equivalents (electrons in form of 
hydrid ions) via electron transfer chains to the covalently cysteine-bound heme in the 
catalytic site of the monooxygenase domain (see section 1.4.3).103 Commonly these 
electrons are supplied to the redox partners from the reduced pyridine nucleotide 
coenzymes NADH or NADPH.104 
The catalytic reaction mechanism of P450s can be divided into several successive 
steps (Figure 1.6). First the substrate enters the active site and binds to the P450s 
ferric ion of the heme moiety with concomitant dissociation of a water molecule (1, 2). 
RH + O
2
 + NAD(P)H + H
+
           ROH + H
2
O + NAD(P)
+
 
Introduction 
35 
 
This goes along with a shift in the spin state of the heme iron from low-spin to high-
spin resulting in a positive shift in the reduction potential.105 This allows the reduction 
of the heme ferric iron (FeIII) (2) to the ferrous iron (FeII) (3) by a first one-electron 
transfer from the redox partner. Next the reduced ferrous (FeII) heme iron binds 
molecular oxygen building the ferric-superoxy-species (4). The subsequent delivery 
of a second electron (second one-electron reduction) leads to the formation of a 
negatively charged ferric-peroxo-intermediate (5a). Protonation of this intermediate 
results in a ferric-hydroperoxy-complex (5b). A successive second protonation, which 
occurs at the distal oxygen atom, results in cleavage of the dioxygen bond of the 
ferric-hydroperoxy-complex. This is accompanied by the release of a water molecule 
and the formation of the ferryl-oxo-complex, the reactive intermediate in P450s called 
Compound I (6).  
 
 
Figure 1.6: Catalytic reaction cycle of cytochrome P450 monooxygenases. Graphic adapted from 
Denisov et al. 2005.
104
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Finally the oxygenation (frequently hydroxylation) of the substrate by the activated 
oxygen atom of Compound I takes place (7) and the oxygenated substrate is 
subsequently released.104, 106 
In addition to the above mentioned catalytic reaction steps, the catalytic reaction 
cycle of P450s can be interrupted by three so-called uncoupling pathways: the 
autoxidation shunt, the peroxide shunt, and the oxidase shunt. The autoxidation 
shunt happens if the delivery of the second electron to the ferric-superoxy-complex 
(4) is disturbed, resulting in the return of the enzyme to the resting state and the 
formation of superoxide. The peroxide shunt occurs due to a collapse of the ferric-
hydroperoxy-complex (5b) with the concomitant release of hydrogen peroxide and 
thus resulting in the unproductive two-electron reduction of oxygen. The oxidase 
shunt means that instead of the oxygenation of the substrate molecule by the 
reactive ferryl-oxo-complex (6, Compound I) a molecule of water is built.104 These 
uncoupling pathways may occur as a result of delayed electron delivery or 
protonation or by the missing or inappropriate positioning of the substrate in the 
active site for oxidative attack and they all have in common that reducing equivalents 
from the coenzyme NAD(P)H are consumed without the concomitant formation of 
product.106 
 
1.4.3   Classification 
 
Usually the electrons necessary for P450-catalyzed reactions are transferred from 
the coenzymes NAD(P)H to the active site of the monooxygenase domain via 
flavoproteins and/or iron-sulfur redox proteins. Today, based on the topology of these 
redox partners ten classes of P450 systems differing in their electron transfer chain 
can be distinguished.107 In the traditional classification of P450 systems only two 
main classes were differentiated: the class I system, separated into a bacterial and a 
mitochondrial system, and the class II microsomal system. The class I systems 
comprise three soluble components. While in the bacterial class I system (Figure 1.7 
A) the electrons from NAD(P)H are transferred by a NAD(P)H-dependent FAD-
containing flavoprotein reductase via an iron-sulfur protein (ferredoxin [2Fe-2S]) to 
the P450 enzyme,108 in the mitochondrial class I system (Figure 1.7 B) the ferredoxin 
is the only soluble electron transfer component of the mitochondrial matrix. Here the 
reductase and the P450 component are membrane-associated and membrane-
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bound to the inner mitochondrial membrane, respectively.107 P450cam from 
Pseudomonas putida was described as the prototype of bacterial P450 
systems.109, 110 In the class II microsomal system (Figure 1.7 C) usually a membrane-
anchored P450 receives electrons from a membrane-anchored NADPH-dependent 
cytochrome P450 reductase (CPR), which has both a FAD and a FMN 
cofactor.107, 108, 111 However, there are a few exceptions from the class II system 
described above, for example CYP105A3 from Streptomyces carbophilus which is a 
soluble P450 system.112 
 
 
Figure 1.7: Schematic organization of P450 systems differing in their type of employed electron 
transfer chain. A Class I, bacterial system. B Class I, mitochondrial system. C Class II, microsomal 
system. D Class VII, bacterial [PFOR]–[P450] fusion system. E Class VIII, bacterial [CPR]–[P450] 
fusion system. Graphic adapted from Hannemann et al. 2007.
107
 
 
Today there are some more P450 redox systems known displaying different 
topological arrangements of their redox partners compared to those covered by the 
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traditional classification. As already mentioned, ten classes can be distinguished.107 
Two of those, class VII (Figure 1.7 D) and class VIII (Figure 1.7 E), are of special 
interest as they comprise natural fusion systems. In CYP116B2 (P450RhF) from 
Rhodococcus sp., an exemplary member of the class VII bacterial [PFOR]-[P450] 
fusion system, the N-terminal P450 domain is fused to the C-terminal PFOR 
(phthalate-family oxygenase reductase) domain by a short linker region of 16 amino 
acids, with the reductase component containing a FMN-binding domain, a NADH-
binding domain and a [2Fe-2S] ferredoxin domain.113 As the most investigated 
example of the class VIII bacterial [CPR]–[P450] fusion system, CYP102A1 
(P450BM3, EC 1.14.14.1) from Bacillus megaterium can be mentioned. Its heme-
containing P450 domain is fused to the FAD- and FMN-containing diflavin reductase 
domain (CPR) by a short protein linker.114 The other classes of P450 systems, not 
mentioned here, are described in detail by Hannemann and co-workers.107 
 
1.4.4   CYP102A1 from Bacillus megaterium 
 
The cytosolic fatty acid hydroxylase CYP102A1 (P450 BM3, EC 1.14.14.1) from 
Bacillus megaterium belongs to the class VIII of cytochrome P450 systems. It is a 
natural self-sufficient fusion enzyme consisting of a FAD- and FMN-containing 
diflavin reductase domain (CPR) which is fused to the heme-containing domain via a 
short protein linker114, 115 requiring only NADPH and molecular oxygen to function.116 
CYP102A1 has a molecular weight of 119 kDa114 and is a single polypeptide which is 
fully soluble.117 Since its identification more than forty years ago116, 118-120 it has been 
extensively studied,121 not least due to the fact that it is the P450 enzyme with the 
highest known activity of all investigated P450 systems so far.122-124 CYP102A1 
catalyzes not only the hydroxylation of saturated straight-chain substrates with 
pentadecanoic acid as the preferred substrate, but also the hydroxylation of other 
substrates like unsaturated fatty acids.116 Thus, CYP102A1 was originally found to be 
a fatty acid hydroxylase with a preference for medium- to long-chain fatty acids (from 
lauric acid (C12) to octadecanoic acid (C18)), which were hydroxylated exclusively at 
sub-terminal positions.115, 116, 121, 122 In addition to saturated and unsaturated fatty 
acids, CYP102A1 is known to accept fatty amides and alcohols,125 hydroxylated fatty 
acids126-128 and ω-oxo fatty acids129 as substrates. Within a period of many years in 
the past, protein engineering techniques like rational protein design and directed 
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evolution were applied to broaden the substrate profile of CYP102A1. Hence, a 
variety of CYP102A1 variants was generated with mutations at numerous amino acid 
residues aiming at the oxidation of non-natural substrates like terpenes, alkanes and 
aromatic compounds making these enzyme variants suitable for applications in 
commercial-scale industrial processes, for example the synthesis of fine 
chemicals.39, 121 Moreover, new reactions catalyzed by CYP102A1 variants were 
established by means of enzyme engineering. Here, the carbene transfer to olefins 
resulting in highly diastereo- and enantioselective cyclopropanation reactions, which 
were catalyzed by engineered variants of CYP102A1, can be mentioned as an 
interesting example.130 
Two of the most addressed mutation sites in CYP102A1 are the amino acid residues 
F87 and A328.121 These two amino acids are located opposite to each other in high 
proximity to the heme group of the active site and are therefore assumed to be key 
residues playing important roles concerning the positioning of the substrate to the 
activated heme oxygen, thus influencing activity, specificity and selectivity of the 
enzymes catalytic reactions.121, 131 In a recent study both residues have been 
mutated by means of rational protein design to generate a focused minimal and 
highly enriched mutant library. Therefor the five hydrophobic amino acids alanine, 
leucine, isoleucine, phenylalanine, and valine were combined to a total of 24 variants 
in addition to the wild type and were successfully screened for the conversion of 
various terpene substrates (geranylacetone, nerylacetone, (4R)-limonene, 
(+)-valencene). Eleven variants converted at least one of the substrates displaying 
distinct differences in the regio- or stereoselectivity compared to the wild type 
enzyme.132 Further variants of CYP102A1, generated based on the results of a 
preliminary screening of the above mentioned focused library, were successfully 
screened for hydroxylation activity towards cyclic and acyclic alkanes (n-octane, 
cyclooctane, cyclodecane and cyclododecane).133 Hence the generation of variants 
of CYP102A1 is a powerful tool towards the application of CYP102A1 in 
biotransformations of non-natural substrates with improved activities and selectivities. 
 
1.4.5   CYP116B3 from Rhodococcus ruber 
 
Members of the CYP116B subfamily belong to the class VII of P450 redox systems. 
As mentioned above, these enzymes are natural P450-redox partner fusion enzymes 
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consisting of a P450 component linked to a reductase component of the PFOR-type 
(phthalate family oxygenase reductase) containing a FMN-binding domain, a 
[2Fe-2S] ferredoxin domain and a NAD(P)H-binding domain.113, 134-136 Same as 
CYP102A1 from B. megaterium the CYP116B-type P450-redox partner fusion 
enzymes have all functionally necessary protein partners covalently linked together 
and are thus catalytically self-sufficient requiring only the cofactor NAD(P)H as an 
electron donor and a substrate for oxidative catalysis.137 Examples for the above 
mentioned CYP116B-type enzymes are CYP116B1 from Cupriavidus 
metallidurans138 and CYP116B2 (P450RhF) from Rhodococcus sp. NCIMB 
9784.113, 139 Another example of a natural self-sufficient P450 belonging to this 
CYP116B-type subfamily of fusion enzymes is CYP116B3 from Rhodococcus ruber 
DSM 44319. The gene of this P450 enzyme was identified by directional genome 
walking using PCR,140 and the respective protein was found to be built of 771 amino 
acids with a sequence identity of 93% compared to P450RhF from Rhodococcus sp. 
NCIMB 9784.139 CYP116B3 was characterized and described as being composed of 
a ferredoxin domain and a FMN-containing NADPH-dependent flavoprotein 
reductase domain fused to a heme-containing P450 domain. It was recombinantly 
expressed in Escherichia coli with a N-terminal His-tag, purified by immobilized metal 
affinity chromatography (IMAC) and an apparent molecular mass of 89 kDa was 
detected by SDS-PAGE analysis. With the fluorescent substrate 7-ethoxycoumarin 
(7-EC), shown previously to be successfully converted to 7-hydroxycoumarin (7-HC) 
by O-dealkylation with the highly homologous P450RhF,139 the oxidation activity was 
investigated. In addition to 7-EC, the CYP116B3-catalyzed conversion of various 
monocyclic and polycyclic aromatic hydrocarbon substrates with and without alkyl 
side chains (acenaphthene, fluorene, indene, naphthalene, toluene, m-xylene and 
ethyl benzene) was investigated. While some of these substrates, for example 
naphthalene, were monohydroxylated at the ring, the alkyl aromatic substrates were 
hydroxylated exclusively at the side chains. This alkyl chain hydroxylation activity 
towards aromatic substrates makes CYP116B3 an interesting enzyme for biocatalytic 
applications, though, compared to the conversion of 7-EC, the activity towards 
aromatic hydrocarbons was much lower.140 In order to increase the dealkylation 
activity of CYP116B3 a site-specific mutagenesis approach was combined with 
directed evolution to generate 7800 mutant variants of CYP116B3 followed by high-
throughput screening towards the model substrate 7-EC. Finally, after four rounds of 
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directed evolution, a CYP116B3 variant with five amino acid substitutions 
(A86T/T91S/A109F/I179F/I267L) was found with a 240-fold increased activity 
compared to the wild type enzyme.141 Hence, CYP116B3 is an interesting enzyme 
candidate for the conversion of aromatic compounds. 
 
1.5   Vanillin – an aromatic compound of interest 
 
Vanillin (4-hydroxy-3-methoxybenzaldehyde; CAS no. 121-33-5) is one of the most 
popular and widely used flavor compounds in the world. Besides being extensively 
applied as a flavor ingredient in the food and beverages industries,142, 143 it is applied 
as a fragrance component in perfumes and cosmetics144 and as an intermediate in 
the chemical and pharmaceutical industries.145 Originally, natural vanillin is extracted 
from the orchids Vanilla planifolia, Vanilla tahitiensis, and Vanilla pompon.143, 146 The 
vanilla extract comprises more than 200 components. Though vanillin is the most 
characteristic flavor component of vanilla, its concentration is only 1-2% in cured 
vanilla pods.147 Pure vanillin is a white crystalline powder with a low solubility in water 
at ambient temperature.142, 143 More than 15000 tons of vanillin were produced and 
sold in 2010. However, the production of vanillin, which is naturally obtained from 
vanilla pods, is a very time consuming and expensive process (1 kg of vanillin 
produced per 500 kg of vanilla pods).147 In addition, a number of factors like the 
weather conditions as well as plant diseases influence the market price for vanillin 
extracted from vanilla pods. Thus it varies between about 1200 US$/kg and more 
than 4000 US$/kg.145 Due to the above mentioned restricted availability and high 
price and due to the steadily increasing global demand for vanillin, less than 1% of 
vanillin is produced from vanilla pods worldwide today.148 Nowadays, the majority of 
vanillin is produced synthetically, reducing the market price below 15 US$/kg, via 
alternative processes like the chemical synthesis from eugenol, guaiacol, or lignin as 
starting materials or via biotechnology-based approaches starting from substances 
such as ferulic acid, eugenol, isoeugenol, glucose, lignin, phenolic stilbenes, vanillic 
acid or aromatic amino acids obtained from renewable feedstocks and employing 
various production systems like fungi, bacteria, yeasts, plant cells, or genetically 
engineered production strains. Compared to the environmentally rather unfriendly 
chemical synthesis of vanillin, biotechnology-based approaches have several 
advantages, for example the reduced production of waste.142, 143 As an example of 
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such a biotechnological process, the synthesis of vanillin from isoeugenol with a yield 
of 32.5 g/l employing a Bacillus fusiformis strain can be mentioned.149 Moreover, the 
biotechnology-based microbial synthesis of vanillin from natural precursors yields 
“natural” vanillin according to the current European150 and US food legislation.151 
 
1.6   Aim of the project 
 
In the scope of the present project, the selective hydroxylation of aromatic 
compounds, which is one of the most challenging chemical reactions, was addressed 
enzymatically. In order to establish a novel route to the valuable aromatic vanillin, as 
an example of consecutive enzyme-catalyzed oxidation reactions, a selection of 
enzymes was investigated. According to the proposed reaction pathway (Figure 1.8), 
vanillin was intended to be synthesized by conversion of the simple aromatic 
substrate 3-methylanisole via the intermediate products 3-methoxybenzyl alcohol, 
4-methylguaiacol and vanillyl alcohol. For this purpose, the following tasks were 
defined: 
 
 Preparation (expression, purification, determination of activity) of a selection of 
enzymes and application in in vitro biotransformation reactions, combined with 
efficient cofactor recycling, for the selective oxidation of both the aromatic 
substrate and intermediate compounds of the vanillin synthesis pathway. 
 
 Improvement of activity and selectivity of the biocatalysts, concerning the 
hydroxylation of the aromatic target substrates, by means of (rational) protein 
design. 
 
 Combination of the most suitable enzymes and enzyme variants in one 
reaction system (both in vitro and in vivo) for the final cascade synthesis of 
vanillin.  
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Figure 1.8: Proposed reaction pathway for the synthesis of vanillin. Two different enzyme-catalyzed 
cascade reaction routes are conceivable, starting with the substrate 3-methylanisole (1). Via the 
intermediate products 3-methoxybenzyl alcohol (2) or 4-methylguaiacol (3), the vanillin precursor 
vanillyl alcohol (4) could be produced and further converted to vanillin (5) either by combination of a 
flavoprotein monooxygenase (FPMO) and/or a cytochrome P450 monooxygenase (P450) and an 
alcohol dehydrogenase (ADH) (blue route) or alternatively by combination of a FPMO and/or a P450 
with a vanillyl alcohol oxidase (VAO) (green route). 
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2   Materials and methods 
 
2.1   Materials 
 
2.1.1   Genes, proteins, vectors, primers and strains 
 
Genes, proteins, vectors, primers and strains used in this work are listed in 
supplementary material section 7.1. 
 
The genes mobA from Comamonas testosteroni GZ39, cyp116B3 from Rhodococcus 
ruber DSM 44319 and vaoA from Penicillium simplicissimum CBS 170.90 were 
obtained as synthetic genes (GeneArt® Gene Synthesis, Life Technologies GmbH, 
Darmstadt, Germany), codon-optimized for the heterologous expression in 
Escherichia coli. Plasmid pET-11a harbored mobA (integrated between the restriction 
sites NdeI and BamHI with a C-terminal His6-tag), pET-24a(+) contained cyp116B3 
(integrated between the restriction sites NdeI and EcoRI, with a N-terminal His6-tag) 
and pMK-RQ comprised vaoA (integrated between the restriction sites NdeI and 
XhoI). Plasmids harboring cyp102A1 wild type gene (from Bacillus megaterium ATCC 
14581) and some variants thereof (integrated in pET-28a(+) and pET-22b(+) between 
the restriction sites BamHI and EcoRI) were provided by Dr. Alexander Seifert 
(Institute of Technical Biochemistry (ITB), University of Stuttgart, Stuttgart, Germany) 
as indicated in Table 7.2 (supplementary material). 
 
2.1.2   Media, buffers and solutions 
 
Media, buffers and solutions used in this work are described in detail in 
supplementary material section 7.2.1. 
 
2.1.3   Chemicals and cloning enzymes 
 
All chemicals were of analytical-reagent grade or higher quality. Tryptone from casein 
was purchased from Fluka (Buchs, Switzerland). Yeast extract and vanillin were 
bought from Roth (Karlsruhe, Germany). β-NADPH tetrasodium salt was obtained 
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from Acros Organics (Geel, Belgium). Glucose-6-phosphate dehydrogenase from 
Saccharomyces cerevisiae was from Roche Diagnostics (Mannheim, Germany). 
3-Methylanisole, 4-methylguaiacol, 3-methoxybenzyl alcohol, vanillyl alcohol, vanillin 
and 3-methoxy-5-methylphenol were purchased from Alfa Aesar (Karlsruhe, 
Germany). 2-Methoxy-6-methylphenol was from Frinton Laboratories (Hainesport, 
NJ, USA). D-Glucose-6-phosphate disodium salt hydrate, m-cresol, 4-methoxy-
2-methylphenol, methylhydroquinone and all other chemicals, solvents, and buffer 
components were purchased from Sigma-Aldrich (Schnelldorf, Germany). 
Endonucleases (BamHI, DpnI, EcoRI, NdeI and XhoI), Pfu DNA Polymerase, 
T4 DNA ligase and the respective necessary buffers were obtained from Fermentas 
(now Fisher Scientific, Schwerte, Germany).   
 
2.2   Methods 
 
2.2.1   General methods 
 
General molecular biological and microbiological experiments were carried out by 
standard methods.152 Plasmid isolation was performed with the ZyppyTM Plasmid 
Miniprep Kit (Zymo Research, Irvine, CA, USA) following the manufacturer’s protocol. 
Purification of DNA fragments was carried out by agarose gel electrophoresis 
followed by using the QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) 
according to the manufacturer’s protocol. DNA concentrations were determined with 
the NanoDropTM 1000 Spectrophotometer (Thermo Fisher Scientific, Waltham, MA, 
USA). 
 
2.2.2   Preparation of competent E. coli cells 
 
For the preparation of chemically competent cells 0.5 ml of an overnight (O/N) 
culture, which was grown from a single colony and contained the desired Escherichia 
coli (E. coli) strain (DH5α or BL21(DE3)), were used for inoculation of 50 ml of sterile 
lysogeny broth (LB) medium, followed by incubation at 37°C and 180 rpm until 
reaching an optical density at a wavelength of 600 nm (OD600) of 0.4 – 0.6. After 
keeping the cell culture on ice for 15 min, the cells were harvested by centrifugation 
at 4°C and 3200 × g for 10 min. The cells were resuspended in 20 ml of ice-cold Tfb I 
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buffer, kept on ice for 15 min and centrifuged again as described above. The 
supernatant (S/N) was discarded and the cell pellet was resuspended in 2 ml of ice-
cold Tfb II buffer and incubated on ice for 15 min. Aliquots of 200 µl in sterile 
Eppendorf tubes were immediately frozen in liquid nitrogen and stored at -80°C until 
use. 
 
2.2.3   Transformation of competent E. coli cells 
 
Competent E. coli cells were thawed on ice and 10 µl of competent cells (DH5α or 
BL21(DE3)) were mixed under sterile conditions with 1 µl of plasmid containing a 
target gene insert for retransformation. Alternatively, for transformation after ligation, 
100 µl of competent cells (DH5α) were mixed with 10 µl of ligation mixture. After 
incubation on ice for 30 min a heat shock treatment at 42°C for 45 s was performed, 
followed by incubation on ice for 2 min. Depending on the volume of the sample, 
80 µl or 800 µl of sterile SOC medium were added, respectively, and the cells were 
incubated at 37°C and 500 rpm for 1 h. For re-transformation, 100 µl of the 
transformed cells were directly spread onto LB agar plates containing the respective 
antibiotic and incubated at 37°C overnight. For transformation after ligation the cells 
were harvested by centrifugation at room temperature (RT) at 11000 × g for 1 min. 
810 µl of the S/N were discarded by pipetting and the cell pellet was resuspended in 
the residual S/N volume. The complete resuspension was spread onto LB agar plates 
containing the respective antibiotic and incubated at 37°C overnight. Sterile DEPC-
treated water instead of plasmid was used as negative control for the 
re-transformation. For transformation after ligation a ligation mixture with sterile 
DEPC-treated water instead of a gene insert was applied.  
Single cell colonies of the transformation plates were used for inoculation of 5 ml 
sterile LB medium containing the respective antibiotic and incubated at 37°C and 
180 rpm overnight. Plasmid isolation from the O/N cultures was performed with the 
ZyppyTM Plasmid Miniprep Kit (Zymo Research, Irvine, CA, USA) as recommended 
by the manufacturer. Glycerol stocks of cells were prepared by mixing of equal 
volumes of the O/N culture and a 50% glycerol solution. Aliquots of 100 µl in sterile 
tubes were stored at -80°C until use. 
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2.2.4   Agarose gel electrophoresis 
 
Agarose gels with a concentration of 1% (1% agarose in TAE buffer) were cast using 
a gel comb for the loading of small (5-10 µl) or larger (25-50 µl) sample volumes for 
analytical or preparative agarose gel electrophoresis, respectively. For the detection 
of the DNA under UV light the agarose gel was supplemented with GelRedTM 
(Biotium, Hayward, CA, USA) in a 1x concentration. As a reference standard, 1 µl of 
GeneRulerTM 1 kb DNA ladder from Fermentas (now Fisher Scientific, Schwerte, 
Germany) was mixed with 1 µl of DNA sample loading buffer and deionized water to 
a final volume of 5 µl and loaded onto the gel. DNA samples were mixed with DNA 
sample loading buffer (ratio of loading buffer to DNA sample of 1:5) and loaded onto 
the gel. The gel was run in 1x TAE buffer at 120 V for 40 min. DNA bands of interest 
were excised from the gel under UV light and extracted using the QIAquick Gel 
Extraction Kit (QIAGEN, Hilden, Germany) as recommended by the manufacturer.   
 
2.2.5   Site-directed mutagenesis 
 
Site-directed mutations were introduced according to the QuikChange standard 
protocol using the oligonucleotides indicated in supplementary material section 7.1.4 
(Table 7.5). Successful mutagenesis was verified by automated DNA-sequencing 
(GATC Biotech, Konstanz, Germany). 
 
MobA: The variant V257A of MobA was mutated using the plasmid pET-11a_MobA.  
 
CYP102A1: Variants of CYP102A1 were generated using plasmids pET-22b(+) and 
pET-28a(+) harboring the gene of the CYP102A1 wild type or respective mutant (in 
the case of multiple mutations). Some vector constructs were provided, as indicated 
in Table 7.2 (supplementary material; respective ITB No. tagged with *).  
 
VAO: The variants F454Y and T505S of VAO were created using the plasmid 
pET-22b(+)_VAO.  
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2.2.6   Generation of a focused mutant library of CYP116B3 
 
2.2.6.1   Homology modelling of CYP116B3 
 
In cooperation with the bioinformatics group of the ITB (University of Stuttgart, 
Stuttgart, Germany), a homology model of CYP116B3 was generated by Dr. Łukasz 
Gricman. First, the CYP116B3 wild type amino acid sequence was used for a blastp 
search (protein-protein BLAST) against the Protein Data Bank proteins on the NCBI 
BLAST Homepage.153, 154 One sequence was chosen and aligned to the sequence of 
the monooxygenase domain of CYP116B3 employing a standard numbering scheme 
for class I P450 sequences based on structural information.155 On the basis of this 
alignment, a homology model of the CYP116B3 monooxygenase domain was 
generated with SWISS-MODEL.156-160 
 
2.2.6.2   Identification of mutation sites 
 
Based on the homology model of the CYP116B3 monooxygenase domain, 
sequential information and literature information,141 five amino acid positions (A109, 
V316, A317, A318, F420) located close to the active site were chosen for site-
directed mutagenesis (performed as mentioned in section 2.2.5 with the respective 
primers (Table 7.4, supplementary material)). Each amino acid at the selected 
positions was replaced by the hydrophobic amino acids alanine (Ala, A), 
phenylalanine (Phe, F), isoleucine (Ile, I), leucine (Leu, L) and valine (Val, V), 
respectively. 
 
2.2.7   Protein expression and purification 
 
2.2.7.1   General expression and purification protocol 
 
General expression protocol: For protein expression, the particular vector construct 
was transformed into competent E. coli BL21(DE3) cells and transformants were 
selected on LB agar plates with ampicillin (100 µg ml-1 for pET-11a and pET-22b(+) 
vector constructs) or kanamycin (30 µg ml-1 for pET-24a(+) and pET-28a(+) vector 
constructs), respectively. An overnight (O/N) culture of 5 ml LB medium containing 
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the adequate antibiotic was grown from a single colony at 37°C with shaking at 
180 rpm. 400 ml LB medium supplemented with antibiotic was inoculated with 2 ml 
O/N culture and grown at 37°C and shaking at 180 rpm. At an OD600 of 0.7-0.8 
expression was induced by supplementation of the culture with inducer isopropyl-β-D-
thiogalactopyranoside (IPTG) and grown for a defined time at reduced temperature 
and shaking speed (exact values are mentioned in sections 2.2.7.2 – 2.2.7.5). Cells 
were harvested by centrifugation (10800 × g, 20 min, 4°C) and resuspended in buffer 
solution (50 mM Tris-HCl buffer pH 7.5 containing 500 mM NaCl, 5% glycerol, 
0.1 mM phenylmethylsulfonyl fluoride (PMSF)). Cells were disrupted by sonication on 
ice (6 x 1 min, interspaced by 30 sec), cell debris was removed by centrifugation 
(37000 × g, 30 min, 4°C), and the soluble protein fraction was recovered, filtered 
through a 0.45 μm sterile filter and aliquots were stored at -20°C. Samples of protein 
expression were analyzed by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE). 
 
Protein purification: Protein purification was performed from the soluble protein 
fraction by Ni-based immobilized metal affinity chromatography (IMAC) using a 5 ml 
HisTrap FF column (GE Healthcare, Freiburg, Germany) with an ÄKTA protein 
purification system (GE Healthcare, Freiburg, Germany), taking advantage of the 
His6-tag. The soluble protein fraction was diluted with equilibration buffer (50 mM 
Tris-HCl buffer pH 7.5 containing 500 mM NaCl, 5% glycerol, 0.1 mM PMSF) and 
applied to the column which was pre-equilibrated with the same buffer. Non-
specifically bound proteins were removed from the column in washing steps with 
equilibration buffer containing low imidazole concentrations. Specifically bound 
protein was eluted with equilibration buffer containing a higher imidazole 
concentration (exact concentrations are mentioned in section 2.2.7.2 and 2.2.7.3). 
Fractions containing protein of interest were pooled, concentrated via ultrafiltration 
with an Amicon® Ultra 4 ml filter (Merck Millipore, Darmstadt, Germany) with a 
molecular weight cutoff (MWCO) of 10 kDa and dialyzed against 50 mM Tris-HCl 
buffer pH 7.5 containing 5% glycerol and 0.1 mM PMSF using a Spectra/Por® dialysis 
membrane (Spectrum Laboratories, Compton, CA, USA) with a MWCO of 12-14 kDa. 
Aliquots of the purified protein were stored at -20°C. Samples of protein purification 
were analyzed by SDS-PAGE. 
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2.2.7.2   Expression and purification of MobA 
 
Expression study: In an initial expression study, the expression of MobA wild type 
(pET-11a_MobA) was performed at 20°C, 25°C and 30°C with 0.1 mM, 0.5 mM and 
1.0 mM IPTG for expression induction and incubation for up to 96 h with shaking at 
180 rpm (expression according to the protocol mentioned in section 2.2.7.1). 
  
Expression for in vitro biotransformations: Expression of MobA wild type and variant 
V257A for in vitro biotransformations was performed after induction with 0.5 mM 
IPTG at 20°C and 140 rpm O/N following the protocol mentioned in section 2.2.7.1.  
 
Purification of MobA: During protein purification of MobA wild type enzyme, target 
protein was eluted from the IMAC-column with equilibration buffer containing 100 mM 
imidazole, after washing steps with 20-50 mM imidazole.  
 
2.2.7.3   Expression and purification of CYP116B3 
 
Expression study: In an initial expression study, the expression of CYP116B3 wild 
type (pET-24a(+)_CYP116B3) was investigated at 20°C, 25°C and 30°C after 
induction with 0.1 mM, 0.5 mM and 1.0 mM IPTG and incubation for up to 48 h with 
shaking at 180 rpm (expression according to the protocol mentioned in section 
2.2.7.1).  
 
Cloning and expression of His-tag variants of CYP116B3 wild type: His-tag variants 
of CYP116B3 were construced by PCR amplification (PCR protocol with Pfu DNA 
Polymerase: i) 95°C for 4 min; ii) 30 cycles of 95°C for 1 min, 72°C±4°C for 1.5 min, 
72°C for 5 min; iii) 72°C for 5 min) based on pET-24a(+)_CYP116B3 using the 
oligonucleotides mentioned in Table 7.4 (supplementary material). The resulting 
fragments and empty pET-24a(+) vector were digested with the restriction enzymes 
NdeI and EcoRI at 37°C for 5 h and purified by agarose gel electrophoresis (section 
2.2.4). Fragments and linearized vector were ligated in a vector to insert ratio of 1:3 
with T4 DNA ligase and T4 ligation buffer. The ligation was performed at RT for 1 h. 
After transformation and plasmid amplification in E. coli DH5α, the plasmids were 
isolated and the sequence of the resulting DNA constructs, encoding for CYP116B3 
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with a N-terminal MetGlySerSer (MGSS)-sequence prior to the His6-tag (pET-
24a(+)_CYP116B3_Var1), with a C-terminal His6-tag (pET-24a(+)_CYP116B3_Var2) 
and without a His-tag (pET-24a(+)_CYP116B3_Var3), was verified by automated 
DNA-sequencing (GATC Biotech, Konstanz, Germany). Expression of the His-tag 
variants of CYP116B3 was performed following the general expression protocol 
(section 2.2.7.1) with 0.1 mM IPTG induction, co-addition of 0.5 mM 5-aminolevulinic 
acid (5-ALA) and 0.1 mM FeSO4 and incubation at 20°C and 140 rpm O/N.  
 
Cloning and expression of CYP116B3 on pET-22b(+): For expression of 
CYP116B3_Var1 in E. coli BL21(DE3) using a pET-22b(+) vector system, the 
cyp116B3_Var1 gene was cloned from pET-24a(+) into pET-22b(+) by digestion of 
pET-24a(+)_CYP116B3_Var1 and pET-22b(+) with the restriction enzymes NdeI and 
EcoRI at 37°C for 5 h. Insert-DNA and linearized vector were purified by agarose gel 
electrophoresis, ligated in a vector to insert ratio of 1:3 with T4 DNA ligase and 
T4 ligation buffer (1 h incubation at RT) and transformed into E. coli DH5α for 
plasmid amplification. The plasmids were isolated and the sequence of the pET-
22b(+)_CYP116B3_Var1 construct was verified by automated DNA-sequencing 
(GATC Biotech, Konstanz, Germany). Expression of this vector system, according to 
the general expression protocol (section 2.2.7.1), was induced with 0.4 mM IPTG 
(co-addition of 0.5 mM 5-ALA and 0.1 mM FeSO4) and incubated at 20°C and 
140 rpm O/N. 
 
Expression for in vitro biotransformations: Expression of CYP116B3 wild type and 
variants for in vitro biotransformations was performed in E. coli BL21(DE3) with 
0.1 mM IPTG induction and co-addition of 0.1-0.5 mM 5-ALA and 0.1 mM FeSO4, 
following the protocol mentioned in section 2.2.7.1. After induction, cell cultures were 
incubated at 20°C and 140 rpm O/N.   
 
Purification of CYP116B3: During protein purification of CYP116B3 wild type enzyme, 
target protein was eluted from the IMAC-column with equilibration buffer containing 
50 mM imidazole, after a washing step with 20 mM imidazole. 
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2.2.7.4   Expression of CYP102A1 
 
Heterologous expression of CYP102A1 wild type and mutants in E. coli BL21(DE3) 
was done as reported previously,161 similar to the expression protocol mentioned in 
section 2.2.7.1. 
 
2.2.7.5   Expression of VAO 
 
Cloning of vaoA into pET-22b(+): The vaoA gene was obtained as pMK-RQ_VAO 
vector construct. As pET-22b(+) was chosen for expression of VAO on a 
T7 promoter-based vector, pMK-RQ_VAO and pET-22b(+) were digested with the 
restriction enzymes NdeI and XhoI at 37°C for 5 h. Insert and linearized vector were 
purified and ligated in a vector to insert ratio of 1:3 with T4 DNA ligase (Promega, 
Madison, WI, USA) and T4 ligation buffer. The ligation was performed at RT for 1 h. 
After transformation into E. coli DH5α for plasmid amplification, the plasmids were 
isolated and the sequence of the pET-22b(+)_VAO construct was verified by 
automated DNA-sequencing (GATC Biotech, Konstanz, Germany). 
 
Expression of VAO: Wild type and variants of VAO were expressed in E. coli 
BL21(DE3) induced by addition of 0.5 mM IPTG (final concentration) to the 
expression culture and incubation at 20°C and 140 rpm O/N, following the general 
expression protocol (section 2.2.7.1). 
 
2.2.8   SDS-PAGE analysis 
 
SDS-PAGE was performed for analysis of samples of protein expression and protein 
purification. Therefor SDS-PAGE gels consisting of a stacking gel with 4% 
acrylamide and a resolving gel containing 12.5% acrylamide were prepared. As a 
standard 5 µl of PageRulerTM Unstained Protein Ladder from Fermentas (now Fisher 
Scientific, Schwerte, Germany) were applied to the gel.  
For whole cell samples taken prior to induction (pI) and after induction (aI) as well as 
for resuspended insoluble fractions (IF; pellets after cell lysis by sonication and after 
centrifugation), the OD600 was measured. The samples were adjusted to an OD600 
value of 0.25, centrifuged for 1 min at 11000 × g and the supernatant was discarded. 
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The pellets were resuspended in 50 µl of SDS sample loading buffer and heated at 
95°C for 10 min for protein denaturation. For comparison of protein content of the 
different samples, equal volumes of 7.5 µl to 15 µl of each of the normalized samples 
were applied to SDS-PAGE. 
For samples of soluble protein fractions (SF; cell lysates after cell lysis by sonication 
and after centrifugation) and purified protein the protein concentration was 
determined by the Bradford protein assay162 (section 2.2.9.1). The samples were 
diluted with 50 mM Tris-HCl buffer pH 7.5 to a concentration of 2 µg/µl, mixed with 
SDS sample loading buffer to a final concentration of 1 µg/µl and heated at 95°C for 
10 min. For comparison of protein content of the different samples, equal amounts of 
protein of 5 µg to 10 µg (volumes of 5 µl to 10 µl, respectively) of each of the samples 
were applied to SDS-PAGE. The electrophoresis was run in running buffer for 15 min 
at 12 mA followed by 1 h at 25 mA for a single gel. After separation the proteins were 
visualized with a staining solution containing Coomassie® Brilliant Blue R-250 dye. 
Unspecific staining of the gels was removed by washing several times with a 
destaining solution. Finally, the gels were documented on a Quantum ST 4 system 
(Vilber Lourmat, Eberhardzell, Germany). 
Components of buffers and solutions used for SDS-PAGE are described in detail in 
Table 7.10 (supplementary material). 
 
2.2.9   Quantification of proteins 
 
2.2.9.1   Total protein concentration 
 
The Bradford protein assay162 was applied for the determination of the total protein 
concentration in soluble protein fractions. Bovine serum albumin was used to 
establish standard curves (concentration range 0-10 µg/ml). 
 
2.2.9.2   Cytochrome P450 monooxygenase concentration 
 
Concentrations of P450 enzymes were determined by the carbon monoxide (CO) 
differential spectral assay as described previously77, 163 using an extinction coefficient 
of 91 mM-1 cm-1. 
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2.2.10   Investigation of enzyme activity 
 
2.2.10.1   Investigation of MobA activity 
 
2.2.10.1.1   Spectro-photometrical analysis 
 
Purified MobA wild type enzyme (diluted in a ratio of 1:5 with 50 mM Tris-HCl buffer 
pH 7.5) and soluble protein fraction (lysate) of MobA wild type and variant V257A 
were applied in a quartz cuvette for spectro-photometrical measurement (Ultrospec 
3000, Pharmacia Biotech, Uppsala, Sweden) within a wavelength range of 
300-600 nm. 50 mM Tris-HCl buffer pH 7.5 and lysate of empty vector expression of 
pET-11a were used as reference and negative control, respectively.  
 
2.2.10.1.2   Determination of enzyme activity via NADPH depletion 
 
MobA enzyme was applied in biotransformation reactions with the substrate 
3-hydroxybenzoic acid for determination of activity via NADPH depletion. Reaction 
mixtures contained 1 mM 3-hydroxybenzoic acid and 0.5 mg/ml or 1 µM of MobA 
lysate or purified protein, respectively, in a final volume of 1 ml with 50 mM Tris-HCl 
buffer pH 7.5. After incubation at RT for 5 min the reactions were started by addition 
of NADPH at a final concentration of 0.5 mM and the NADPH depletion was 
measured spectro-photometrically over a period of 40 min at an absorption 
wavelength of 340 nm. Lysate of pET-11a empty vector expression was used as 
negative control and a sample containing all components except protein was 
employed as reference. 
 
2.2.10.2   Investigation of CYP116B3 activity (7-ethoxycoumarin assay) 
 
In order to determine the activity of CYP116B3 wild type enzyme and variants 
thereof, an assay based on the selective deethylation of 7-ethoxycoumarin yielding 
7-hydroxycoumarin was applied. This assay was described previously for 
CYP116B3140, 141 and adapted here. For this reason, 50 mM Tris-HCl buffer pH 7.5 
was mixed with 7-ethoxycoumarin and CYP116B3 lysate at a final concentration of 
1 mM and 0.5 µM, respectively, in a final volume of 200 µl in 96-well plates. After 
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incubation at RT for 5 min, reactions were started by addition of NADPH at a final 
concentration of 0.4 mM. The fluorescence intensity of the reaction product 
7-hydroxycoumarin was immediately measured with a multiwell plate reader 
(FLUOstar Omega, BMG LABTECH, Ortenberg, Germany) (excitation at 405 nm, 
emission at 460 nm). The measurements were carried out at 30°C for 20 cycles with 
intervals of 90 s and intermediate moderate shaking. Lysate of empty vector 
expression was used as negative control. 50 mM Tris-HCl buffer pH 7.5 containing 
1 mM 7-ethoxycoumarin and 0.4 mM NADPH was employed as reference. All 
measurements were performed in triplicate. For calculation of the enzyme activity, a 
series of standard solutions consisting of 10-100 µM 7-hydroxycoumarin in 50 mM 
Tris-HCl buffer pH 7.5 was measured at 30°C in triplicate. 50 mM Tris-HCl buffer pH 
7.5 was used as reference. 
 
2.2.10.3   Investigation of VAO activity 
 
The activity of VAO wild type and variants F454Y and T505S was checked by in vitro 
biotransformation of 4-methylguaiacol and vanillyl alcohol according to the protocol 
mentioned in section 2.2.7.1. However, the activity concerning the conversion of 
4-methylguaiacol was investigated in 50 mM Tris-HCl buffer of both pH 7.5 and 
pH 10. All measurements were performed in triplicate with lysate of empty vector 
expression (pET-22b(+)) as negative control. 
 
2.2.11   In vitro biotransformations 
 
2.2.11.1   Single-enzyme catalyzed reactions  
 
Standard reaction conditions: Biotransformations were performed using a final 
volume of 1 ml in 50 mM Tris-HCl buffer pH 7.5, containing the glucose-6-phosphate 
(G6P) and glucose-6-phosphate dehydrogenase (G6PDH) system (1 mM MgCl2, 
5 mM G6P and 5 U/ml G6PDH) for cofactor regeneration. The substrates 
3-methylanisole, 4-methylguaiacol, 3-methoxybenzyl alcohol, vanillyl alcohol and 
other compounds were added at a final concentration of 0.5 mM from a 25 mM stock 
solution in dimethyl sulfoxide (DMSO). Enzyme was added at a defined concentration 
and the reaction was started by addition of 0.2 mM NADPH. Samples were incubated 
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at 30°C and 180 rpm for 2 h. Lysates of empty vector expression (pET-11a, 
pET-22b(+), pET-24a(+) or pET-28a(+) in E. coli BL21(DE3)) were used as a 
negative control for the in vitro biotransformations, respectively. All experiments were 
performed in triplicate unless otherwise noted. Concentrations of employed enzymes 
and deviations from the standard reaction conditions are mentioned below for the 
respective enzymes. 
 
MobA: Lysate of MobA and empty vector was added at a final lysate protein 
concentration of 1 mg/ml in the reaction mixture; purified MobA was added at a final 
concentration of 1 µM. Biotransformations were performed only as single 
measurements. 
 
CYP116B3: Lysate and purified enzyme of CYP116B3 was added at a final 
concentration of 0.5 µM, except as noted otherwise. Empty vector lysate was added 
with an appropriate volume as negative control. 
 
CYP102A1: Lysate of CYP102A1 was added at a final concentration of 1 µM for 
conversion of 3-methylanisole and 0.5 µM for conversion of other substrates. Empty 
vector lysate was added with an appropriate volume as negative control. 
 
VAO: Lysate of VAO and empty vector was added at a final total protein 
concentration of 1 mg/ml in the reaction mixture. No NADPH cofactor and no 
components of the cofactor regeneration system were employed.  
 
2.2.11.2   Bi-enzymatic one-pot cascade reactions 
 
2.2.11.2.1   Combination of two CYP102A1 variants 
 
One-pot cascade reactions with a combination of the CYP102A1 variants A328L and 
R47L/Y51F/F87V/A328V were performed as mentioned in section 2.2.11.1, with the 
exception that each of the two CYP102A1 enzyme variants (lysate) were used at a 
final concentration of 1 µM. The substrate 3-methylanisole was added at a final 
concentration of 2 mM from a 100 mM stock solution in DMSO. As a variation, the 
second enzyme variant was added delayed after 1 h (total reaction time of 2 h). 
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Moreover, in order to investigate a possible negative influence of reactive oxygen 
species on the reactions, the addition of catalase (1200 U/ml final concentration) 
and/or superoxide dismutase (SOD) (100 U/ml final concentration) was investigated 
for a total reaction time of 2 h. All experiments were performed in triplicate, unless 
otherwise noted, with lysate of empty vector expression as negative control. 
 
2.2.11.2.2   Combination of CYP102A1 and VAO 
 
One-pot cascade reactions with a combination of the two enzyme variants 
CYP102A1_A328L and VAO_F454Y were performed as mentioned above (section 
2.2.11.2.1), except that the lysate of VAO was added at a final VAO-lysate protein 
concentration of 1 mg/ml and the co-addition of SOD was not investigated. As a 
variation, the second enzyme variant was added after 1 h (total reaction time of 2 h) 
or 4 h (total reaction time of 8 h). All experiments were performed in triplicate, unless 
otherwise noted, with lysate of empty vector expression (pET-22b(+) and 
pET-28a(+)) as negative control. 
 
2.2.12   In vivo biotransformations 
 
Preparation of the cells: Competent E. coli BL21(DE3) cells were transformed with 
the plasmids pET-28a(+)_CYP102A1_A328L and pET-22b(+)_VAO_F454Y and 
protein expression was performed according to the protocol mentioned previously 
(section 2.2.7.1). However, the LB medium was supplemented with both kanamycin 
(30 µg ml-1) and ampicillin (100 µg ml-1) and protein expression was induced by 
addition of 1.0 mM IPTG, 0.1 mM 5-ALA and 0.1 mM FeSO4. After incubation at 20°C 
and 140 rpm for 18 h, cells were harvested by centrifugation (2700 × g, 20 min, 4°C), 
washed twice with 50 mM Tris-HCl buffer pH 7.5 and resuspended in the 
biotransformation medium. 
 
Biotransformations: In vivo biotransformations were carried out in 100 ml shake 
flasks with a volume of 30 ml biotransformation medium consisting of fresh cell 
suspension (50 g cell wet weight (cww) l-1) in 50 mM Tris-HCl buffer pH 7.5 with 
1% (w/v) glycerol, 0.4% (w/v) D-glucose, 30 µg ml-1 kanamycin and 100 µg ml-1 
ampicillin. Biotransformations started by addition of the substrate 3-methylanisole 
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(from a 200 mM stock solution in dimethyl sulfoxide) at a final concentration of 4 mM. 
Reactions were run at 30°C and 180 rpm for 24 h. Cells were fed with a 
glycerol/glucose mixture (1% (w/v) glycerol, 0.4% (w/v) D-glucose) after 12 h. 
Samples were collected at time points 0, 15 and 30 min and 1, 2, 3, 4, 6, 8, 12 and 
24 h after substrate addition and prepared for GC-FID analysis as described 
subsequently (section 2.2.9). E. coli BL21(DE3) cells transformed with empty vectors 
(pET-22b(+) and pET-28a(+)) were used as a negative control for the in vivo 
biotransformations. All experiments were performed in triplicate.   
 
2.2.13   Product analysis 
 
2.2.13.1   Sample treatment 
 
General method: Substrate conversion was stopped with 20 µl concentrated HCl. For 
exact determination of substrate conversion and product distribution, extraction from 
the aqueous reaction mixture was performed with 0.25 ml ethyl acetate containing 
the internal standard benzaldehyde (0.1 mM) or catechol (0.5 mM) for gas 
chromatography (GC)-analysis or high-performance liquid chromatography (HPLC)-
analysis, respectively. After vigorous mixing for 2 min and centrifugation at 20200 × g 
for 5 min, 100 µl of organic phase was transferred to a vial with insert and capped. 
 
Primary CYP102A1 library screening: For primary screening of the focused 
CYP102A1 library by HPLC, substrate and formed products were extracted from the 
aqueous reaction mixture by addition of 0.5 g of K2CO3 and 0.5 ml of a 40/60 (% v/v) 
mixture of n-hexane/2-propanol, vigorous mixing for 2 min and centrifugation at 
20200 × g for 3 min. 100 µl of organic phase was combined with 100 µl of n-hexane 
in a vial with insert and capped. 
 
2.2.13.2   HPLC-analysis 
 
General method: Samples were analyzed by normal phase HPLC on a 1200 Series 
HPLC from Agilent Technologies (Waldbronn, Germany), equipped with a Luna Silica 
5 µm column (particle size: 5 µm, pore size: 100 Å, length: 150 mm, inner diameter: 
4.6 mm) from Phenomenex (Aschaffenburg, Germany). The mobile phase consisted 
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of 2-propanol with 0.2 M formic acid (A), 2-propanol (B) and n-hexane (C). 
Concentration of A was kept constant at 5% throughout the measurement. 
Concentration of B gradually increased from 0% to 25% after 4 min, was then 
instantly raised to 45% and kept constant for 8 min, followed by a decrease to 0% 
within 3 min for regeneration of the starting conditions for the next measurement. 
Concentration of C complemented the mobile phase solvents to 100%, respectively. 
The temperature of the column was kept constant at 30°C at a flow rate of 
0.8 ml/min. For exact determination of 4-methylguaiacol conversion and product 
distribution, 15 µl of extracted sample were injected and the substrate and products 
were detected at a wavelength of 280 nm. To obtain straight-line calibration plots 
(determination of the internal response factor) a series of standard solutions 
consisting of 0.01-0.5 mM reference substances in 50 mM Tris-HCl buffer pH 7.5 
were extracted with ethyl acetate containing internal standard (0.5 mM catechol) and 
analyzed by HPLC. 
 
Primary CYP102A1 library screening: For primary screening of the focused 
CYP102A1 library, 40 µl of extracted sample were injected to the HPLC and the 
substrate and products were detected with a diode array detector (DAD) at a 
wavelength of 272 nm. 
 
2.2.13.3   GC-FID-analysis 
 
Samples were analyzed by GC coupled to a flame ionization detector (FID) on a GC-
FID GC-2010 from Shimadzu (Kyoto, Japan) equipped with a DB-5 capillary column 
(length: 30 m, internal diameter: 0.25 mm, film thickness: 0.25 µm) from Agilent 
Technologies (Waldbronn, Germany) and with hydrogen as carrier gas (flow rate: 
0.88 ml min-1, linear velocity: 30 cm s-1). The injector and detector temperatures were 
set at 200°C and 330°C, respectively. The temperature program of the column oven 
was as follows: 100°C for 3 min, raised to 190°C at a rate of 10°C min-1, raised to 
320°C at a rate of 75°C min-1 and held isotherm for 3 min. Reaction products were 
identified by the characteristic retention time of analyzed reference substances. For 
determination of conversion and product distribution, a series of standard solutions 
consisting of 0.01-0.5 mM reference substances in 50 mM Tris-HCl buffer pH 7.5 
were extracted with ethyl acetate containing internal standard (0.1 mM 
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benzaldehyde) and analyzed by GC-FID to obtain straight-line calibration plots 
(determination of the internal response factor). 
 
2.2.13.4   GC-MS-analysis 
 
Samples were analyzed by GC coupled to a mass spectrometer (MS) on a GC-2010 
with GCMS-QP2010 from Shimadzu (Kyoto, Japan) equipped with a DB-5MS 
capillary column (length: 30 m, internal diameter: 0.25 mm, film thickness: 0.25 µm) 
from Agilent Technologies (Waldbronn, Germany) and with helium as carrier gas 
(flow rate: 4.3 ml min-1, linear velocity: 30 cm s-1). The injector temperature was set at 
250°C. Mass spectra were collected using electrospray ionization (70 eV). The 
temperature program of the column oven was as follows: 80°C for 1 min, raised to 
140°C at a rate of 60°C min-1 and held isotherm for 3 min, raised to 160°C at a rate of 
20°C min-1 and held isotherm for 5 min, raised to 320°C at a rate of 75°C min-1 and 
held isotherm for 2 min. Reaction products were identified by the characteristic 
retention time of analyzed reference substances and by comparison of the respective 
fragmentation patterns. 
 
2.2.14   Molecular dynamics simulations 
 
Molecular dynamics (MD) simulations of CYP102A1 with 4-methylguaiacol were 
performed in cooperation with the bioinformatics group of the ITB (University of 
Stuttgart, Stuttgart, Germany) by Dr. Alexander Seifert. 
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3   Results 
 
3.1   Enzyme selection, preparation and application in initial 
biotransformations 
 
The m-hydroxybenzoate hydroxylase MobA from Comamonas testosteroni GZ39 and 
the cytochrome P450 monooxygenases CYP116B3 from Rhodococcus ruber DSM 
44319 and CYP102A1 from Bacillus megaterium ATCC 14581 as well as variants 
thereof were selected as catalysts for the hydroxylation of aromatic compounds 
(Figure 1.8, introduction). 
 
3.1.1   Preparation of the m-hydroxybenzoate hydroxylase MobA 
 
3.1.1.1   Site-directed mutagenesis, expression and purification of MobA 
 
The gene of the m-hydroxybenzoate hydroxylase MobA was obtained as a synthetic 
gene (GeneArt® Gene Synthesis, Life Technologies GmbH, Darmstadt, Germany) 
with a C-terminal His6-tag, codon-optimized for the heterologous expression in 
E. coli, and integrated in the vector pET-11a.  
As in literature the MobA single mutant variant V257A was reported to broaden the 
substrate range of the enzyme, hydroxylating for example phenol and resorcinol,60 
this variant was generated by site-directed mutagenesis based on the pET-
11a_MobA vector construct. The sequence of the variant was verified by automated 
DNA-sequencing (GATC Biotech, Konstanz, Germany). 
In an initial expression study, the expression of MobA wild type in E. coli BL21(DE3) 
was investigated at 20, 25 and 30°C after induction with 0.1, 0.5 or 1 mM IPTG. 
According to the SDS-PAGE analysis of the expression samples (Figure 7.2, 
supplementary material), MobA, with a calculated molecular weight of 71.3 kDa 
(calculated from the amino acid sequence using the CloneManager (Sci-Ed Software, 
Cary, NC, USA) software), was detected for all investigated expression conditions 
with an apparent molecular weight of about 70 kDa. Apparently, induction with 
0.5 mM IPTG and incubation at 20°C for 15-18 h was sufficient for a high yield of 
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expressed MobA protein. Thus, these conditions were applied for subsequent 
expression of MobA wild type enzyme and variant V257A.  
Furthermore, after cell harvest and cell disruption by sonication, the MobA wild type 
enzyme was purified from the soluble protein fraction by means of immobilized metal 
affinity chromatography (IMAC), taking advantage of the C-terminal His6-tag. After 
elution of the protein with 100 mM imidazole, MobA-containing fractions (identified by 
the yellow color due to the presence of the FAD cofactor) were pooled, concentrated 
via ultrafiltration and dialyzed. The total protein concentration of the purified enzyme 
was determined to be about 17 mg/ml, which corresponds to a yield of 37 mg purified 
protein per litre cell culture. Samples of the expression of MobA wild type and variant 
V257A as well as the purified wild type enzyme were analyzed by SDS-PAGE 
(Figure 3.1).    
 
 
 
 
Figure 3.1: SDS-PAGE analysis of the expression (A) and purification (B) of MobA. (A) Expression of 
MobA wild type and variant V257A was investigated for induction with 0.5 mM IPTG and incubation at 
20°C with shaking at 140 rpm O/N. pET-11a empty vector expression was used as a negative control. 
(B) Purified MobA wild type enzyme after IMAC. M, marker (unstained protein ladder (10-200 kDa) – 
respective molecular weight is indicated); pI, whole cells prior to induction; aI, whole cells after 
induction and incubation O/N; SF, soluble protein fraction; IF, insoluble fraction after cell lysis; 
PD, purified and dialyzed protein.  
 
According to the SDS-PAGE analysis, both MobA wild type and variant V257A were 
expressed and obtained in high yield in the soluble protein fraction after cell lysis. 
However, distinct amounts of MobA were still detected in the insoluble fraction. The 
purified MobA wild type enzyme was pure, as only minor protein impurities were 
faintly visible on the gel (Figure 3.1 (B)). 
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To enable a calculation of the MobA concentration after purification, it was assumed 
that the purification yielded completely pure protein. With the molecular weight value 
of 71.3 kDa, a concentration of 240 µM MobA was calculated in the purified and 
dialyzed protein solution.    
 
3.1.1.2   Investigation of MobA activity 
 
3.1.1.2.1   Spectro-photometrical analysis 
 
In order to get a first indication of activity of MobA, both the purified wild type enzyme 
and the soluble protein fraction of wild type and variant V257A were analyzed 
spectro-photometrically within a wavelength range of 300-600 nm (Figure 3.2).  
 
 
Figure 3.2: Spectro-photometrical analysis of MobA. 50 mM Tris-HCl buffer pH 7.5 was used as 
reference. Lysate of empty pET-11a vector expression (red) was applied as a negative control. 
Soluble protein fraction of MobA wild type (light blue) and variant V257A (green) were used in 
concentrated form. Purified and dialyzed MobA wild type enzyme (PD, dark blue) was measured in a 
1:5 dilution with 50 mM Tris-HCl buffer pH 7.5. The black arrow indicates a specific peak, present only 
in the samples with MobA. 
 
All samples, except the negative control (pET-11a) showed a specific peak at a 
wavelength of about 455 to 460 nm. As flavin has an absorption maximum at 
455 nm,58 this is a first indication for the presence of active MobA enzyme. 
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3.1.1.2.2   Determination of enzyme activity via NADPH depletion 
 
To further investigate the activity of MobA, biotransformation reactions with 
concomitant detection of NADPH depletion at a wavelength of 340 nm were set up. 
Therefore 3-hydroxybenzoic acid was employed as a substrate, due to the fact that 
m-hydroxybenzoate is the preferred substrate for MobA.60 As a result, 
protocatechuate is produced under consumption of molecular oxygen and cofactor 
NADPH (Figure 3.3). 
 
     
Figure 3.3: MobA-catalyzed conversion of m-hydroxybenzoate to protocatechuate. Graphic adapted 
from Chang and Zylstra 2008.
60 
 
According to the spectro-photometrical analysis of the NADPH depletion with MobA 
(Figure 3.4), both lysate of the variant V257A and lysate as well as purified MobA 
wild type displayed activity towards the model substrate. Though the measurement 
was started immediately after addition of NADPH to all of the reaction mixtures, the 
NADPH concentration in the samples with lysate of wild type and V257A enzyme was 
already at the beginning of the detection only half of the value of the negative control. 
Only for the purified MobA, the strong initial decline in NADPH concentration could be 
detected. In the negative control (lysate of pET-11a empty vector expression) only a 
minor and unspecific depletion of NADPH was noticed. In all reactions with MobA 
enzyme, NADPH was consumed completely after about 32 min, though the 
absorption value did not reach a value of zero. Hence, the wild type enzyme and the 
variant V257A were definitely active in the soluble protein fraction. Further, the wild 
type enzyme was active after purification and dialysis.  
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Figure 3.4: Spectro-photometrical analysis of MobA activity via NADPH depletion detection. A sample 
without protein was used as reference. Lysate of empty pET-11a vector expression (red) was applied 
as a negative control. Soluble protein fraction of MobA wild type (light blue) and variant V257A (green) 
was employed at a final total protein concentration of 0.5 mg ml
-1
. Purified and dialyzed MobA wild 
type enzyme (PD, dark blue) were assayed at a final concentration of 1 µM. 
 
Summarizing these preliminary results, based on a codon-optimized gene for the 
m-hydroxybenzoate hydroxylase MobA, the wild type enzyme could be successfully 
expressed and purified in an active form. Furthermore, a single mutant variant V257A 
was generated by site-directed mutagenesis and expressed in E. coli with proven 
activity. 
 
3.1.2   Preparation of the cytochrome P450 monooxygenase CYP116B3 
 
3.1.2.1   Expression and purification of CYP116B3 
 
The gene of the cytochrome P450 monooxygenase CYP116B3, integrated into the 
vector pET-24a(+), was obtained as a synthetic gene (GeneArt® Gene Synthesis, Life 
Technologies GmbH, Darmstadt, Germany) with a N-terminal His6-tag, codon-
optimized for the heterologous expression in E. coli.  
Initial investigations on the expression of CYP116B3 were performed in E. coli 
BL21(DE3). After induction with various concentrations of IPTG (0.1 mM, 0.5 mM and 
1 mM) the cell cultures were incubated at different temperatures (20°C, 25°C and 
30°C) and samples (whole cells) for SDS-PAGE analysis were taken at several time 
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points. According to the results of the SDS-PAGE analysis (Figure 7.3, 
supplementary material), expression of CYP116B3 with a calculated molecular 
weight of 86.1 kDa (calculated from the amino acid sequence using the 
CloneManager (Sci-Ed Software, Cary, NC, USA) software) was observed for all 
investigated expression conditions. The apparent molecular weight of the His6-tagged 
CYP116B3 was detected to be around 85 kDa. Induction with 0.1 mM IPTG and 
incubation at 20°C for 15-18 h was sufficient for a reasonable expression of 
CYP116B3. Hence, these conditions were applied for subsequent CYP116B3 
expressions.    
 
 
 
            
Figure 3.5: SDS-PAGE analysis of the expression (A) and purification (B) of CYP116B3. 
(A) Expression of CYP116B3 was investigated for induction with 0.1 mM IPTG and incubation at 20°C 
with shaking at 140 rpm O/N. pET-24a(+) empty vector expression was used as a negative control. 
(B) Purified CYP116B3 after IMAC. M, marker (unstained protein ladder (10-200 kDa) – respective 
molecular weight is indicated); pI, whole cells prior to induction; aI, whole cells after induction and 
incubation O/N; SF, soluble protein fraction; IF, insoluble fraction after cell lysis; PD, purified and 
dialyzed protein. 
 
In the course of the IMAC-purification of CYP116B3 from the soluble protein fraction 
of harvested and disrupted cells, the protein was eluted with 50 mM imidazole. 
CYP116B3-containing fractions (identified by the red color due to the presence of the 
heme) were pooled, concentrated via ultrafiltration and dialyzed. A more detailed 
SDS-PAGE analysis of the CYP116B3 expression and purification revealed that most 
of the CYP116B3 was found in the insoluble fraction after cell lysis (Figure 3.5 A). 
However, the low amount of target enzyme present in the soluble protein fraction was 
successfully purified, though there was still some contamination with other proteins 
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(molecular weight of 50 to 85 kDa) after purification (Figure 3.5 B). The concentration 
of purified CYP116B3 was 9.9 µM, as determined by the CO differential spectral 
assay. 
 
As the His-tag might influence the protein’s folding, several His-tag variants of 
CYP116B3 were cloned by PCR (oligonucleotides are listed in Table 7.3, 
supplementary material), in order to increase the amount of CYP116B3 in the soluble 
protein fraction after cell lysis. Correct protein folding is assumed to lead to reduced 
formation of inclusion bodies and consequently to improved accumulation of the 
enzyme in the soluble fraction. In analogy to the pET-28a(+) vector, where a 
MetGlySerSer(MGSS)-sequence is attached prior to the N-terminal His-tag, the 
variant CYP116B3_Var1 was constructed with three additional amino acids (Gly, Ser, 
Ser) prior to its N-terminal His6-tag. Thus, the new N-terminal sequence was MGSS-
His6. N-terminal amino acids are known to influence a protein’s stability in bacteria, 
as determined by the N-end rule.164 A second His-tag variant, CYP116B3_Var2, was 
constructed with a His6-tag at the C-terminus instead of the N-terminus. A third 
variant, CYP116B3_Var3, contained no His-tag at all. The sequences of all His-tag 
variants were verified by automated DNA-sequencing (GATC Biotech, Konstanz, 
Germany). 
  
 
  
Figure 3.6: SDS-PAGE analysis of the expression of His-tag variants of CYP116B3. CYP116B3_Var1 
has a N-terminal MetGlySerSer (MGSS) sequence prior to the His6-tag. CYP116B3_Var2 has a 
C-terminal His6-tag. CYP116B3_Var3 has no His-tag. Expression was investigated for induction with 
0.1 mM IPTG and incubation at 20°C with shaking at 140 rpm O/N. M, marker (unstained protein 
ladder (10-200 kDa) – respective molecular weight is indicated); pI, whole cells prior to induction; 
aI, whole cells after induction and incubation O/N; SF, soluble protein fraction; IF, insoluble fraction 
after cell lysis. 
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From the SDS-PAGE analysis of the CYP116B3 His-tag variants expression 
(Figure 3.6), one might assume a slightly enhanced amount of CYP116B3 in the 
soluble protein fraction of all three His-tag variants (Var1, Var2, Var3), compared to 
the initial CYP116B3 variant (Figure 3.5 A). However, still considerable amounts of 
insoluble proteins of CYP116B3 could be observed. After the specific determination 
of the CYP116B3 concentration in the soluble protein fraction by CO differential 
spectral assay, a calculation of the expression of soluble CYP116B3 was performed 
(Table 3.1). According to these results, a higher amount of CYP116B3 was found in 
the soluble protein fraction for all newly generated His-tag variants compared to the 
original CYP116B3 enzyme (N-terminal His6-tag). The highest amount of soluble 
CYP116B3 was detected for expression of CYP116B3_Var1 (N-terminal MGSS-His6-
sequence). With a value of 1.42 mg CYP116B3 per g cell wet weight (cww), 
expression of CYP116B3_Var1 yielded almost double the amount of soluble 
CYP116B3 compared to the initial CYP116B3 expression, though the total protein 
concentration was lower.  
 
Table 3.1: Investigation of CYP116B3 His-tag variant expression. The total protein concentration in 
the soluble protein fraction was determined using the Bradford protein assay.
162
 The CO differential 
spectral assay was applied for determination of the CYP116B3 concentration in the soluble protein 
fraction as described previously.
77, 163
 
CYP116B3  
His-tag variant 
c(total protein)  
[mg (l cell culture)
-1
] 
c(CYP116B3)  
[mg (l cell culture)
-1
] 
c(CYP116B3)  
[mg (gcww)
-1
] 
CYP116B3  
(N-term His6-tag) 
229.1 2.62 0.79 
CYP116B3_Var1  
(N-term MGSS-His6-sequence) 
195.9 5.85 1.42 
CYP116B3_Var2 
(C-term His6-tag) 
248.8 4.03 1.04 
CYP116B3_Var3 
(no His-tag) 
240.7 4.29 1.17 
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3.1.2.2   Determination of activity of CYP116B3 
 
To further elucidate which His-tag variant was most suitable for subsequent 
expression of CYP116B3, the activity of all His-tag variants, including the initial 
CYP116B3 in lysate and as purified enzyme, was tested, taking advantage of the 
known dealkylation activity of CYP116B3 towards 7-ethoxycoumarin. The 
accompanying formation of 7-hydroxycoumarin was detected by fluorescence 
spectroscopy (excitation at 405 nm, emission at 460 nm). Then the product formation 
rate, as a measure of activity, was calculated based on an extinction coefficient 
derived from a series of 7-hydroxycoumarin standard solutions. 
  
Table 3.2: Determination of CYP116B3 His-tag variant activity. The dealkylation of 7-ethoxycoumarin 
to 7-hydroxycoumarin was detected by fluorescence spectroscopy. Reaction mixture without protein 
was used as reference and reaction mixture with lysate of empty vector expression as negative 
control. 
CYP116B3 His-tag variant 
Product formation rate  
[µmol (µmol CYP116B3)
-1
 min
-1
] 
CYP116B3   (N-term His6-tag) 0.32 
CYP116B3_Var1   (N-term MGSS-His6-sequence) 0.43 
CYP116B3_Var2   (C-term His6-tag) - 
CYP116B3_Var3   (no His-tag) 0.41 
Reactions were performed in triplicate with a standard deviation of less than 10%. 
 
Highest product formation rate was obtained for the His-tag variant CYP116B3_Var1 
with a value of 0.43 µmol (µmol CYP116B3)-1 min-1. This equals an about 34% higher 
activity compared to the activity of the initial CYP116B3 enzyme. For 
CYP116B3_Var2 no activity could be determined as no 7-hydroxycoumarin formation 
was detectable.  
Subsequently, CYP116B3_Var1 was purified as mentioned previously (section 
2.2.7.3, materials and methods) and the activity was determined to be similar to the 
activity of the enzyme in lysate (product formation rate of 0.42 µmol 
(µmol CYP116B3)-1 min-1, data not shown in Table 3.2). Protein purification had no 
negative effect on activity of CYP116B3.   
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The His-tag variant CYP116B3_Var1, containing an N-terminal MGSS-His6-
sequence, showed highest expression, was successfully purified and displayed 
highest activity towards the model substrate 7-ethoxycoumarin. Therefore, this His-
tag variant of CYP116B3 was chosen for all subsequent experiments. The application 
of CYP116B3 for the conversion of aromatic substrates, aiming at the synthesis of 
vanillin, is described in section 3.1.4.   
 
3.1.3   Preparation of the cytochrome P450 monooxygenase CYP102A1 
 
Both the wild type and variants of the cytochrome P450 monooxygenase CYP102A1 
from B. megaterium were shown to convert various aromatic substrates in previous 
studies.121, 165 Moreover, a minimal and highly enriched CYP102A1 mutant library 
was designed by rational protein design and successfully applied for the conversion 
of a variety of terpene substrates132 and cyclic and acyclic alkanes.133 This focused 
CYP102A1 library, which consists of the wild type and 24 single and double mutant 
variants (combination of the five hydrophobic amino acids Ala, Leu, Ile, Phe and Val 
in the two positions 87 and 328), was chosen as a promising set of CYP102A1 
candidates for the synthesis of vanillin from aromatic compounds in this work. All 
variants of the focused library, including the wild type, were kindly provided by 
Dr. Alexander Seifert (Institute of Technical Biochemistry (ITB), University of 
Stuttgart, Stuttgart, Germany) as indicated in Table 7.2 (supplementary material) and 
expressed in E. coli BL21(DE3) according to an established protocol.161 After cell 
lysis, the soluble protein fractions were applied for in vitro biotransformations of 
aromatic substrates, particularly regarding the synthesis of vanillin (see section 
3.1.4). 
 
3.1.4   Initial biotransformations with selected enzymes and enzyme variants 
 
The m-hydroxybenzoate hydroxylase MobA (wild type and variant V257A), the P450 
CYP116B3 (wild type) and the P450 CYP102A1 (focused mutant library consisting of 
wild type and 24 single and double mutant variants) were prepared as mentioned 
above (section 3.1.1, 3.1.2 and 3.1.3, respectively) and applied in initial in vitro 
biotransformation reactions of aromatic substrates. 
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Table 3.3: Biotransformation results for the in vitro conversion of 3-methylanisole with MobA, 
CYP116B3 and selected single and double mutant variants of the focused CYP102A1 library. 
 
 
Enzyme (wild type) 
            variant 
Product formation [% of initial substrate]  
 
 
Total 
conversion 
[%]
1 
 
 
 
 
 
 
2 
 
 
 
 
 
3 
 
 
 
 
 
6 
 
 
 
 
 
9 
 
 
 
 
 
10 
MobA - - - - - - 
            V257A - - - - - - 
CYP116B3 <1 - <1 1.4 ± 0.1 - 2.1 ± 0.0 
CYP102A1 - - <1 - - <1 
            A328L <1 2.7 ± 0.2 26.6 ± 2.5 <1 - 31.0 ± 2.8 
            F87V <1 <1 12.5 ± 0.2 <1 - 14.9 ± 0.3 
            F87V/A328F 2.2 ± 0.2 1.2 ± 0.1 16.5 ± 1.3 7.1 ± 0.4 - 26.9 ± 2.0 
            F87V/A328I 6.2 ± 0.5 <1 5.6 ± 0.3 4.9 ± 0.3 - 16.9 ± 1.1 
            F87V/A328L 9.1 ± 0.2 1.6 ± 0.1 23.2 ± 0.4 12.0 ± 0.8 13.5 ± 0.8 59.3 ± 1.8 
            F87V/A328V 4.9 ± 0.5 <1 23.1 ± 0.9 3.0 ± 0.5 2.1 ± 0.1 34.1 ± 2.0 
-, not detected or <0.05%; 2, 3-methoxybenzyl alcohol; 3, 4-methylguaiacol; 6, 4-methoxy-2-methylphenol; 9, m-cresol; 
10, methylhydroquinone. Reactions were performed in triplicate with soluble protein fractions and run at 30°C and 180 rpm for 
2 h. MobA was employed at a final lysate protein concentration of 1 mg/ml. CYP116B3 and CYP102A1 were used at a final 
P450 concentration of 0.5 µM and 1 µM, respectively. Samples were analyzed by GC-FID. Negative controls showed no 
conversion. 
1
Total conversion was calculated from the determined product formations and was not equivalent to the substrate 
consumption due to the volatility of 3-methylanisole. 
 
In addition to 3-methylanisole (1), the primary substrate of the proposed vanillin 
synthesis pathway (Figure 1.8, introduction), the intermediate products 
3-methoxybenzyl alcohol (2) and 4-methylguaiacol (3) were employed as substrates. 
Moreover, the vanillin (5) precursor vanillyl alcohol (4) was used as a substrate to 
investigate a possible overoxidation reaction.  
Results of the 3-methylanisole conversion with soluble protein fractions are shown in 
Table 3.3. Similarly to MobA and CYP116B3, none of the above mentioned 
intermediate substrates was converted by any of the variants of the focused 
CYP102A1 minimal mutant library. However, the wild type of CYP102A1 and 22 of 
the variants of the focused library were identified to be active with 3-methylanisole in 
a primary screening (Table 7.13, supplementary material). Only two variants were 
completely inactive and six variants, including the wild type, exhibited less than 5% 
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conversion. A 3-methylanisole conversion of more than 25% was detected for six 
variants, the single mutant variants F87V and A328L and the four double mutant 
variants F87V/A328F/I/L/V. Thus, five of the six variants with a conversion higher 
25%, had a phenylalanine to valine substitution in amino acid position 87. 
Consequently, these most active six variants and the wild type were studied in more 
detail for exact determination of the product formation and the total conversion 
(Table 3.3). Compared to CYP116B3, the wild type of CYP102A1 revealed a total 
conversion of lower than 1%, with 4-methoxy-2-methylphenol as exclusive product. 
This is less than half the conversion compared to the CYP116B3 wild type, though 
twice as much enzyme was used. However, all of the six chosen single and double 
mutant variants of CYP102A1 displayed a much higher total conversion compared to 
the CYP102A1 wild type. But the values were lower in comparison to the conversion 
values of the primary screening (Table 7.13, supplementary material). This was due 
to the fact that the substrate 3-methylanisole is a volatile compound, which, in 
contrast to the primary screening by HPLC, has been considered for detailed 
investigation by GC-FID (Table 3.3). 
Apparently, variants with high activity demonstrated only poor selectivity. Hence, not 
only the anticipated intermediate products 3-methoxybenzyl alcohol (2) and 
4-methylguaiacol (3), but also the byproducts 4-methoxy-2-methylphenol (6), 
m-cresol (9) and methylhydroquinone (10) were generated (Figure 3.7). In addition, 
product formation of 2-methoxy-6-methylphenol (8) was detected with less than 1% 
for the CYP102A1 variants F87V and F87V/A328F (data not shown in Table 3.3). 
The formation of 3-methoxy-5-methylphenol (7) was not discovered at all.   
Five of the selected CYP102A1 variants revealed 4-methoxy-2-methylphenol as main 
product. Only variant F87V/A328I converted the substrate to a mixture of 
3-methoxybenzyl alcohol, 4-methoxy-2-methylphenol and m-cresol in comparable 
amounts. Even though for the single mutant variants F87V and A328L a total 
conversion of 15% and 31%, respectively, was detected, the corresponding double 
mutant variant F87V/A328L exhibited the highest determined activity of about 59% 
total conversion. Furthermore, product formation of 3-methoxybenzyl alcohol and 
m-cresol reached a maximum of about 9% and 12%, respectively, with this variant, 
whereas the single mutant variant A328L yielded overall highest 4-methylguaiacol 
formation of 2.7%. Only for the variants F87V/A328L and F87V/A328V overoxidation 
with methylhydroquinone as product could be observed. Thereby, methyl-
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hydroquinone was identified to be synthesized via the aromatic hydroxylation of 
m-cresol. This was elucidated in an investigation of the in vitro conversion (standard 
reaction conditions as described in section 2.2.11.1, materials and methods) of both 
4-methoxy-2-methylphenol and m-cresol. Whilst 4-methoxy-2-methylphenol was not 
converted at all, m-cresol conversion resulted in methylhydroquinone formation as 
exclusive product (data not shown). 
 
 
Figure 3.7: Products of the conversion of 3-methylanisole (1) with selected CYP102A1 variants. Three 
types of reaction were possible (indicated with colored arrows): benzylic hydroxylation (blue), aromatic 
hydroxylation (green) and O-demethylation (red). The respective reaction product is shown in colored 
frame. Formation of 3-methoxy-5-methylphenol (7) was not detected. Main product 4-methoxy-
2-methylphenol (6) is highlighted in bold. 2, 3-methoxybenzyl alcohol; 3, 4-methylguaiacol; 
8, 2-methoxy-6-methylphenol; 9, m-cresol; 10, methylhydroquinone. 
 
In summary, these first biotransformations revealed that neither MobA (wild type and 
variant V257A), nor CYP116B3 or any of the variants of the focused CYP102A1 
library displayed activity towards the intermediate substrates 3-methoxybenzyl 
alcohol, 4-methylguaiacol or vanillyl alcohol. However, in contrast to MobA, both 
CYP116B3 and CYP102A1 wild type showed marginal conversion of 
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3-methylanisole. In a screening of the focused minimal mutant library of CYP102A1, 
several variants were identified with much higher activity compared to the wild type.     
In addition to the formation of 4-methylguaiacol (3), 4-methoxy-2-methylphenol (6) 
and 2-methoxy-6-methylphenol (8) by aromatic hydroxylation, 3-methoxybenzyl 
alcohol was produced by benzylic hydroxylation. Moreover, O-demethylation of 
3-methylanisole (1) generated m-cresol (9), which was further converted to 
methylhydroquinone (10) by aromatic hydroxylation (Figure 3.7). Thus, three different 
types of reaction were catalyzed by variants of CYP102A1, demonstrating the 
catalytic flexibility of this large enzyme family.    
 
3.2   Expansion of the spectrum of enzymes and variants for further 
biotransformations 
 
As neither the wild type nor the single mutant variant V257A of the 
m-hydroxybenzoate hydroxylase MobA was shown to convert any of the substrates 
into vanillin or a precursor thereof, a focus was set on CYP116B3 and CYP102A1 in 
subsequent investigations. In order to realize the vanillin synthesis according to the 
proposed reaction pathway (Figure 1.8, introduction), both CYP116B3 and 
CYP102A1 had to be improved towards the conversion of 3-methylanisole and 
especially towards the intermediate compounds 3-methoxybenzyl alcohol and 
4-mehylguaiacol. For this purpose, rational protein design was applied. Moreover, for 
the final step of the intended cascade reaction, the synthesis of vanillin from vanillyl 
alcohol, a vanillyl alcohol oxidase was tested. 
 
3.2.1   Generation of a focused mutant library of CYP116B3 
 
3.2.1.1   Homology modelling of CYP116B3  
 
The generation of a focused mutant library is an efficient method to expand a 
proteins substrate spectrum and enhance its activity and/or selectivity, as previously 
shown for CYP102A1 with the substrate 3-methylanisole (section 3.1.4). Compared 
to the wild type, which displayed only marginal substrate conversion, many of the 
variants of the focused mutant library were identified with considerably increased 
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activity. As the wild type activity of CYP116B3 towards 3-methylanisole was already 
higher compared to the CYP102A1 wild type, the generation of a focused library of 
CYP116B3 mutants was assumed to be a promising method to increase the 
enzymes’ activity and possibly expand its substrate scope. However, in contrast to 
CYP102A1, there is no crystal structure available for CYP116B3. Thus, a homology 
model of CYP116B3 had to be created. This was done in cooperation with Dr. Łukasz 
Gricman from the bioinformatics group of the ITB (University of Stuttgart, Stuttgart, 
Germany). In a first step, the amino acid sequence of the CYP116B3 wild type was 
employed for a BLAST154 search against the NCBI “Protein Data Bank proteins (pdb)” 
database. From the resulting list of proteins, the sequence with the accession 
number “3CV9_A” was chosen for further processing. This is the sequence of a P450 
monooxygenase domain with a low percentage of gaps (5%) in the displayed 
alignment with the CYP116B3 sequence. In addition, it showed relatively high “Max 
score” and “Ident” values compared to the other listed protein sequences. The 
monooxygenase domain sequence of CYP116B3 was aligned to the 3CV9_A 
sequence by using a standard numbering scheme for class I P450 sequences.155 
According to this standard numbering scheme, the alignment was done based on 
structural information instead of sequence information. Finally, a homology model of 
CYP116B3 (Figure 3.8) was generated with SWISS-MODEL,156-160 based on the 
alignment result.  
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Figure 3.8: Homology model of the monooxygenase domain of CYP116B3. A Surface view. Substrate 
access is indicated by an arrow. B Secondary structure view. C Rotated view of B to visualize the 
location of N- and C-terminus of the protein. D Scrolled in view into A. E Visualization of cavities and 
pockets in the protein. View of the opened active site cavity. Substrate access is indicated by an 
arrow. F Heme with selected residues for site-directed mutagenesis. A-F Heme is colored red. 
Residues A109, V316, A317, A318 and F420 and corresponding surfaces are colored yellow, cyan, 
purple, blue and green, respectively. The images were generated by PyMOL.
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3.2.1.2   Selection of mutation sites and generation of CYP116B3 variants  
 
All subsequently mentioned amino acid positions of CYP116B3 are positions with a 
numbering referred to the wild type sequence, though the construct CYP116B3_Var1 
with an N-terminal MGSS-His6-sequence was used as a basis for the generation of 
the focused CYP116B3 mutant library.  
Mutation sites for the generation of the focused mutant library of CYP116B3 were 
selected based on literature as well as sequence and structural information of 
CYP116B3: 
a) According to the homology model in a previous study, the alanine at position 
109 was reported to be located in a small region at the ceiling of the substrate 
binding pocket, positioned directly above the heme group. Replacement of 
alanine by phenylalanine resulted in higher activity towards a variety of 
aromatic substrates.141 Hence, this position was chosen for the generation of a 
focused CYP116B3 mutant library.  
b) By systematic analysis of numerous crystal structures and a multitude of 
sequences of P450s, in 98.4% of all sequences the 5th amino acid after the 
highly conserved ExxR motive was predicted to be a preferentially 
hydrophobic residue, located close to the heme group and pointing towards 
the heme center.131 By analyzing the amino acid sequence of CYP116B3, five 
ExxR motives were found. Three of those were present in the monooxygenase 
domain. By alignment of sequences of the CYP116B family using the 
Cytochrome P450 Engineering Database (CYPED),167 only two of the five 
ExxR motives of CYP116B3 were identified to be positioned in active site 
areas. From these two motives, only one was highly conserved throughout all 
of the aligned sequences. This was the motive ECLR (amino acid position 
308-311). The fifth amino acid after this highly conserved ExxR motive was a 
valine at position 316 in CYP116B3. Therefore, this position was chosen for 
rational protein design, in addition to the previously selected position 109.  
c) Based on the structure of the created homology model of CYP116B3, the two 
amino acid positions 317 and 318, which were both occupied by an alanine in 
the wild type sequence, were selected for mutagenesis due to their localization 
at the active site, adjacent to V316. Moreover, the phenylalanine at position 
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F420, positioned at the entrance to the active site, opposite to V316, A317 and 
A318, was chosen as further residue.  
Though, according to the homology model (Figure 3.8), the residue A109 is shown 
not to be in direct proximity to the heme (Figure 3.8 E, F), all of the selected five 
amino acid positions are promising candidates for the generation of a focused library 
containing variants with enhanced activity and/or selectivity, as they are located on 
loop regions and thus are expected to be quite flexible.      
All variants of the focused CYP116B3 mutant library were generated by site-directed 
mutagenesis based on the CYP116B3 His-tag variant 1 (CYP116B3_Var1, 
N-terminal MGSS-His6-sequence), using the respective oligonucleotides (Table 7.4, 
supplementary material). CYP116B3_Var1 was chosen due to previous results 
concerning expression and activity of different CYP116B3 His-tag variants (section 
3.1.2). In analogy to the focused CYP102A1 library, the amino acids at the five 
selected mutation sites in CYP116B3 were replaced by the hydrophobic amino acids 
alanine (Ala, A), phenylalanine (Phe, F), isoleucine (Ile, I), leucine (Leu, L) and valine 
(Val, V), respectively. Thus, a CYP116B3 library containing the wild type and 20 
single mutant variants was obtained.  
 
3.2.1.3   CYP116B3 variants expression and determination of enzyme activity 
 
The CYP116B3 variants were expressed in E. coli BL21(DE3) following the standard 
expression conditions mentioned in section 2.2.7.3. According to SDS-PAGE 
analysis (Figure 7.4, supplementary material), all variants were expressed 
successfully and a reasonable amount of CYP116B3 was recovered in the soluble 
protein fraction, with some variance. The CYP116B3 concentration of the variants 
was determined by CO differential spectral analysis (Figure 3.9, Table 3.4). 
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Figure 3.9: CO differential spectral assay of the focused CYP116B3 mutant library variants. Solid 
lines indicate measurements immediately after bubbling of the samples with CO. Dashed lines indicate 
measurements of the same samples after 15 min at RT. All measurements were done in duplicate. 
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The obtained spectra displayed for many of the variants a shoulder or even a peak at 
a wavelength of 420 nm, especially for the repeated measurements after 15 min. This 
A420-peak is an indication for inactive enzyme. Hence, variants V316A, V316F and all 
A318-variants were expected to be rather inactive. As a consequence of the spectra, 
no concentration of CYP116B3 in the soluble protein fraction could be determined for 
these variants, except for variant A318F. In contrast, the variants A317I, A317V, 
F420I and F420L seemed to be relatively stable, according to their spectra. 
 
Table 3.4: CYP116B3 concentration in the soluble protein fraction, expression efficiency and activity 
of CYP116B3 focused mutant library variants towards 7-ethoxycoumarin. 
CYP116B3 variant 
c(CYP116B3)  
[µM]
a
 
c(CYP116B3)  
[mg (gcww)
-1
]
a
 
Product formation rate  
[µmol (µmol CYP116B3)
-1
 min
-1
]
b
 
A109F 2.3 0.99 1.81 
A109I 3.5 1.51 0.59 
A109L 3.6 1.56 0.69 
A109V 4.0 1.70 0.41 
V316A - - y* 
V316F - - n* 
V316I 3.9 1.66 0.52 
V316L 2.6 1.14 3.95 
A317F 0.4 0.19 y* 
A317I 4.1 1.75 0.69 
A317L 2.9 1.23 1.26 
A317V 4.3 1.84 0.81 
A318F 0.8 0.33 0.51 
A318I - - y* 
A318L - - y* 
A318V - - y* 
F420A 3.0 1.28 0.41 
F420I 4.2 1.80 0.49 
F420L 5.5 2.37 0.33 
F420V 3.7 1.61 0.43 
a
-, concentration could not be determined by CO differential spectral assay. 
b
Reactions were performed in triplicate with a 
standard deviation of less than 15%. Lysate of empty vector expression was used as a negative control. CYP116B3 was added 
at a final concentration of 0.5 µM. *Due to the missing information about CYP116B3 concentration or concentration lower 
0.5 µM, 100 µl of lysate were added in the reaction mixture for determination of activity. n, no activity; y, displayed activity, but 
product formation rate could not be determined due to missing information about concentration. 
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For all variants with a determined value of the CYP116B3 concentration in the lysate, 
the expression efficiency was calculated subsequently (Table 3.4). Highest 
expression of 2.37 mg CYP116B3 (gcww)
-1 was identified for the variant F420L. 
Determination of activity was done according to the 7-ethoxycoumarin assay (section 
2.2.10.2) by fluorescence spectroscopy (Table 3.4). Corresponding to the calculation 
of the expression efficiency, only for the variants with a defined CYP116B3 
concentration in the lysate, the activity could be determined. For the variants with a 
very low or undefinable enzyme concentration value, only a qualitative activity 
analysis was possible. 
With respect to the results of the activity determination, the only variant which 
displayed no activity was the variant V316F. For the variants V316A, A317F, A318I, 
A318L and A318V, which were expected to be inactive according to the respective 
CO differential spectra, at least some activity was detected in the fluorescence 
spectroscopy. Product 7-hydroxycoumarin was generated to some extent. Highest 
activity was determined for the variant V316L with a product formation rate of 
3.95 µmol (µmol CYP116B3)-1 min-1. 
Determination of the relative activity of the CYP116B3 variants compared to the wild 
type enzyme revealed that the activity increased for four of the variants, especially for 
V316L with almost six times higher activity (Figure 3.10). For two variants (A109L 
and A317I) activity did not change significantly and for eight variants the activity 
towards 7-ethoxycoumarin decreased. As mentioned previously, the variants V316A, 
A317F, A318I, A318L and A318V displayed activity, though the product formation 
rate could not be determined. Variant V316F was the only variant without any 
detectable activity. 
 
All variants of the created CYP116B3 library were successfully expressed in E. coli 
BL21(DE3). Both variants with increased and with decreased activity towards the 
standard substrate 7-ethoxycoumarin were detected as a result of the introduced 
mutations into CYP116B3. However, in order to investigate the hydroxylation activity 
and thus applicability of the variants concerning the synthesis of vanillin, the library 
was screened with the respective aromatic substrates. 
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Figure 3.10: Relative activity of CYP116B3 focused mutant library variants compared to the wild type 
enzyme. Wild type expressed on pET-22b(+) was used as reference. Wild type activity corresponds to 
100% and is indicated by a dashed line. *Activity was detected but relative activity could not be 
determined. 
 
3.2.1.4   In vitro biotransformations with the focused CYP116B3 mutant library 
 
Variants of the focused mutant library of CYP102A1 were previously shown to 
convert the aromatic substrate 3-methylanisole with enhanced activity and changed 
selectivity (Table 3.3, section 3.1.4). In comparison to the CYP102A1 wild type, the 
wild type enzyme of CYP116B3 was identified to be more active towards 
3-methylanisole. Hence, aiming at the final synthesis of vanillin in accordance with 
the proposed reaction pathway (Figure 1.8, introduction), the application of the newly 
created focused mutant library of CYP116B3 in an in vitro biotransformation 
screening for the conversion of aromatic substrates was promising. In addition to 
3-methylanisole, the intermediate compounds 3-methoxybenzyl alcohol and 
4-methylguaiacol were employed as substrates. Also the conversion of the vanillin 
precursor vanillyl alcohol was investigated to gain information about overoxidation of 
this compound. 
For the conversion of 3-methylanisole (Table 3.5), only three different products were 
identified. These are 3-methoxybenzyl alcohol, 4-methoxy-2-methylphenol and 
m-cresol, with a preference for m-cresol and thus for the demethylation reaction, 
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detected for most of the variants. However, two variants, F420I and F420V, displayed 
a shifted chemoselectivity, as aromatic hydroxylation was the preferred reaction, 
yielding 4-methoxy-2-methylphenol as main product. In the case of the variant F420I, 
benzylic hydroxylation with 3-methoxybenzyl alcohol formation was also favored over 
the demethylation reaction. 
 
Table 3.5: Biotransformation results for the in vitro conversion of 3-methylanisole with the focused 
CYP116B3 mutant library. 
CYP116B3 variant 
Product formation [% of initial substrate] Total 
conversion 
[%]
1
 2 3 6 9 
wild type <1 - <1 1.4 ± 0.1 2.1 ± 0.0 
A109F - - <1 2.2 ± 0.1 3.3 ± 0.2 
A109I <1 - <1 2.1 ± 0.4 3.8 ± 0.9 
A109L <1 - <1 2.0 ± 0.3 3.4 ± 0.5 
A109V <1 - <1 1.4 ± 0.1 2.4 ± 0.3 
V316A
a
 <1 - <1 <1 0.7 ± 0.1 
V316F
a
 - - - - - 
V316I <1 - <1 1.3 ± 0.1 2.1 ± 0.2 
V316L 1.5 ± 0.1 - 1.1 ± 0.2 2.8 ± 0.1 5.4 ± 0.5 
A317F
b
 <1 - <1 1.1 ± 0.1 1.7 ± 0.2 
A317I <1 - <1 1.1 ± 0.1 2.0 ± 0.2 
A317L <1 - <1 1.0 ± 0.1 2.0 ± 0.2 
A317V <1 - <1 1.7 ± 0.1 2.8 ± 0.2 
A318F
b
 - - - - - 
A318I
a
 <1 - <1 <1 0.9 ± 0.1 
A318L
a
 <1 - <1 <1 1.1 ± 0.1 
A318V
a
 <1 - <1 <1 0.6 ± 0.1 
F420A <1 - <1 <1 0.4 ± 0.1 
F420I 1.2 ± 0.2 - 1.3 ± 0.1 <1 2.8 ± 0.3 
F420L <1 - <1 <1 1.0 ± 0.1 
F420V <1 - 1.0 ± 0.2 <1 2.2 ± 0.4 
-, not detected or <0.05%; 2, 3-methoxybenzyl alcohol; 3, 4-methylguaiacol; 6, 4-methoxy-2-methylphenol; 9, m-cresol. 
Reactions were performed with soluble protein fractions and run at 30°C and 180 rpm for 2 h. CYP116B3 was employed at a 
final P450 concentration of 0.5 µM. Reactions were performed in triplicate with a standard deviation of less than 15%. Lysate of 
empty vector expression was used as a negative control. Samples were analyzed by GC-FID. Negative controls showed no 
conversion. 
1
Total conversion was calculated from the determined product formations and was not equivalent to the substrate 
consumption due to the volatility of 3-methylanisole. 
a
Due to the missing information about CYP116B3 concentration, 200 µl of 
lysate were added to the reaction mixture. 
b
Due to the low CYP116B3 concentration in the lysate, the CYP116B3 enzyme was 
applied at a final concentration of 0.1 µM.  
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Concerning the synthesis of the vanillin pathway intermediate 4-methylguaiacol, no 
product formation was detected with any of the CYP116B3 library variants to more 
than 0.05% of the initial substrate concentration. In a comparison of the total 
conversion of the variants with the wild type enzyme, only the variants F420A and 
F420L demonstrated a significant loss of activity. Highest activity of 5.4% total 
conversion was obtained for the variant V316L. However, for all variants with non-
determinable or very low enzyme concentration in the lysate, the determined product 
formation and conversion values cannot be compared to the wild type or the other 
variants. Most of these variants were shown to be active towards 3-methylanisole, 
except the two variants V316F and A318F. V316F was also shown to be inactive with 
7-ethoxycoumarin, previously (section 3.2.1.3). Overoxidation of m-cresol to 
methylhydroquinone, detected for some of the CYP102A1 variants in the screening 
of the focused mutant library (section 3.1.4), was not identified for any of the variants 
of the CYP116B3 library. 
In addition, none of the variants exhibited activity towards 3-methoxybenzyl alcohol. 
However, towards 4-methylguaiacol as substrate, three variants (V316L, F420I, 
F420V) were active, producing low amounts of vanillyl alcohol (Table 3.6). Again, 
highest activity was determined for V316L (1.9% total conversion). The 
accompanying formation of a very low amount of vanillin (0.11% for V316L) can be 
attributed to E. coli enzymes in the lysate. This is assumed due to the fact that the 
negative controls with empty vector lysates showed also a basic level of conversion 
of vanillyl alcohol to vanillin. Both with empty vector lysates and with lysates of all 
investigated variants a marginal product formation of vanillin from vanillyl alcohol with 
values between 0.2% and 0.4% was obtained. Only for variant V316L a slightly 
increased vanillin synthesis was determined, with a maximum of 0.8% total 
conversion (data not shown in table). 
Table 3.6: Biotransformation results for the in vitro conversion of 4-methylgaiacol with the focused 
CYP116B3 mutant library. 
CYP116B3 variant 
Product formation [% of initial substrate] Total conversion 
[%] Vanillyl alcohol Vanillin 
V316L 1.8 ± 0.3 0.11 ± 0.0 1.9 ± 0.0 
F420I 0.6 ± 0.1 0.07 ± 0.0 0.7 ± 0.0 
F420V 0.6 ± 0.1 0.07 ± 0.0 0.7 ± 0.0 
Reactions were performed in triplicate with soluble protein fractions and run at 30°C and 180 rpm for 2 h. CYP116B3 was used 
at a final concentration of 0.5 µM. Samples were analyzed by HPLC. Negative controls showed no conversion. 
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Some variants of the generated focused mutant library of CYP116B3 revealed an 
increased activity and/or changed chemoselectivity towards 3-methylanisole. 
However, the total conversion values are much lower compared to selected variants 
of the CYP102A1 mutant library. Moreover, only minor product formation of 
3-methoxybenzyl alcohol and no explicit synthesis of 4-methylguaiacol was detected. 
In contrast to the CYP102A1 variants, three CYP116B3 variants were identified, 
which were shown to convert 4-methylguaiacol to vanillyl alcohol, though only to a 
very low extent. Thus, by creation of a focused CYP116B3 mutant library, variants 
with improved conversion performance were found, although, due to the overall low 
activity, the applicability for the synthesis of vanillin is not given yet. Further enzyme 
optimization regarding an increase of the enzymes activity would be necessary first. 
  
3.2.2   Generation and application of further CYP102A1 variants 
 
3.2.2.1   Screening of a set of triple mutant variants of CYP102A1 
 
Previous results demonstrated the beneficial effect of single and double mutations on 
the conversion of 3-methylanisole with CYP102A1 (section 3.1.4, Table 3.3). In order 
to further increase the activity and selectivity, an additional mutation site was 
investigated. Therefore, the amino acid position 437, which is occupied by a leucine 
in the wild type enzyme (L437) (Figure 3.12), was selected based on the results of a 
previous study. There, the amino acid at position 437, in addition to the positions 87 
and 328, was reported to have an effect on both activity and selectivity of the 
respective CYP102A1 variants by influencing the orientation of substrates to the 
active site’s heme oxygen.168 Due to the preference of P450 enzymes for 
hydrophobic amino acids in substrate-interacting positions,131 the CYP102A1 double 
mutant variant F87V/A328L, which exhibited the highest total conversion of 
3-methylanisole in the initial biotransformations (section 3.1.4, Table 3.4), was 
combined with the hydrophobic amino acids alanine, phenylalanine, isoleucine and 
valine at position 437, alternatively to leucine in the wild type. The respective triple 
mutant variants of CYP102A1 (F87V/A328L/L437A/F/I/V), were available at the ITB 
(University of Stuttgart, Stuttgart, Germany) and kindly provided by Dr. Alexander 
Seifert as indicated in Table 7.2 (supplementary material). Soluble protein fractions of 
the triple mutant variants were applied for in vitro biotransformation reactions of the 
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aromatic substrates 3-methylanisole, 3-methoxybenzyl alcohol, 4-methylguaiacol and 
vanillyl alcohol.  
As for the single and double mutant variants of CYP102A1, no conversion of 
3-methoxybenzyl alcohol, 4-methylguaiacol and vanillyl alcohol was detected with 
any of the triple mutant variants. However, all variants were active towards 
3-methylanisole as a substrate (Table 3.7). Compared to the variant F87V/A328L as 
a reference, the additional mutation of L437 clearly had an impact on both activity 
and selectivity of the investigated CYP102A1 variants. A considerable decrease in 
total conversion was determined for the variants with an alanine or phenylalanine 
instead of the leucine in position 437. In contrast, replacement of leucine by 
isoleucine and valine did not affect the variant’s activity, though the product 
distribution changed. This is an indication for an altered selectivity of the respective 
triple mutant variants F87V/A328L/L437I and F87V/A328L/L437V. With these 
variants, about twice as much 3-methoxybenzyl alcohol was generated, compared to 
the corresponding double mutant variant F87V/A328L, and overoxidation of m-cresol 
to methylhydroquinone increased marginally. Besides, product formation of 
4-methylguaiacol, 4-methoxy-2-methylphenol and m-cresol was diminished 
approximately by half. 
 
Table 3.7: Biotransformation results for the in vitro conversion of 3-methylanisole with selected L437 
triple mutant variants of CYP102A1. Results of conversion with variant F87V/A328L are shown for 
comparison. 
CYP102A1 variant 
Product formation [% of initial substrate] Total 
conversion 
[%]
1
 2 3 6 9 10 
F87V/A328L 9.1 ± 0.2 1.6 ± 0.1 23.2 ± 0.4 12.0 ± 0.8 13.5 ± 0.8 59.3 ± 1.8 
F87V/A328L/L437A 1.6 ± 0.1 <1 3.1 ± 0.2 4.7 ± 0.2 - 9.5 ± 0.5 
F87V/A328L/L437F 1.7 ± 0.2 <1 5.7 ± 0.9 7.3 ± 1.0 <1 15.5 ± 2.3 
F87V/A328L/L437I 20.0 ± 0.9 <1 14.0 ± 0.7 7.4 ± 1.3 19.3 ± 0.5 61.3 ± 2.9 
F87V/A328L/L437V 22.3 ± 2.0 <1 10.5 ± 1.0 7.0 ± 0.8 18.5 ± 2.7 58.9 ± 5.3 
-, not detected or <0.05%; 2, 3-methoxybenzyl alcohol; 3, 4-methylguaiacol; 6, 4-methoxy-2-methylphenol; 9, m-cresol; 
10, methylhydroquinone. Reactions were performed in triplicate with soluble protein fractions and run at 30°C and 180 rpm for 
2 h. CYP102A1 was used at a final concentration of 1 µM. Samples were analyzed by GC-FID. Negative controls showed no 
conversion. 
1
 Total conversion was calculated from the determined product formations and was not equivalent to the substrate 
consumption due to the volatility of 3-methylanisole. 
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This additional mutation in position 437 did influence both activity and selectivity of 
the investigated conversion of 3-methylanisole. Nevertheless, no activity with any of 
the other substrates was detected. 
 
3.2.2.2   Molecular dynamics simulations of CYP102A1 with 4-methylguaiacol 
 
Regarding the previous biotransformation results for a selection of single, double and 
triple mutant variants of CYP102A1 (section 3.1.4 and section 3.2.1.1), 
3-methylanisole was accepted as a substrate by nearly all of the investigated 
variants. Apart from intense byproduct formation, the desired intermediate products 
3-methoxybenzyl alcohol and 4-methylguaiacol were produced in varying amounts by 
means of benzylic and aromatic hydroxylation, respectively. These compounds were 
needed for further conversion to the vanillin precursor vanillyl alcohol following the 
proposed vanillin synthesis pathway (Figure 1.8, introduction). The benzylic 
hydroxylation of 3-methylanisole was clearly favored over the aromatic hydroxylation 
in para position to the methyl group, as, according to the biotransformation results 
(Table 3.3 and Table 3.7), the maximal product formation of 3-methoxybenzyl alcohol 
(about 22%) was much higher compared to the maximal product formation of 
4-methylguaiacol (about 3%). However, none of these intermediate compounds was 
further converted to vanillyl alcohol or any other product. 
In order to find out why the synthesis of vanillyl alcohol was ineffective with any of the 
previously in this study employed CYP102A1 variants, molecular dynamics (MD) 
simulations were carried out by Dr. Alexander Seifert from the bioinformatics group of 
the ITB (University of Stuttgart, Stuttgart, Germany). Concerning the two alternative 
routes of the proposed vanillin synthesis pathway (Figure 1.8, introduction) to 
produce vanillyl alcohol, either via 3-methoxybenzyl alcohol or via 4-methylguaiacol 
as intermediates, and due to the identified preference of the CYP102A1 variants for 
benzylic hydroxylation compared to aromatic hydroxylation in para position to the 
methyl group, the route via benzylic hydroxylation of 4-methylguaiacol was assumed 
to be more promising. Hence, 4-methylguaiacol was chosen as substrate molecule 
for the MD simulations in combination with the CYP102A1 variant F87V/A328I, which 
was selected based on product formation results of the primary 3-methylanisole 
conversion screening of the focused CYP102A1 library (data not shown). In total, 30 
repeated 100 ns MD simulations of the enzyme substrate complex were performed to 
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discover if 4-methylguaiacol binds in the active site of the enzyme in productive 
orientations. As a result, 4-methylguaiacol was frequently detected in three different 
regions: close to its starting position (distance of 10 Å to the activated heme oxygen - 
in five simulations), in proximity to the activated heme oxygen (distance suitable for 
oxidation - in six simulations) and in the substrate access channel (distance of about 
20 Å to the activated heme oxygen - in four simulations) (Figure 3.11).  
   
 
                                                           
Figure 3.11: MD simulation of CYP102A1 variant F87V/A328I with the substrate 4-methylguaiacol 
(4-MG). Regions in the active site cavity are shown, where 4-methylguaiacol was frequently detected 
(A and B (B is zoomed in on A)). Heme moiety with oxygen is shown in red. The blue 
4-methylguaiacol molecule displays the starting position, the green molecule the position close to the 
heme center, and in yellow the position in a pocket shaped by the β1 sheet and the A’ helix is 
illustrated. An orange arrow indicates the direction of the substrate access channel in A. C is an 
illustration with a focus on the yellow 4-methylguaiacol molecule located in high distance to the heme, 
where additionally the substrate channel residues R47 and Y51 are shown as sticks in close proximity 
to 4-methylguaiacol (rotated view). The images were generated by PyMOL.
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In principle, 4-methylguaiacol seems to be able to bind in a productive confirmation to 
the activated heme oxygen of the CYP102A1 variant, as for example in one of the 
simulations, the 4-methylguaiacol molecule approached the heme within the first 
10 ns and exposed its ring methyl group to the activated oxygen for the remaining 
90 ns with a distance of less than 4 Å (Figure 7.5, supplementary material). However, 
in the simulations where 4-methylguaiacol moved away from the active site to a more 
distant pocket (formed by the β1 sheet and the A’ helix of CYP102A1) in the substrate 
access channel, the molecule was stabilized by polar interaction/hydrogen bonds 
with the residues R47 and Y51 (Figure 7.6, supplementary material). This might be a 
reason for the inactivity of the previously in this study investigated CYP102A1 
variants concerning the conversion of 4-methylguaiacol, though 4-methylguaiacol 
differs from 3-methylanisole, a proven good substrate, by only one hydroxyl group. 
 
3.2.2.3   Biotransformations with R47L/Y51F-variants of CYP102A1 
 
As the MD simulations revealed a stabilizing effect of the polar substrate channel 
residues R47 and Y51 (Figure 3.11, Figure 3.12) on the substrate 4-methylguaiacol, 
these residues were replaced by the hydrophobic residues leucine and 
phenylalanine, respectively, in order to enable the conversion of 4-methylguaiacol by 
variants of CYP102A1. Therefore, by means of rational protein design using 
respective oligonucleotides (Table 7.4, supplementary material), the mutations R47L 
and Y51F were introduced into selected variants of CYP102A1, which displayed the 
highest biotransformation activity with 3-methylanisole in previous investigations 
(Table 3.3, section 3.1.4 and Table 3.7, section 3.2.2.1). 
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Figure 3.12: Substrate and heme access region in CYP102A1 (PDB ID: 1BU7, chain A). Substrate 
channel residues R47 and Y51 and active site residues, including the heme group (red), as well as 
parts of the I-helix, the B/C loop with F87 and the substrate recognition site 5 (SRS5) with residues 
A328 and L437 (positioned at the entrance to the active site cavity) are depicted. The entrance route 
of the substrate to the active site is indicated by a black arrow. The image was generated by 
PyMOL.
166 
 
As a result, a set of double, triple, quadruple and one quintuple mutant variants of 
CYP102A1 was generated (some variants were already available at the ITB 
(University of Stuttgart, Stuttgart, Germany) and kindly provided by Dr. Alexander 
Seifert as indicated in Table 7.2 (supplementary material)) and investigated for 
conversion of both 4-methylguaiacol and the compounds 3-methylanisole, 
3-methoxybenzyl alcohol and vanillyl alcohol. 
Six out of the set of eight investigated CYP102A1 variants, carrying the R47L and 
Y51F mutations, successfully converted 4-methylguaiacol to vanillyl alcohol 
(Table 3.8). Only the variants R47L/Y51F and R47L/Y51F/A328L were completely 
inactive with 4-methylguaiacol. The highest production of vanillyl alcohol with a 
conversion of 4.5% was determined for the variant R47L/Y51F/F87V/A328V. In 
addition to vanillyl alcohol, an unknown byproduct was detected as a very small peak 
for all quadruple mutants and the one quintuple mutant variant (data not shown). 
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Table 3.8: Biotransformation results for the in vitro conversion of 4-methylguaiacol with R47L/Y51F-
variants of CYP102A1. 
CYP102A1 variant Conversion to vanillyl alcohol [%] 
R47L/Y51F - 
R47L/Y51F/A328L - 
R47L/Y51F/F87V <1 
R47L/Y51F/F87V/A328F 1.6 ± 0.1 
R47L/Y51F/F87V/A328I 3.0 ± 0.3 
R47L/Y51F/F87V/A328L <1 
R47L/Y51F/F87V/A328V 4.5 ± 0.3 
R47L/Y51F/F87V/A328L/L437I 3.1 ± 0.6 
-, not detected or <0.05%; Reactions were performed in triplicate with soluble protein fractions and run at 30°C and 180 rpm for 
2 h. CYP102A1 was used at a final concentration of 0.5 µM. Samples were analyzed by HPLC. Negative controls showed no 
conversion. 
 
In contrast to 4-methylguaiacol, the substrates 3-methoxybenzyl alcohol and vanillyl 
alcohol were not converted by any of the R47L/Y51F-variants. However, all variants 
were active with 3-methylanisole (Table 3.9).        
 
Table 3.9: Biotransformation results for the in vitro conversion of 3-methylanisole with R47L/Y51F-
variants of CYP102A1. 
CYP102A1 variant 
Product formation [% of initial substrate] Total 
conversion 
[%]
1
 2 3 6 9 10 
R47L/Y51F <1 - 1.5 ± 0.1 - - 1.6 ± 0.1 
R47L/Y51F/A328L <1 1.2 ± 0.1 12.5 ± 1.3 <1 - 14.8 ± 1.5 
R47L/Y51F/ 
F87V 
2.1 ± 0.1 1.6 ± 0.1 35.1 ± 3.1 1.2 ± 0.1 2.0 ± 0.3 42.5 ± 3.7 
R47L/Y51F/ 
F87V/A328F 
2.1 ± 0.3 1.3 ± 0.2 26.1 ± 3.5 5.1 ± 0.4 5.8 ± 1.4 40.3 ± 5.8 
R47L/Y51F/ 
F87V/A328I 
10.4 ± 1.1 <1 9.5 ± 0.8 6.9 ± 0.5 1.6 ± 0.3 28.8 ± 2.7 
R47L/Y51F/ 
F87V/A328L 
4.9 ± 0.5 <1 13.9 ± 0.9 9.7 ± 0.3 7.9 ± 0.9 37.4 ± 2.6 
R47L/Y51F/ 
F87V/A328V 
5.0 ± 0.3 <1 24.0 ± 0.8 3.0 ± 0.1 2.1 ± 0.2 34.9 ± 1.4 
R47L/Y51F/ 
F87V/A328L/L437I 
13.5 ± 0.4 <1 10.1 ± 0.5 7.7 ± 0.2 17.8 ± 0.8 50.4 ± 1.8 
-, not detected or <0.05%; 2, 3-methoxybenzyl alcohol; 3, 4-methylguaiacol; 6, 4-methoxy-2-methylphenol; 9, m-cresol; 
10, methylhydroquinone. Reactions were performed in triplicate with soluble protein fractions and run at 30°C and 180 rpm for 
2 h. Samples were analyzed by GC-FID. Negative controls showed no conversion. CYP102A1 was used at a final concentration 
of 1 µM. 
1
Total conversion was calculated from the determined product formations and was not equivalent to the substrate 
consumption due to the volatility of 3-methylanisole. 
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Low conversion of 3-methylanisole was detected for the variant R47L/Y51F. For the 
quadruple variant R47L/Y51F/F87V/A328V, both total conversion and product 
distribution was comparable to the values of the respective double mutant variant 
F87V/A328V. All other R47L/Y51F-variants displayed varying activity towards 
3-methylanisole, compared to the respective variants without the R47L and Y51F 
mutations, whereas the product distribution did not change significantly. Only 
methylhydroquinone, the product of the overoxidation of m-cresol, was produced for 
some more variants as a result of the higher activity. With a total conversion of 50%, 
the quintuple variant R47L/Y51F/F87V/A328L/L437I demonstrated highest activity, 
although lower compared to the respective triple mutant variant F87V/A328L/L437I.  
 
The additional R47L and Y51F mutations had different effects on enzyme activity and 
selectivity with respect to the conversion of 3-methylanisole. However, when 
4-methylguaiacol was used as a substrate for the R47L/Y51F-variants of CYP102A1, 
the formation of vanillyl alcohol was detected for the first time in a CYP102A1-
catalyzed reaction. These additionally introduced substrate channel mutations were 
shown to expand the spectrum of the investigated CYP102A1 variants to 
4-methylguaiacol as expected after MD simulation. 
 
3.2.3   Investigation of the vanillyl alcohol oxidase VAO from P. simplicissimum  
 
Various variants of CYP116B3 and especially of CYP102A1 were previously 
generated and identified to catalyze the first two steps of the proposed vanillin 
synthesis cascade reaction (Figure 1.8, introduction) from 3-methylanisole to 
4-methylguaiacol and from 4-methylguaiacol to vanillyl alcohol. In literature, the 
flavoenzyme vanillyl alcohol oxidase (VAO) from Penicillium simplicissimum was 
reported not only to be highly selective for the conversion of vanillyl alcohol to 
vanillin, but also to accept 4-methylguaiacol as a substrate.72, 169 Thereby, the VAO-
catalyzed conversion of 4-methylguaiacol proceeds via vanillyl alcohol directly to 
vanillin as final product. Hence, VAO was selected for application in the vanillin 
cascade synthesis reported here.  
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3.2.3.1   Site-directed mutagenesis, expression and investigation of activity of 
VAO 
 
The vaoA gene from P. simplicissimum CBS 170.90 was obtained as a synthetic 
gene (GeneArt® Gene Synthesis, Life Technologies GmbH, Darmstadt, Germany), 
codon-optimized for the heterologous expression in E. coli. From the pMK-RQ_VAO 
vector construct, the vaoA gene was cloned into pET-22b(+) by restriction enzyme 
digestion with NdeI and XhoI and ligation with linearized pET-22b(+) vector. The 
sequence of the pET-22b(+)_VAO construct was verified by automated DNA-
sequencing (GATC Biotech, Konstanz, Germany). Moreover, as single mutant 
variants of VAO, created by random mutagenesis with an up to 40-fold increased 
catalytic efficiency (kcat/KM) towards 4-methylguaiacol as substrate were reported in a 
previous study,69 two of these mutations were chosen for investigation concerning 
their applicability in the vanillin synthesis pathway here. Single mutant variants 
F454Y and T505S, which were described to have the highest catalytic efficiency at 
pH 7.5 and pH 10, respectively, were generated by site-directed mutagenesis based 
on the pET-22b(+)_VAO vector construct using the appropriate oligonucleotides 
(Table 7.4, supplementary material). The sequence of the variants was verified by 
automated DNA-sequencing (GATC Biotech, Konstanz, Germany). SDS-PAGE 
analysis of the expression of both the VAO wild type and the variants F454Y and 
T505S in E. coli BL21(DE3) indicated VAO enzyme, with a calculated molecular 
weight of 63.0 kDa (calculated from the amino acid sequence using the 
CloneManager (Sci-Ed Software, Cary, NC, USA) software) and an apparent 
molecular weight of about 60 kDa, in the soluble protein fraction. The majority of the 
enzyme seemed to be present in the insoluble fraction (Figure 3.13). 
In order to investigate the enzyme activity, wild type and variants of VAO were 
applied for in vitro biotransformation of 4-methylguaiacol at pH 7.5 and pH 10. At both 
pH-conditions the highest conversion of 4-methylguaiacol was determined for the 
variant F454Y (Table 3.10). According to the literature, at pH 10 the variant T505S 
was reported to have the higher catalytic efficiency.69 Main product of the 
4-methylguaiacol conversion was vanillin for all of the investigated reactions. Only for 
the wild type enzyme the intermediate product vanillyl alcohol was detected to a very 
low extent, which is a result of the lower enzyme activity. 
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Figure 3.13: SDS-PAGE analysis of the expression of VAO wild type and variants. Expression was 
investigated for induction with 0.5 mM IPTG and incubation at 20°C with shaking at 140 rpm O/N. 
M, marker (unstained protein ladder (10-200 kDa) – respective molecular weight is indicated); 
pI, whole cells prior to induction; aI, whole cells after induction and incubation O/N; SF, soluble protein 
fraction; IF, insoluble fraction after cell lysis. 
 
Table 3.10: Biotransformation results for the in vitro conversion of 4-methylguaiacol with VAO wild 
type and variants F454Y and T505S at pH 7.5 and pH 10. 
Enzyme (wild type) 
            variant 
Product formation [% of initial substrate] Total conversion 
[%] Vanillyl alcohol Vanillin 
pH 7.5 
VAO <1 53.2 ± 5.5 54.1 ± 5.7 
            F454Y - 80.3 ± 3.2 80.3 ± 3.2 
            T505S - 69.6 ± 7.5 69.6 ± 7.5 
pH 10 
VAO <1  2.8 ± 0.5  3.6 ± 0.5 
            F454Y - 81.3 ± 4.2 81.3 ± 4.2 
            T505S - 71.9 ± 5.1 71.9 ± 5.1 
Reactions were performed in triplicate with soluble protein fractions and run at 30°C and 180 rpm for 2 h. VAO lysate was used 
at a final total protein concentration of 1 mg/ml. Samples were analyzed by HPLC. Negative controls showed no conversion. 
 
Compared to the wild type enzyme, activity was clearly increased for both variants 
F454Y and T505S, with comparable synthesis of vanillin at pH 7.5 and at pH 10, 
respectively. In contrast, for the wild type enzyme the activity at pH 10 was much 
lower compared to the activity at pH 7.5. 
VAO VAO_F454Y 
       M    pI    aI   SF   IF    pI    aI   SF   IF    pI    aI   SF    IF    M         
50 
60 
VAO_T505S 
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Concerning the activity towards vanillyl alcohol as substrate, the wild type enzyme 
and the variants were applied in in vitro biotransformation reactions at pH 7.5. As a 
result, complete conversion of vanillyl alcohol to vanillin was detected both for the 
wild type and for the variants. Moreover, no byproduct formation or overoxidation of 
vanillin was identified.  
To further explore the applicability of VAO in the proposed vanillin synthesis cascade 
pathway, possible side-reactions with all compounds, potentially present in the 
reaction mixture of a one-pot setup, were investigated. These are, next the substrate 
3-methylanisole, the intermediate compounds 3-methoxybenzyl alcohol and 
4-methylguaiacol as well as the side-products 4-methoxy-2-methylphenol, 
2-methoxy-6-methylphenol and m-cresol and the overoxidation product 
methylhydroquinone. Neither by the VAO wild type nor by the variants F454Y or 
T505S, any of these compounds were accepted as a substrate (data not shown). 
 
All enzymes were successfully expressed and shown to be active (complete 
conversion of vanillyl alcohol to vanillin at pH 7.5). However, compared to the wild 
type enzyme, a much higher activity towards 4-methylguaiacol was determined for 
both variants. Finally, the variant F454Y exhibited highest activity towards 
4-methylguaiacol at pH 10, slightly higher compared to its activity at pH 7.5.  
 
3.3   In vitro one-pot cascade synthesis of vanillin 
 
In order to synthesize vanillin from 3-methylanisole in a multi-enzymatic three-step 
cascade reaction, a variety of enzymes and variants thereof was investigated in 
previous in vitro biotransformations concerning the realization of the two possible 
routes of the proposed vanillin synthesis reaction pathway (Figure 1.8, introduction). 
As none of the investigated enzymes and variants was able to convert 
3-methoxybenzyl alcohol, this route was not considered in the further proceeding. As 
a consequence, focus was set on the synthesis of vanillin according to the route via 
4-methylguaiacol. Enzymes and variants were identified and applied in separate in 
vitro reactions for all three different steps of this route, previously. While most 
efficient conversion of 3-methylanisole to 4-methylguaiacol was achieved with the 
CYP102A1 variant A328L, the quadruple CYP102A1 variant 
R47L/Y51F/F87V/A328V showed highest conversion of 4-methylguaiacol to vanillyl 
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alcohol. For the third and final reaction step from vanillyl alcohol to vanillin, the well-
known VAO variant F454Y was shown to be a suitable catalyst. Moreover, 
VAO_F454Y was also shown to convert 4-methylguaiacol to vanillin in high yield, via 
the intermediate compound vanillyl alcohol.69 
In a first in vitro one-pot reaction setup, the two P450 variants CYP102A1_A328L 
and CYP102A1_R47L/Y51F/F87V/A328V were combined to examine the two-step 
cascade synthesis of the vanillin precursor vanillyl alcohol from 3-methylanisole. After 
2 h reaction time, containing both enzyme variants in the reaction mixture from the 
start of the reaction, about 25% of the substrate was converted, with 4-methoxy-
2-methylphenol as main product (Table 3.11). Even though 4-methylguaiacol was 
produced to 1.2% of the initial substrate, no concomitant synthesis of vanillyl alcohol 
was detected. By successive addition of the second enzyme variant 
(R47L/Y51F/F87V/A328V) after 1 h (half of the reaction time), the conversion was 
increased to about 30% and formation of 4-methylguaiacol was doubled. However, 
still no vanillyl alcohol was identified. 
 
Table 3.11: Biotransformation results for the in vitro conversion of 3-methylanisole with a combination 
of enzymes in one reaction system. 
Enzymes 
Conver-
sion 
time [h] 
Product formation [% of initial substrate] Total 
conversion 
[%]
1
 2 3 5 6 
CYP102A1_ 
A328L 
+ 
CYP102A1_ 
R47L/Y51F/F87V/A328V 
2 2.2 ± 0.1 1.2 ± 0.1 - 19.3 ± 1.3 24.7 ± 1.6 
1+1 1.2 ± 0.2 2.4 ± 0.5 - 25.6 ± 4.8 30.3 ± 5.7 
CYP102A1_A328L 
+ 
VAO_F454Y 
2 <1 <1 <1 19.8 ± 2.7 22.9 ± 3.1 
1+1 1.0 ± 0.1 <1 1.2 ± 0.1 25.0 ± 2.2 29.0 ± 2.5 
8 <1 <1 1.2 ± 0.5 20.1 ± 3.0 23.2 ± 3.5 
4+4 1.1 ± 0.1 <1 2.0 ± 0.2 27.1 ± 2.3 31.4 ± 2.7 
-, not detected or <0.05%; 2, 3-methoxybenzyl alcohol; 3, 4-methylguaiacol; 5, vanillin; 6, 4-methoxy-2-methylphenol. Reactions 
were performed in triplicate with soluble protein fractions lysate and run at 30°C and 180 rpm. Conversion time “1+1” or “4+4” 
indicate successive addition of the second enzyme after 1 h or 4 h, respectively. Samples were analyzed by GC-FID. Negative 
controls showed no conversion. 
1
Total conversion was calculated from the determined product formations and was not 
equivalent to the substrate consumption due to the volatility of 3-methylanisole. 
 
As a further variation, both separate and combined addition of catalase and 
superoxide dismutase (SOD) to the biotransformation mixture was investigated, in 
order to increase the enzyme’s activity by minimizing the negative influence of 
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possibly generated reactive oxygen species. No significant change in product 
distribution and total conversion was measured (data not shown). 
 
In a further in vitro one-pot reaction setup CYP102A1_A328L was combined with the 
vanillyl alcohol oxidase variant VAO_F454Y aiming at the direct three-step 
biocatalytic cascade synthesis of vanillin. The total conversion of 3-methylanisole and 
the product formation of the main product 4-methoxy-2-methylphenol were 
comparable to the first reaction setup with two CYP102A1 variants (Table 3.11). 
Moreover, again an increase in total conversion (from about 23% to 29%) was 
detected by successive addition of the second enzyme, here the VAO variant F454Y, 
after half of the reaction time. However, in contrast to the first cascade reaction 
setup, vanillin was synthesized with 1.2% for the successive addition of the enzymes, 
whereas the determined production of 4-methylguaiacol was reduced to less than 
1%. Formation of the vanillin precursor vanillyl alcohol was not detected for any of the 
investigated reactions. Consequently, this is an indication that in a first reaction step 
the CYP102A1 variant A328L catalyzed the conversion of 3-methylanisole to 
4-methylguaiacol, which was further converted in two successive reactions via vanillyl 
alcohol to vanillin, catalyzed by the VAO variant F454Y (Figure 3.14). Thereby, as no 
vanillyl alcohol was identified, the last step was a complete conversion.  
 
 
Figure 3.14: Cascade conversion of 3-methylanisole (1) via 4-methylguaiacol (3) and vanillyl 
alcohol (4) to vanillin (5), catalyzed by the CYP102A1 variant A328L and the VAO variant F454Y. 
 
In order to increase the vanillin synthesis, the total reaction time was extended to 8 h. 
However, conversion as well as product formation did not change significantly, 
though the vanillin production increased to 2% in the setup with the successive 
addition of the enzymes (4+4) (Table 3.11). Furthermore, the addition of catalase to 
the reaction mixture with VAO was investigated (for 2 h total reaction time), as in the 
VAO-catalyzed reactions hydrogen peroxide is known to be produced. However, this 
1 3 4 
VAO 
F454Y 
5 
VAO 
F454Y 
CYP102A1 
A328L 
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resulted in dramatically lower conversion (less than half of the total conversion 
compared to the reactions without catalase; data not shown). While the side-product 
m-cresol was detected in all reactions in very low amounts, the overoxidation product 
methylhydroquinone was only identified for the biotransformations with the 
CYP102A1 variant R47L/Y51F/F87V/A328V (<1%; data not shown). 
 
In conclusion, it was shown that vanillyl alcohol could not be synthesized by a 
combination of the two CYP102A1 variants A328L and R47L/Y51F/F87V/A328V in 
vitro. However, in contrast to the first reaction setup, vanillin was synthesized by a 
combination of the CYP102A1 variant A328L and the VAO variant F454Y. 
Consequently, the second route of the proposed vanillin synthesis cascade reaction 
was successfully realized in vitro, as a proof-of-principle.  
 
3.4   In vivo one-pot cascade synthesis of vanillin 
 
Due to the previously shown synthesis of vanillin from 3-methylanisole in a one-pot 
two-enzymatic three-step cascade conversion in vitro (section 3.3), the same system 
was now investigated for its applicability in vivo. Therefore, E. coli BL21(DE3), which 
was chosen as expression host, was transformed with the plasmids 
pET-28a(+)_CYP102A1 _A328L and pET-22b(+)_VAO_F454Y. Expression was 
investigated by SDS-PAGE (Figure 3.15), showing strong protein bands at around 
60 kDa and 120 kDA, indicating successful expression of VAO (63.0 kDa calculated 
molecular weight) and CYP102A1 (117.8 kDa calculated molecular weight), 
respectively, with a preference for VAO expression. After protein expression, the cells 
were harvested, washed with buffer and adjusted in the biotransformation medium to 
a final cell wet weight of 50 g l-1 for in vivo whole-cell conversion of 3-methylanisole. 
Samples of the in vivo biotransformation were taken at several time points for up to 
24 h and analyzed by GC-FID. 
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Figure 3.15: SDS-PAGE analysis of the expression for in vivo whole-cell biotransformation of 
3-methylanisole with a combination of CYP102A1_F454Y and VAO_F454Y. Expression was 
investigated for induction with 0.1 mM IPTG and incubation at 20°C with shaking at 140 rpm O/N. 
M, marker (unstained protein ladder (10-200 kDa) – respective molecular weight is indicated); 
pI, whole cells prior to induction; aI, whole cells after induction and incubation O/N. 
 
According to the analysis, 4-methoxy-2-methylphenol was the only conversion 
product present within the first hour of reaction (Table 3.12). Moreover, this 
compound was detected to be the main reaction product during all measurements, as 
determined in previous in vitro biotransformations with CYP102A1 enzyme (section 
3.1.4 and section 3.2.2). In addition to 4-methoxy-2-methylphenol, the byproducts 
3-methoxybenzyl alcohol and the m-cresol were detected in low amounts after 3 h. 
A low product formation of 4-methylguaiacol, the intermediate product in the intended 
cascade synthesis of vanillin, was determined in the biotransformation samples after 
2 h. The vanillin precursor vanillyl alcohol was not detected at all during the in vivo 
biotransformations. However, while the concentration of 3-methoxybenzyl alcohol 
and m-cresol did not change significantly throughout the whole investigation, the 
product formation of 4-methylguaiacol decreased after 4 h and finally disappeared, 
while the formation of vanillin increased steadily from 3 h to 12 h reaction time with a 
maximum of 1.1% after 12 h (Figure 3.16). Total conversion also reached a 
maximum after 12 h with a value of almost 12%, although the biotransformation 
medium was supplemented with fresh glycerol and glucose after 12 h. 
 
 
22 + 28 
  M      pI       aI       M       pI      aI      
50 
60 
85 
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A328L + F454Y 
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Table 3.12: Biotransformation results for the in vivo conversion of 3-methylanisole with a combination 
of CYP102A1_A328L and VAO_F454Y in one cellular whole-cell reaction system. 
Conversion 
time [h] 
Product formation [% of initial substrate] Total 
conversion 
[%]
1
 2 3 5 6 9 
0 - - - - - - 
0.25 - - - <0.5 - <0.5 
0.5 - - - <0.5 - <0.5 
1 - - - <0.5 - <0.5 
2 - <0.5 - 0.9 ± 0.1 - 1.0 ± 0.1 
3 <0.5 <0.5 <0.5 3.6 ± 0.4 <0.5 4.3 ± 0.4 
4 <0.5 <0.5 0.5 6.4 ± 0.1 <0.5 7.6 ± 0.2 
6 <0.5 <0.5 0.8 8.1 ± 0.2 <0.5 9.7 ± 0.3 
8 <0.5 <0.5 0.9 ± 0.1 9.2 ± 0.8 <0.5 10.8 ± 1.0 
12 <0.5 - 1.1 ± 0.1 9.9 ± 1.3 <0.5 11.7 ± 1.4 
24 <0.5 - 1.1 ± 0.3 9.9 ± 2.4 <0.5 11.7 ± 2.6 
-, not detected or <0.05%; 2, 3-methoxybenzyl alcohol; 3, 4-methylguaiacol; 5, vanillin; 6, 4-methoxy-2-methylphenol; 
9, m-cresol. Reactions were performed in triplicate at 30°C and 180 rpm for 24 h. Samples at different time points were 
analyzed by GC-FID. Negative controls showed no conversion. 
1
Total conversion was calculated from the determined product 
formations and was not equivalent to the substrate consumption due to the volatility of 3-methylanisole. 
 
 
 
Figure 3.16: Product formation of 4-methylguaiacol (3) and vanillin (5) during the in vivo whole-cell 
biotransformation of 3-methylanisole. 
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The results of the in vivo whole-cell biotransformation clearly indicate that, as for the 
in vitro one-pot cascade synthesis of vanillin (section 3.3.), 3-methylanisole was 
converted via 4-methylguaiacol to vanillyl alcohol, which was then completely 
oxidized to vanillin. Successful vanillin synthesis was also confirmed by GC-MS 
analysis (Figure 7.7, supplementary material).   
 
Thus, by a combination of two different enzymes, the cytochrome P450 
monooxygenase CYP102A1 (variant A328L) and the vanillyl alcohol oxidase VAO 
(variant F454Y), the synthesis of vanillin was achieved both in vitro and in vivo 
according to the proposed cascade reaction pathway (Figure 1.8, introduction). 
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4   Discussion 
 
The catalytic aerobic oxidation of thermodynamically strong and kinetically inert C-H 
bonds in hydrocarbons is one of the most sought-after but also one of the most 
difficult chemical reactions to achieve.10, 14, 15, 170 The realization of such a reaction, 
especially with functionally complex compounds and with controlled and high chemo-, 
regio-, and stereoselectivities under environmentally friendly and safe conditions, still 
remains very challenging,9, 11-13 though with the usage of transition metal complexes 
and the development of various methods for catalytic functionalization the activation 
of C-H bonds has been shown with many substrates, particularly arenes.17 However, 
the concomitant formation of product mixtures is still the main challenge for 
chemocatalysis. 
For the intended oxidation of C-H bonds in aromatic compounds, biocatalysis, 
employing enzymes as catalysts, can be applied as an alternative to chemical 
syntheses by heterogeneous or homogeneous catalysis.10 Naturally evolved 
enzymes that can be found in virtually all habitats in nature, are known to catalyze a 
variety of reactions, for example the above mentioned challenging C-H bond 
functionalization in aqueous solution at ambient temperature and pressure.18 
Thereby, cofactors, that are positioned in the active site of the enzyme, are involved 
in the enzymatic mechanisms and the reactivity of the catalytic enzyme depends on 
the type of the employed cofactor.9, 19 Moreover, the positioning of these cofactors 
plays an important role in controlling the substrate scope of the enzyme and the 
selectivity of the reaction.19 
Challenges in biocatalysis, like insufficient enzyme activity, recombinant enzyme 
expression, enzyme purification, cofactor supply, organic solvent and oxygen 
tolerance, stability and substrate scope37-41 can be addressed by laboratory evolution 
techniques like, for example, protein engineering (directed evolution, rational protein 
design) and metabolic engineering of production hosts, which allows the combination 
of enzymes from different organisms.9 As an example for successful application of 
laboratory evolution techniques in biocatalysis, the olefin cyclopropanation via 
carbene transfer catalyzed by engineered P450s can be mentioned.130 Thereby, 
natural enzymes were screened for non-native activity against synthetic reagents, 
and both activity and stereoselectivities could be improved.  
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In this project, the establishment of a consecutive enzyme-catalyzed oxidation 
reaction yielding the valuable and sought-after aromatic compound vanillin as an 
exemplary product of interest was investigated. In order to realize the establishment 
of this cascade reaction according to the proposed reaction pathway as shown 
previously (Figure 1.8, introduction), a selection of enzymes was chosen as catalysts 
for initial investigations on the hydroxylation of aromatic substrates. 
 
4.1   Enzyme selection, preparation and application in initial 
biotransformations 
 
As, amongst others, flavoproteins and heme enzymes have been described to be of 
special interest concerning the challenging hydroxylation of aromatic substrates,9 the 
m-hydroxybenzoate hydroxylase MobA from C. testosteroni GZ39 and the 
cytochrome P450 monooxygenases CYP116B3 from R. ruber DSM 44319 and 
CYP102A1 from B. megaterium ATCC 14581 as well as variants thereof were 
chosen as representatives of these enzyme families, respectively, and employed for 
investigations in initial biotransformation reactions. 
 
The FAD-dependent m-hydroxybenzoate hydroxylase MobA from C. testosteroni 
GZ39, a single-component FPMO, was reported to display a generally strict substrate 
specificity, with the conversion of 3-hydroxybenzoate (m-hydroxybenzoate) to 
3,4-dihydroxybenzoate under consumption of equimolar amounts of NADPH and 
molecular oxygen as an exemplary reaction.57 In order to alter the substrate 
specificity of MobA, mutants were reported to have been generated by means of 
directed evolution followed by in vivo screening. One of these mutants was the MobA 
variant V257A, which was shown to successfully convert phenol to catechol, besides 
other substituted phenols that were reported to be converted with enhanced 
efficiency.60 Hence, both MobA wild type and variant V257A were chosen for 
investigation in initial aromatic substrate biotransformations in vitro. The variant 
V257A was generated by site-directed mutagenesis and both wild type enzyme and 
variant V257A of MobA were expressed in E. coli BL21(DE3). High yields of MobA 
wild type and variant V257A were obtained in the soluble protein fraction after cell 
lysis, though distinct amounts were still detected in the insoluble fraction. In addition, 
MobA wild type was purified by IMAC. A first indication for the activity of MobA wild 
Discussion 
104 
 
type and variant V257A, obtained by spectro-photometrical analysis, was confirmed 
by the investigation of the NADPH depletion in an in vitro conversion reaction of 
m-hydroxybenzoate to protocatechuate catalyzed by respective enzyme samples. 
Nevertheless, neither for MobA wild type nor for variant V257A conversion towards 
the aromatic compounds was detected in in vitro biotransformation reactions. This is 
in accordance with the known generally strict substrate specificity of MobA which was 
reported previously.57 The reason for this narrow substrate range could be the 
topology and the properties of the enzymes substrate channel and active site cavity. 
The environment of the tunnel interior was reported to be characterized by distinctly 
divided hydrophilic and hydrophobic regions. Additionally, the size of the tunnel 
entrance is assumed to play an important role in enzymatic substrate selection by the 
amphiphilic nature and molecular size of the substrate.51 Finally, as there was no 
initial activity indicated with the substrates of interest, no further investigations of 
MobA were undertaken at this point. 
 
The cytochrome P450 monooxygenases CYP116B3 from R. ruber DSM 44319 was 
chosen as candidate for initial biotransformation reactions towards the realization of 
the proposed vanillin synthesis pathway (Figure 1.8, introduction) as this enzyme was 
shown previously to catalyze the conversion of various monocyclic and polycyclic 
aromatic hydrocarbon substrates with and without alkyl side chains (acenaphthene, 
fluorene, indene, naphthalene, toluene, m-xylene and ethyl benzene).140 Besides, 
CYP116B3 was reported to be a self-sufficient fusion enzyme being composed of a 
ferredoxin domain and a FMN-containing NADPH-dependent flavoprotein reductase 
domain fused to a heme-containing P450 domain requiring only the cofactor NADPH 
as an electron donor and a substrate for oxidative catalysis,137, 140 which makes this 
enzyme relatively comfortable to handle. 
CYP116B3 with a N-terminal His6-tag was recombinantly expressed in E. coli 
BL21(DE3) and purified by IMAC. In order to increase the amount of soluble 
CYP116B3 by reduction of inclusion body formation, His-tag variants of this enzyme 
were created as the His-tag might influence the folding of the protein. According to 
the subsequent determination of CYP116B3 concentration in the soluble protein 
fraction after expression, the amount of soluble CYP116B3 was increased for all new 
His-tag variants, especially for CYP116B3_Var1, which has a N-terminal MGSS-His6-
sequence. This effect of an increased amount of soluble CYP116B3 can be attributed 
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to the introduced additional three amino acids (Gly, Ser, Ser) prior to the original 
N-terminal His6-tag. An explanation for this effect could be given by the N-end rule,
164 
which states that N-terminal amino acids are known to influence a protein’s stability in 
bacteria. Determination of activity of CYP116B3 by fluorescence spectroscopic 
analysis of the conversion of 7-ethoxycoumarin to 7-hydroxycoumarin and calculation 
of the product formation rate demonstrated CYP116B3_Var1 to be the most active 
His-tag variant of CYP116B3, whereas CYP116B3_Var2 (C-terminal His6-tag) was 
completely inactive. These results clearly confirm the significant influence of the His-
tag on the enzymes properties. 
As the His-tag variant CYP116B3_Var1 displayed best expression, was successfully 
purified and showed highest activity towards the model substrate 7-ethoxycoumarin, 
it was applied as basis for subsequent investigations concerning the conversion of 
aromatic substrates of interest aiming at the synthesis of vanillin. In initial CYP116B3-
catalyzed in vitro biotransformation reactions of the respective aromatic substrates, 
only for the substrate 3-methylanisole a low total conversion of 2.1% was determined 
with m-cresol as main product and 3-methoxybenzyl alcohol and 4-methoxy-
2-methylphenol as byproducts. Hence, though the total conversion was rather low, 
CYP116B3 did not show an explicit selectivity for any of the possible products. 
Nevertheless, a slight preference for demethylation over aromatic or aliphatic 
hydroxylation was detected. This is in accordance with the results reported by Liu 
and co-workers,140 where dealkylation is preferred over aromatic hydroxylation and 
aliphatic side-chain oxidation of aromatic substrates is preferred over aromatic ring 
hydroxylation. Hence, CYP116B3 is a good candidate for further protein engineering 
approaches, as a basic level of activity towards the substrate of interest is already 
present in the wild type enzyme. 
 
As a third and alternative enzyme to the above mentioned ones CYP102A1 from 
B. megaterium was investigated in this work. From previous studies both wild type 
enzyme and some variants of CYP102A1 were known to convert various aromatic 
substrates.121, 165 Hence the members of a focused CYP102A1 mutant library 
consisting of the wild type and 24 single and double mutant variants, which were 
selectively replaced by a set of five hydrophobic amino acids (alanine, leucine, 
isoleucine, phenylalanine, valine) in the positions F87 and A328 by means of rational 
protein design in a previous study,132 were now screened for their applicability in the 
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in vitro biotransformation of aromatic substrates concerning the synthesis of vanillin 
according to the proposed vanillin synthesis cascade reaction (Figure 1.8, 
introduction).  
Only with 3-methylanisole as a substrate, conversion was detected while the other 
substrates were not converted at all. Thereby the marginal conversion of 
3-methylanisole by aromatic hydroxylation catalyzed by the CYP102A1 wild type is in 
accordance with the results reported in a preceding study.171 Single and double 
mutant variants, especially those having a valine instead of a phenylalanine at 
position 87, displayed a much higher substrate conversion compared to the wild type. 
This is assumed to arise from the smaller size of the side-chain of valine compared to 
the one of phenylalanine, which allows a better access and positioning of the 
substrate to the activated heme oxygen in the active site. Such a beneficial effect of 
the F87V mutation on the hydroxylation of aromatic compounds, which resulted in an 
improved NADPH consumption rate and coupling efficiency, was described by 
Sulistyaningdyah and co-workers in a previous work.172 The formation of a variety of 
side-products accompanying the production of the intended intermediate compounds 
3-methoxybenzyl alcohol and 4-methylguaiacol is an indication for a rather inefficient 
positioning of the substrate in the active site, resulting in a relatively low regio- and 
chemoselectivity of the most active variants. Consequently, oxidation of the aromatic 
ring occurred in three of the four possible positions with a preference for the para 
position to the methoxy group. This reaction yielded 4-methoxy-2-methylphenol as 
main product of the 3-methylanisole conversion. In addition to aromatic and benzylic 
hydroxylation a demethylation reaction of the methoxy group was detected. Thus, the 
different types of reaction catalyzed by variants of CYP102A1 clearly demonstrate 
the catalytic flexibility of this enzyme. Solely oxidation of the aromatic ring in meta 
position to the methoxy group did not occur in the investigated in vitro 
biotransformations. This is in conformity with the results of a study, where among 
other benzene derivatives the conversion of toluene and anisole was investigated. 
The reported conversion reaction was catalyzed by CYP102A1 wild type with the 
assistance of short-alkyl-chain perfluorinated carboxylic acids. These molecules 
serve as ‘dummy’ substrates as they have a structural similarity to the natural 
substrate. Partial binding of these molecules to the substrate binding site of 
CYP102A1 was reported to initiate the activation of molecular oxygen leading to the 
generation of compound I, while small non-natural substrate molecules can occupy 
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the residual space in the active site and thus are efficiently hydroxylated. Here, only 
the ortho and para hydroxylated products, with a preference for the ortho position, 
were reported.173 Steric properties of the active site rather than C-H bond reactivity 
were indicated to be important factors for the selectivity of aromatic and benzylic 
hydroxylation.174 
 
4.2   Expansion of  the spectrum of enzymes and variants for further 
biotransformations 
 
The focus was now set on CYP116B3 and CYP102A1, as the wild types of both 
enzymes were already shown to accept 3-methylanisole as a substrate. Optimization 
of these enzymes was necessary to yield higher substrate conversions with 
3-methylanisole, to yield more of the intermediate products of the vanillin synthesis 
cascade reaction and to expand the substrate profile to the intermediate substrates 
3-methoxybenzyl alcohol and 4-methylguaiacol. The investigation of a rationally 
designed focused mutant library of CYP102A1 was already shown to be an efficient 
tool of enzyme engineering. Previous experimental data indicated that the wild type 
enzyme of CYP116B3 displays a higher initial activity towards 3-methylanisole 
compared to the wild type enzyme of CYP102A1 and thus, a focused mutant library 
of CYP116B3 was generated. Therefor a homology model of the monooxygenase 
domain of CYP116B3 was created, in cooperation with the bioinformatics group of 
the ITB (University of Stuttgart, Stuttgart, Germany) by Dr. Łukasz Gricman, based 
on structural information by employment of a standard numbering scheme for class I 
P450 sequences. After generation of the CYP116B3 homology model a focused 
minimal mutant library of CYP116B3 was created in analogy to the focused mutant 
library of CYP102A1. Therefore the five amino acid positions A109, V316, A317, 
A318 and F420 were chosen based on information from literature,141 from the protein 
sequence and from the protein structure according to the homology model. Each of 
the selected amino acids was replaced by the hydrophobic amino acids alanine, 
phenylalanine, isoleucine, leucine and valine, respectively. While, according to a 
previously generated homology model, the alanine at amino acid position 109 was 
reported to be positioned directly above the heme group in a small region at the 
ceiling of the substrate binding pocket,141 according to the newly generated homology 
model it is positioned in rather big distance to the active site. However, its location on 
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a flexible loop region could explain its influence on the enzymes activity reported by 
Liu and co-workers after replacement of alanine by phenylalanine.141 Valine at 
position 316, identified as the fifth amino acid after the highly conserved ExxR 
motive, was assumed to play an important role in the positioning of the substrate to 
the activated heme oxygen in the active site, as amino acids at this position were 
reported to be located close to the heme group and pointing towards the heme 
center.131 This anticipated central position of V316 is in agreement with the 
positioning shown in the homology model of CYP116B3. In addition, the residues 
A317 and A318, located in direct proximity to V316 and thus in central positions in 
the active site, as well as F420, positioned at the entrance to the enzymes active site 
opposite to V316, A317 and A318, are located on loop regions according to the 
homology model. 
Subsequent to the generation of the CYP116B3 mutant library, consisting of the wild 
type and 20 single mutant variants, by site-directed mutagenesis, all CYP116B3 
variants were expressed in E. coli BL21(DE3) followed by determination of 
concentration by CO differential spectral analysis. The activity of the enzyme variants 
was examined with the 7-ethoxycoumarin assay. Only one out of the 20 CYP116B3 
variants was completely inactive while the residual 19 variants were shown to be 
active towards 7-ethoxycoumarin. Subsequently, the relative activity of the 
CYP116B3 variants compared to the wild type enzyme was determined. While 
variant V316F was completely inactive, four of the variants displayed an increased 
relative activity with V316L as the most active one (almost six times higher activity 
compared to the wild type enzyme). This clearly indicates the importance of the 
amino acid position 316. However, most of the amino acid exchanges located in the 
other addressed positions also resulted in altered enzyme activity. Thereby the 
activity for the A109F variant was increased almost threefold compared to the wild 
type which is in agreement with the increase in activity towards 7-ethoxycoumarin 
reported in a former study.141 Interestingly, the mutations of the alanine and 
phenylalanine in the positions 318 and 420, respectively, led to a decrease in activity 
in all investigated cases. We assume the amino acid residues in these positions to be 
involved in the positioning of the substrate to the active site heme oxygen. 
Finally, in order to investigate the hydroxylation activity of the CYP116B3 variants, a 
screening of the focused CYP116B3 library with the respective aromatic substrates 
concerning the synthesis of vanillin according to the proposed cascade reaction 
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(Figure 1.8, introduction) was performed. With 3-methylanisole as substrate only 
three different products were found, namely 3-methoxybenzyl alcohol, 4-methoxy-
2-methylphenol and m-cresol, while most of the variants showed a preference for the 
demethylation reaction of the methoxy group yielding m-cresol as main product. This 
could be seen as an indication for a rather strict selectivity of CYP116B3 compared to 
the results obtained with CYP102A1 variants. On the other hand, selectivity of 
CYP116B3 might decrease with an increasing activity of the enzyme, which was 
rather low for all variants. Only for V316L, the most active variant, activity compared 
to the CYP116B3 wild type was increased about 2.5 times to 5.4%, which is still 
lower compared to selected variants of the CYP102A1 mutant library. An altered 
chemoselectivity was detected solely for the variants F420V and F420I, with a shift 
from demethylation towards aromatic hydroxylation and, for F420I, also towards 
benzylic hydroxylation as the preferred reaction. This clearly indicates that, though 
the activity could not be increased dramatically for these variants, the amino acid at 
position 420 and its size determines the catalytic reaction by influencing the enzymes 
chemoselectivity. Very interestingly three variants were found to successfully convert 
4-methylguaiacol to vanillyl alcohol by benzylic hydroxylation of the methyl group, 
though to a very low extent. These are again the variants V316L, F420I, and F420V 
mentioned above. Hence, the generation of a focused mutant library of CYP116B3 
yielded interesting results for the conversion of aromatic substrates concerning the 
intended vanillin synthesis reaction. 
 
Regarding CYP102A1, in a previous study additional mutations in position 437 were 
shown to be of benefit for the conversion of (4R)-limonene to perillyl alcohol. This 
was believed to be induced by the strong influence of the respective amino acid at 
position 437 on the orientation of the substrate to the heme oxygen in the active 
site.168 For this reason, triple mutant variants based on F87V/A328L, exhibiting the 
highest total conversion of 3-methylanisole in initial biotransformations, combined 
with an additional amino acid exchange of leucine at position 437 in the wild type to 
other hydrophobic amino acids (alanine, phenylalanine, isoleucine and valine) were 
investigated. Hydrophobic amino acids were chosen, as a preference for those in 
substrate-interacting positions of P450s was reported.131 After expression, soluble 
protein fractions of the triple mutant variants were screened for in vitro 
biotransformation of aromatic substrates towards the intended cascade synthesis of 
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vanillin. All variants were found to be active exclusively towards 3-methylanisole 
while enzymatic activity differed strongly from a dramatic decrease to an almost 
equal value compared to the activity of the double mutant F87V/A328L. Additionally, 
a shift in product distribution was determined as the result of an altered 
chemoselectivity of the triple mutant variants towards a higher preference for benzylic 
hydroxylation, yielding twice as much 3-methoxybenzyl alcohol as product as before. 
The altered selectivity is presumed to be a result of the expected change in the 
orientation of the substrate to the activated heme oxygen.  
Due to the fact that 3-methylanisole was successfully converted in in vitro 
biotransformations with CYP102A1 variants, but neither 3-methoxybenzyl alcohol nor 
4-methylguaiacol was converted to vanillyl alcohol or even accepted as a substrate 
for any kind of reaction, this second reaction step of the intended cascade reaction 
was a bottleneck towards the synthesis of vanillin. However, in principle, both 
benzylic hydroxylation of the methyl group as well as aromatic hydroxylation in para 
position to the methyl group was detected, with a preference for benzylic 
hydroxylation, as shown with 3-methylanisole as substrate. Therefore, in order to 
gain more information about this bottleneck of the cascade reaction, MD simulations 
were carried out by Dr. Alexander Seifert from the bioinformatics group of the ITB 
(University of Stuttgart, Stuttgart, Germany). As the route via benzylic hydroxylation 
of 4-methylguaiacol was thought to be more promising due to the above mentioned 
preference for benzylic hydroxylation of the CYP102A1 variants, the MD simulations 
were performed with 4-methylguaiacol as substrate molecule in combination with a 
CYP102A1 double mutant variant to examine if the substrate binds in the enzymes 
active site in a productive manner. According to the results obtained by the MD 
simulations this seems feasible. However, in some of the MD simulations the amino 
acids R47 and Y51, located in the substrate access channel in a more distant pocket 
to the active site, were identified to stabilize the 4-methylguaiacol substrate molecule 
via hydrogen bonds. This could be an explanation for the inactivity of the CYP102A1 
variants towards conversion of 4-methylguaiacol, as this molecule is stabilized in the 
substrate channel impeding access of further substrate molecules to the active site. 
R47 and Y51 have already been reported in previous studies, to be key residues 
positioned at the entrance of the substrate channel.121 Substitution of R47 and Y51 
by hydrophobic residues has been shown to result in an increased activity towards 
various substrates. For example, a six-fold increased activity in the epoxidation of 
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geranylacetone was measured.175 Hence the polar substrate channel residues R47 
and Y51 were replaced by the hydrophobic residues leucine and phenylalanine by 
means of site-directed mutagenesis in selected single, double and triple mutant 
variants of CYP102A1, which displayed the highest activity with 3-methylanisole in 
previous investigations, yielding R47L/Y51F-variants, respectively. Screening of 
these variants for conversion of 4-methylguaiacol as well as other aromatic 
(intermediate) substrates of the intended cascade synthesis of vanillin revealed that, 
as expected, 4-methylguaiacol was successfully converted to vanillyl alcohol by most 
of the investigated variants. This clearly confirms the successful elimination of 
4-methylguaiacol stabilization in the substrate access channel in distance to the 
active site. As a consequence the substrate spectrum of the respective CYP102A1 
variants was expanded. 
 
To address conversion of vanillyl alcohol to vanillin in a cascade, the portfolio of 
investigated enzymes was expanded to a vanillyl alcohol oxidase from 
P. simplicissimum. This enzyme was reported in literature not only to convert vanillyl 
alcohol to vanillin with high selectivity but also to catalyze the conversion of 
4-methylguaiacol to vanillin via vanillyl alcohol as intermediate product.72, 169 
Consequently VAO seemed to be an ideal candidate for application in cascade 
synthesis of vanillin reported in this work. As not only the wild type enzyme but also 
some variants with intensively increased catalytic efficiency (kcat/KM) towards 
4-methylguaiacol have been reported in literature,69 the single mutant variants F454Y 
and T505S were generated by site-directed mutagenesis based on the VAO wild type 
gene (vaoA) which was employed as a codon-optimized gene for the heterologous 
expression in E. coli. Though the majority of the protein seemed to be present in the 
insoluble protein fraction after cell lysis, activity of the wild type enzyme and the 
single mutant variants F454Y and T505S was successfully tested with soluble protein 
fractions in in vitro biotransformations of both vanillyl alcohol and 4-methylguaiacol as 
substrates. Thereby variant F454Y displayed highest activity towards 4-methyl-
guaiacol at pH 7.5 yielding exclusively vanillin as product. As vanillyl alcohol was 
even completely converted to vanillin without any byproduct or overoxidation product 
formation, this demonstrates not only the activity but also the high selectivity of the 
investigated VAO both for the wild type and for the variants thereof. In addition, none 
of the investigated aromatic compounds, which were previously reported to be 
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yielded as byproducts in the conversion of 3-methylanisole by CYP102A1 variants, 
was accepted as a substrate. All these results indicate that the VAO variant F454Y 
could be an ideal candidate for application in one-pot cascade reactions for the 
synthesis of vanillin.        
 
4.3   In vitro one-pot cascade synthesis of vanillin 
 
In order to realize the proposed multi-enzymatic three-step cascade reaction for the 
synthesis of vanillin (Figure 1.8, introduction) a variety of enzymes and variants 
thereof was investigated previously. Consequently, the best enzyme variants were 
combined in in vitro one-pot cascade reactions for the conversion of 3-methylanisole. 
Thus, in a first reaction setup the CYP102A1 variants A328L and 
R47L/Y51F/F87V/A328V catalyzing the first and second step of the cascade 
reaction, respectively, were combined. Though the successive time-shifted addition 
of R47L/Y51F/F87V/A328V after half of the reaction time, instead of direct addition of 
both enzymes from the beginning, was beneficial concerning total substrate 
conversion (increase from 24.7% to 30.3%) and formation of 4-methylguaiacol 
(increase from 1.2% to 2.4%), 4-methoxy-2-methylphenol was found as main product 
and no production of vanillyl alcohol was measured. This is assumed to be a result of 
the low amount of 4-methylguaiacol that is produced by A328L, in combination with 
the competitive conversion of 3-methylanisole and 4-methylguaiacol by the second 
enzyme, with a clear preference for 3-methylanisole conversion. The addition of 
catalase and superoxide dismutase was investigated in order to reduce the 
concentration of reactive oxygen species like hydrogen peroxide or superoxide, 
which could have arisen from inefficient coupling in CYP102A1 and might possibly 
negatively influence the enzymes activity. 
As an alternative, in a second reaction setup the CYP102A1 quadruple variant 
R47L/Y51F/F87V/A328V was replaced by the VAO variant F454Y in order to directly 
convert intermediately produced 4-methylguaiacol via vanillyl alcohol to vanillin. With 
22.9% total conversion of 3-methylanisole was comparable to the first reaction setup 
after 2 h and could be increased by successive addition of the VAO variant F454Y 
after half of the reaction time to 29.0%, too. However, with this setup the formation of 
1.2% vanillin was detected, accompanied by a decreased amount of 4-methyl-
guaiacol in the mixture, while vanillyl alcohol was not detected at all due to immediate 
Discussion 
113 
 
and complete conversion to vanillin. These results definitely confirm the realization of 
the intended in vitro one-pot synthesis of vanillin in a multi-enzymatic three-step 
cascade reaction following the proposed route from 3-methylanisole via 4-methyl-
guaiacol and vanillyl alcohol to vanillin (Figure 1.8, introduction). Highest vanillin 
formation of 2% was determined in a reaction setup with successive addition of both 
enzymes and a total conversion of 31.4% after a total reaction time of 8 h. 
 
4.4   In vivo one-pot cascade synthesis of vanillin 
 
To demonstrate the proof-of-principle, E. coli BL21(DE3) was chosen as host for 
expression of CYP102A1 variant A328L and VAO variant F454Y using a two-plasmid 
system and for subsequent whole-cell substrate conversion. Success of the 
expression of both enzymes was confirmed by SDS-PAGE analysis showing bands 
at expected molecular weights. Finally, harvested whole cells were applied in a 
biotransformation medium for in vivo conversion of 3-methylanisole. 4-Methoxy-
2-methylphenol was the first product coming up and persisted over the whole period 
of reaction as the main product detected in the samples. This product formation can 
surely be attributed to the selectivity of the CYP102A1 variant A328L. In contrast, the 
formation of 4-methylguaiacol increased at the beginning to a low level followed by a 
decrease until it completely disappeared while the formation of vanillin steadily 
increased up to a final concentration of 1.1%. Surely the reaction performed by 
CYP102A1 variant A328L is the limiting step of the cascade reaction. However, other 
effects like substrate delivery into and product release from the host cell, substrate 
and product inhibition and/or toxicity, oxygen supply, cofactor availability and 
regeneration, stability of the P450 enzyme, host metabolic effects, cell viability/host 
cell death as well as other unknown factors could have had an influence on total 
conversion, concomitantly on product formation and thus finally on the synthesis of 
vanillin. Though, compared to the in vitro one-pot results, the final product formation 
of vanillin was lower in the in vivo reactions the outcome of the investigations was 
basically the same.  
In summary, as a proof-of-principle, the valuable aromatic flavor compound vanillin 
was synthesized in a novel in vivo two-enzymatic three-step cascade system from 
the simple and low-cost chemical starting material 3-methylanisole. Though further 
optimizations are inevitable, the newly designed biocatalytic cascade for the 
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exemplary synthesis of vanillin, realized within this project, demonstrates the 
capability of biocatalysis. 
Conclusion and outlook 
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5   Conclusion and outlook 
 
The selective hydroxylation of aromatic compounds, which is one of the most 
challenging chemical reactions, was addressed enzymatically within the present 
project. Therefore as an example of consecutive enzyme-catalyzed oxidation 
reactions, a multi-enzymatic three-step cascade reaction starting with the simple low-
cost aromatic substrate 3-methylanisole was investigated as a novel route to the 
valuable aromatic compound vanillin. 
In a first step a defined set of enzymes had to be selected for initial investigations. In 
this context, the m-hydroxybenzoate hydroxylase MobA from C. testosteroni GZ39 
and the cytochrome P450 monooxygenases CYP116B3 from R. ruber DSM 44319 
and CYP102A1 from B. megaterium ATCC 14581 as well as variants thereof were 
chosen as promising enzyme candidates. After successful recombinant expression in 
E. coli, purification of some of the enzymes and determination of activity, the 
enzymes were applied in in vitro biotransformation reactions, combined with efficient 
cofactor recycling, for the selective oxidation of both aromatic substrate and 
intermediate compounds of the pursued vanillin synthesis pathway. In addition to the 
wild type enzymes some variants thereof were created by means of rational protein 
design and examined in in vitro reactions, too. While MobA was not suitable for the 
intended purpose as it did not show activity with any of the investigated aromatic 
compounds of interest, CYP116B3 displayed a basic level of activity already with the 
wild type enzyme. Moreover, by investigation of a focused mutant library of 
CYP102A1, several single and double mutant variants were identified with a higher 
activity towards the substrate 3-methylanisole compared to the wild type. Hence, for 
the synthesis of both target intermediate products, namely 3-methoxybenzyl alcohol 
and 4-methylguaiacol, enzyme candidates were found, though the byproduct 
4-methoxy-2-methylphenol was produced as main product in most of the conversion 
reactions. 
In order to improve both activity and selectivity of the biocatalysts to gain higher 
yields of intermediate products and subsequent conversion of those to vanillyl alcohol 
as precursor of vanillin, further enzyme variants of CYP102A1 and CYP116B3 were 
created by rational protein design. For this reason, for CYP116B3 a focused mutant 
library based on literature, sequence and structure (homology model) information 
was generated in analogy to the focused CYP102A1 mutant library. However, none 
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of the variants showed a dramatic increase in either activity or selectivity towards the 
synthesis of the intermediate products 3-methoxybenzyl alcohol and 
4-methylguaiacol, nor did any of the new variants display significant conversion of 
those intermediate compounds to vanillyl alcohol. 
Specific and more detailed investigation of the second step of the intended cascade 
reaction by molecular dynamics simulations, with a defined focus on the conversion 
of 4-methylguaiacol to vanillyl alcohol, yielded improved variants of CYP102A1, that 
were successfully applied in respective in vitro biotransformation reactions. In 
addition, rationally designed variants of a vanillyl alcohol oxidase from 
P. simplicissimum were proven to be highly active towards 4-methylaguaiacol, 
accompanied by a strict selectivity yielding exclusively vanillin as final product of 
interest, by catalysis of both the conversion of 4-methylguaiacol to vanillyl alcohol 
and the consecutive conversion of vanillyl alcohol to vanillin. 
Consequently enzymes and variants thereof were identified for each of the necessary 
reaction steps of the intended cascade synthesis of vanillin. The most suitable ones, 
CYP102A1 variant A328L and VAO variant F454Y, were combined in one reaction 
system both in vitro in one-pot biotransformation reactions and in vivo in 
biotransformations with whole cells of E. coli as expression and production host. As a 
proof-of-principle, vanillin was successfully produced in both systems. However, the 
yield of vanillin was rather low due to the bottleneck of the reaction, which is the 
sufficient production of the intermediate compound 4-methylguaiacol in the first step 
of the cascade reaction, to supply the highly active and selective VAO variant with 
enough substrate. 
 
In order to optimize the cascade, alternative enzymes, which could be better 
applicable for the addressed task, could be searched for by proteome analysis after 
screening of a diversity of strains for growth on minimal media containing the 
substrate of interest as sole carbon source. Moreover, as an alternative approach to 
rational protein design, a semi-rational approach like iterative saturation mutagenesis 
or combinatorial active site saturation testing (CASTing) in the identified key residues 
might be applied, or a random enzyme engineering method like directed evolution 
could help to find better variants of the chosen enzymes, though in this case, an 
efficient high throughput screening system would be necessary. These approaches 
could help to overcome the bottleneck reaction of the established cascade, the 
Conclusion and outlook 
117 
 
conversion of 3-methylanisole to 4-methylguaiacol. In addition, enzymes and variants 
which are able to convert the intermediate compound 3-methoxybenzyl alcohol to 
vanillyl alcohol could be identified and thus increase the substrate concentration for 
the VAO-catalyzed reaction step. Furthermore, usage of respectively diverse 
plasmids to enable selective induction of expression could be beneficial for the 
regulation of the expression of the different enzymes in the whole-cell systems. 
Regarding the production of vanillin, identification of a biological system for the 
synthesis of the substrate 3-methylanisole would be economically advantageous, as 
the produced vanillin could then be designated as ‘natural’ vanillin. Finally, the 
application of a multi-enzymatic cascade reaction approach, as described in this 
work, could be transferred to alternative substrates and products of interest to 
illustrate the versatility and capability of biocatalysis. 
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7   Supplementary material 
 
7.1   Genes, proteins, vectors, primers and strains 
 
7.1.1   Genes 
 
The genes mobA, cyp116B3 and vaoA were synthesized (GeneArt® Gene Synthesis, 
Life Technologies GmbH, Darmstadt, Germany), codon-optimized for the 
heterologous expression in E. coli. His-tags are underlined in the wild type gene 
sequences shown below. 
 
 
Codon-optimized mobA gene from Comamonas testosteroni GZ39 
ATGCAGTTTCATCTGAATGGTTTTCGTCCGGGTAATCCGCTGATTGCACCGGCAAGTCCGCTGGCACCGGCACAT
ACCGAAGCAGTTCCGAGCCAGGTTGATGTTCTGATTGTTGGTTGTGGTCCGGCAGGTCTGACCCTGGCAGCACAG
CTGGCAGCATTTCCGGATATTCGTACCTGTATTGTGGAACAGAAAGAAGGTCCGATGGAACTGGGTCAGGCAGAT
GGTATTGCATGTCGTACCATGGAAATGTTTGAAGCATTTGAATTTGCCGATAGCATCCTGAAAGAAGCATGTTGG
ATTAACGATGTGACCTTTTGGAAACCTGATCCGGCACAGCCTGGTCGTATTGCACGTCATGGTCGTGTTCAGGAT
ACCGAAGATGGTCTGAGCGAATTTCCGCATGTTATTCTGAATCAGGCACGTGTTCATGATCATTATCTGGAACGT
ATGCGTAATAGCCCGAGCCGTCTGGAACCGCATTATGCACGTCGTGTTCTGGATGTTAAAATTGATCATGGTGCA
GCAGATTATCCGGTTACCGTTACCCTGGAACGTTGTGATGCAGCACATGCAGGTCAGATTGAAACCGTTCAGGCA
CGTTATGTTGTGGGTTGTGATGGTGCACGTAGCAATGTTCGTCGTGCAATTGGTCGTCAGCTGGTTGGTGATAGC
GCAAATCAGGCATGGGGTGTTATGGATGTTCTGGCAGTTACCGATTTTCCGGATGTTCGTTATAAAGTTGCCATT
CAGAGCGAACAGGGTAATGTTCTGATTATTCCGCGTGAAGGTGGTCATCTGGTTCGTTTTTATGTGGAAATGGAT
AAACTGGATGCCGATGAACGTGTTGCAAGCCGTAATATTACCGTTGAACAGCTGATTGCAACCGCACAGCGTGTT
CTGCATCCGTATAAACTGGACGTTAAAAATGTTCCGTGGTGGTCAGTGTATGAAATTGGTCAGCGTATTTGCGCC
AAATATGATGATGTTGCAGATGCAGTTGCAACACCGGATAGTCCGCTGCCTCGTGTTTTTATTGCCGGTGATGCA
TGTCATACCCATAGCCCGAAAGCAGGTCAGGGTATGAATTTTAGCATGCAGGATTCATTTAATCTGGGTTGGAAA
CTGGCAGCAGTTCTGCGTAAACAGTGTGCACCGGAACTGCTGCATACCTATAGCAGCGAACGTCAGGTTGTTGCA
CAGCAGCTGATTGATTTTGATCGTGAATGGGCCAAAATGTTTAGCGATCCGGCAAAAGAAGGTGGTCAAGGCGGA
GTTGATCCGAAAGAATTTCAGAAATATTTCGAACAGCACGGTCGTTTTACCGCAGGCGTTGGCACCCATTATGCA
CCGAGCCTGCTGACAGGTCAGGCAAGCCATCAGGCACTGGCAAGCGGTTTTACCGTTGGTATGCGTTTTCATAGC
GCACCGGTTGTTCGTGTTAGTGATGCAAAACCGCTGCAGCTGGGTCATTGTGGTAAAGCAGATGGTCGTTGGCGT
CTGTATGCATTTGCAGGTCAGAATGATCTGGCACAGCCGGAAAGCGGTCTGCTGGCACTGTGTCGTTTTCTGGAA
AGTGATGCAGCTTCACCGCTGCGTCGTTTTACCCCGAGCGGTCAGGATATTGATAGCATTTTTGATCTGCGTGCC
ATTTTTCCGCAGGCATATACCGAAGTTGCACTGGAAACCCTGCCTGCACTGCTGCTGCCTCCGAAAGGTCAGCTG
GGTATGATTGATTATGAAAAAGTGTTCAGTCCGGATCTGAAAAATGCAGGCCAGGATATTTTCGAACTGCGTGGT
ATTGATCGTCAGCAGGGTGCACTGGTTGTTGTTCGTCCGGATCAGTATGTTGCACAGGTTCTGCCGCTGGGTGAT
CATGCAGCACTGAGCGCATATTTTGAAAGCTTTATGCGTGCACATCATCATCATCACCACTAA 
 
GenBank ID of not codon-optimized gene sequence: AY450844 
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Codon-optimized cyp116B3 gene from Rhodococcus ruber DSM 44319 
ATGCATCATCATCATCACCATAGCGCAAGCGTTCCGGCAAGCGCATGTCCGGTTGATCATGCAGCACTGGCAGGC
GGTTGTCCGGTTAGCACCAATGCAGCAGCATTTGATCCGTTTGGTCCGGCATATCAGGCAGATCCGGCAGAAAGC
CTGCGTTGGAGCCGTGATGAAGAACCGGTTTTTTATAGTCCGGAACTGGGTTATTGGGTTGTTACCCGTTATGAA
GATGTGAAAGCCGTGTTTCGTGATAATCTGGTTTTTAGTCCGGCAATTGCCCTGGAAAAAATTACACCGGTTAGC
GAAGAAGCAACCGCAACCCTGGCACGTTATGATTATGCAATGGCACGTACCCTGGTGAATGAAGATGAACCGGCA
CACATGCCTCGTCGTCGTGCACTGATGGATCCGTTTACCCCGAAAGAACTGGCACATCATGAAGCAATGGTTCGT
CGTCTGACCCGTGAATATGTTGATCGTTTTGTTGAAAGCGGTAAAGCAGATCTGGTTGATGAAATGCTGTGGGAA
GTTCCGCTGACCGTTGCACTGCATTTTCTGGGTGTTCCGGAAGAGGATATGGCAACCATGCGTAAATATTCAATT
GCCCATACCGTTAATACCTGGGGTCGTCCGGCACCGGAAGAACAGGTTGCAGTTGCAGAAGCAGTTGGTCGTTTT
TGGCAGTATGCAGGCACCGTTCTGGAAAAAATGCGTCAGGATCCGAGCGGTCATGGTTGGATGCCGTATGGTATT
CGTATGCAGCAGCAGATGCCGGATGTTGTTACCGATAGCTATCTGCATAGCATGATGATGGCAGGTATTGTTGCA
GCACATGAAACCACCGCAAATGCAAGCGCAAATGCATTTAAACTGCTGCTGGAAAATCGTCCGGTTTGGGAAGAA
ATTTGTGCAGATCCGAGCCTGATTCCGAATGCAGTTGAAGAATGTCTGCGTCATAGCGGTAGCGTTGCAGCATGG
CGTCGTGTTGCAACCACCGATACCCGTATTGGTGATGTTGATATTCCGGCAGGCGCAAAACTGCTGGTTGTTAAT
GCAAGCGCCAATCATGATGAACGTCATTTTGATCGTCCGGATGAATTTGATATTCGTCGTCCGAATAGCAGCGAT
CATCTGACCTTTGGTTATGGTAGCCATCAGTGTATGGGTAAAAATCTGGCACGTATGGAAATGCAGATCTTTCTG
GAAGAACTGACCACCCGTCTGCCGCACATGGAACTGGTTCCGGATCAAGAATTTACCTATCTGCCGAATACCAGC
TTTCGTGGTCCGGATCATGTTTGGGTTCAGTGGGATCCGCAGGCAAATCCGGAACGTACCGATCCGGCAGTTCTG
CAGCGTCAGCATCCGGTTACCATTGGTGAACCGAGCACCCGTAGCGTTAGCCGTACCGTTACCGTTGAACGTCTG
GATCGTATTGTTGATGATGTTCTGCGTGTTGTTCTGCGTGCACCGGCAGGTAATGCACTGCCTGCATGGACACCG
GGTGCACATATTGATGTTGATCTGGGTGCACTGAGCCGTCAGTATAGCCTGTGTGGTGCACCTGATGCACCGACC
TATGAAATTGCAGTTCTGCTGGATCCGGAAAGCCGTGGTGGTAGCCGTTATGTTCATGAACAGCTGCGTGTTGGT
GGTAGCCTGCGTATTCGTGGTCCGCGTAATCATTTTGCACTGGATCCGGATGCAGAACATTATGTTTTTGTTGCC
GGTGGTATTGGTATTACACCGGTGCTGGCAATGGCAGATCATGCACGTGCTCGTGGTTGGAGCTATGAACTGCAT
TATTGTGGTCGTAATCGTAGCGGTATGGCATATCTGGAACGTGTTGCAGGTCATGGTGATCGTGCAGCTCTGCAT
GTTAGTGCCGAAGGCACCCGTGTTGATCTGGCAGCACTGCTGGCAACACCGGTGAGCGGCACCCAGATTTATGCA
TGTGGTCCGGGTCGTCTGCTGGCAGGTCTGGAAGATGCAAGCCGTCATTGGCCTGATGGTGCACTGCATGTTGAA
CATTTTACCAGCAGCCTGACCGCACTGGATCCTGACGTTGAACATGCATTTGATCTGGATCTGCGTGATAGTGGT
CTGACCGTTCGTGTTGAACCGACCCAGACCGTTCTGGATGCACTGCGTGCAAATAATATTGATGTTCCGAGCGAT
TGCGAAGAGGGTCTGTGTGGTAGCTGTGAAGTTACCGTGCTGGAAGGTGAAGTTGATCATCGTGATACCGTTCTG
ACCAAAGCAGAACGTGCAGCAAATCGTCAGATGATGACCTGTTGTAGCCGTGCATGTGGTGATCGTCTGACCCTG
CGTCTGTAA 
 
GenBank ID of not codon-optimized gene sequence: AY957485 
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cyp102A1 gene from Bacillus megaterium ATCC 14581 
ATGACAATTAAAGAAATGCCTCAGCCAAAAACGTTTGGAGAGCTTAAAAATTTACCGTTATTAAACACAGATAAA
CCGGTTCAAGCTTTGATGAAAATTGCGGATGAATTAGGAGAAATCTTTAAATTCGAGGCGCCTGGTCGTGTAACG
CGCTACTTATCAAGTCAGCGTCTAATTAAAGAAGCATGCGATGAATCACGCTTTGATAAAAACTTAAGTCAAGCG
CTTAAATTTGTACGTGATTTTGCAGGAGACGGGTTATTTACAAGCTGGACGCATGAAAAAAATTGGAAAAAAGCG
CATAATATCTTACTTCCAAGCTTCAGTCAGCAGGCAATGAAAGGCTATCATGCGATGATGGTCGATATCGCCGTG
CAGCTTGTTCAAAAGTGGGAGCGTCTAAATGCAGATGAGCATATTGAAGTACCGGAAGACATGACACGTTTAACG
CTTGATACAATTGGTCTTTGCGGCTTTAACTATCGCTTTAACAGCTTTTACCGAGATCAGCCTCATCCATTTATT
ACAAGTATGGTCCGTGCACTGGATGAAGCAATGAACAAGCTGCAGCGAGCAAATCCAGACGACCCAGCTTATGAT
GAAAACAAGCGCCAGTTTCAAGAAGATATCAAGGTGATGAACGACCTAGTAGATAAAATTATTGCAGATCGCAAA
GCAAGCGGTGAACAAAGCGATGATTTATTAACGCATATGCTAAACGGAAAAGATCCAGAAACGGGTGAGCCGCTT
GATGACGAGAACATTCGCTATCAAATTATTACATTCTTAATTGCGGGACACGAAACAACAAGTGGTCTTTTATCA
TTTGCGCTGTATTTCTTAGTGAAAAATCCACATGTATTACAAAAAGCAGCAGAAGAAGCAGCACGAGTTCTAGTA
GATCCTGTTCCAAGCTACAAACAAGTCAAACAGCTTAAATATGTCGGCATGGTCTTAAACGAAGCGCTGCGCTTA
TGGCCAACTGCTCCTGCGTTTTCCCTATATGCAAAAGAAGATACGGTGCTTGGAGGAGAATATCCTTTAGAAAAA
GGCGACGAACTAATGGTTCTGATTCCTCAGCTTCACCGTGATAAAACAATTTGGGGAGACGATGTGGAAGAGTTC
CGTCCAGAGCGTTTTGAAAATCCAAGTGCGATTCCGCAGCATGCGTTTAAACCGTTTGGAAACGGTCAGCGTGCG
TGTATCGGTCAGCAGTTCGCTCTTCATGAAGCAACGCTGGTACTTGGTATGATGCTAAAACACTTTGACTTTGAA
GATCATACAAACTACGAGCTGGATATTAAAGAAACTTTAACGTTAAAACCTGAAGGCTTTGTGGTAAAAGCAAAA
TCGAAAAAAATTCCGCTTGGCGGTATTCCTTCACCTAGCACTGAACAGTCTGCTAAAAAAGTACGCAAAAAGGCA
GAAAACGCTCATAATACGCCGCTGCTTGTGCTATACGGTTCAAATATGGGAACAGCTGAAGGAACGGCGCGTGAT
TTAGCAGATATTGCAATGAGCAAAGGATTTGCACCGCAGGTCGCAACGCTTGATTCACACGCCGGAAATCTTCCG
CGCGAAGGAGCTGTATTAATTGTAACGGCGTCTTATAACGGTCATCCGCCTGATAACGCAAAGCAATTTGTCGAC
TGGTTAGACCAAGCGTCTGCTGATGAAGTAAAAGGCGTTCGCTACTCCGTATTTGGATGCGGCGATAAAAACTGG
GCTACTACGTATCAAAAAGTGCCTGCTTTTATCGATGAAACGCTTGCCGCTAAAGGGGCAGAAAACATCGCTGAC
CGCGGTGAAGCAGATGCAAGCGACGACTTTGAAGGCACATATGAAGAATGGCGTGAACATATGTGGAGTGACGTA
GCAGCCTACTTTAACCTCGACATTGAAAACAGTGAAGATAATAAATCTACTCTTTCACTTCAATTTGTCGACAGC
GCCGCGGATATGCCGCTTGCGAAAATGCACGGTGCGTTTTCAACGAACGTCGTAGCAAGCAAAGAACTTCAACAG
CCAGGCAGTGCACGAAGCACGCGACATCTTGAAATTGAACTTCCAAAAGAAGCTTCTTATCAAGAAGGAGATCAT
TTAGGTGTTATTCCTCGCAACTATGAAGGAATAGTAAACCGTGTAACAGCAAGGTTCGGCCTAGATGCATCACAG
CAAATCCGTCTGGAAGCAGAAGAAGAAAAATTAGCTCATTTGCCACTCGCTAAAACAGTATCCGTAGAAGAGCTT
CTGCAATACGTGGAGCTTCAAGATCCTGTTACGCGCACGCAGCTTCGCGCAATGGCTGCTAAAACGGTCTGCCCG
CCGCATAAAGTAGAGCTTGAAGCCTTGCTTGAAAAGCAAGCCTACAAAGAACAAGTGCTGGCAAAACGTTTAACA
ATGCTTGAACTGCTTGAAAAATACCCGGCGTGTGAAATGAAATTCAGCGAATTTATCGCCCTTCTGCCAAGCATA
CGCCCGCGCTATTACTCGATTTCTTCATCACCTCGTGTCGATGAAAAACAAGCAAGCATCACGGTCAGCGTTGTC
TCAGGAGAAGCGTGGAGCGGATATGGAGAATATAAAGGAATTGCGTCGAACTATCTTGCCGAGCTGCAAGAAGGA
GATACGATTACGTGCTTTATTTCCACACCGCAGTCAGAATTTACGCTGCCAAAAGACCCTGAAACGCCGCTTATC
ATGGTCGGACCGGGAACAGGCGTCGCGCCGTTTAGAGGCTTTGTGCAGGCGCGCAAACAGCTAAAAGAACAAGGA
CAGTCACTTGGAGAAGCACATTTATACTTCGGCTGCCGTTCACCTCATGAAGACTATCTGTATCAAGAAGAGCTT
GAAAACGCCCAAAGCGAAGGCATCATTACGCTTCATACCGCTTTTTCTCGCATGCCAAATCAGCCGAAAACATAC
GTTCAGCACGTAATGGAACAAGACGGCAAGAAATTGATTGAACTTCTTGATCAAGGAGCGCACTTCTATATTTGC
GGAGACGGAAGCCAAATGGCACCTGCCGTTGAAGCAACGCTTATGAAAAGCTATGCTGACGTTCACCAAGTGAGT
GAAGCAGACGCTCGCTTATGGCTGCAGCAGCTAGAAGAAAAAGGCCGATACGCAAAAGACGTGTGGGCTGGGTAA 
 
GenBank ID of gene sequence:  J04832 
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Codon-optimized vaoA gene from Penicillium simplicissimum CBS 170.90 
ATGAGCAAAACCCAAGAATTTCGTCCGCTGACCCTGCCTCCGAAACTGAGCCTGAGCGATTTTAATGAATTTATC
CAGGATATCATTCGCATCGTGGGTAGCGAAAATGTTGAAGTTATTAGCAGCAAAGATCAGATTGTGGATGGCAGC
TATATGAAACCGACCCATACCCATGATCCGCATCATGTTATGGATCAGGATTATTTTCTGGCAAGCGCAATTGTT
GCACCGCGTAATGTTGCAGATGTTCAGAGCATTGTTGGTCTGGCAAACAAATTTAGCTTTCCGCTGTGGCCGATT
AGCATTGGTCGTAATAGCGGTTATGGTGGTGCAGCACCGCGTGTTAGCGGTAGCGTTGTTCTGGATATGGGCAAA
AACATGAATCGTGTTCTGGAAGTTAATGTGGAAGGTGCCTATTGTGTTGTTGAACCGGGTGTTACCTATCATGAT
CTGCATAATTATCTGGAAGCCAATAACCTGCGTGATAAACTGTGGCTGGATGTTCCGGATCTGGGTGGTGGTAGC
GTTCTGGGTAATGCAGTTGAACGTGGTGTTGGTTATACCCCGTATGGTGATCATTGGATGATGCATAGCGGTATG
GAAGTTGTGCTGGCAAATGGTGAACTGCTGCGTACCGGTATGGGTGCACTGCCGGATCCGAAACGTCCGGAAACA
ATGGGTCTGAAACCGGAAGATCAGCCGTGGTCAAAAATTGCACACCTGTTTCCGTATGGTTTTGGTCCGTATATT
GATGGTCTGTTTAGCCAGAGCAATATGGGTATTGTTACCAAAATTGGCATTTGGCTGATGCCGAATCCGGGTGGT
TATCAGAGCTATCTGATTACCCTGCCGAAAGATGGTGATCTGAAACAGGCAGTTGATATTATCCGTCCGCTGCGT
CTGGGTATGGCACTGCAGAATGTTCCGACCATTCGTCATATTCTGCTGGATGCCGCAGTTCTGGGTGATAAACGT
AGCTATAGCAGTAAAACCGAACCGCTGAGTGATGAAGAACTGGATAAAATTGCAAAACAGCTGAATCTGGGTCGC
TGGAACTTTTATGGTGCACTGTATGGTCCGGAACCGATTCGTCGTGTGCTGTGGGAAACCATTAAAGATGCATTT
AGCGCAATTCCGGGTGTGAAATTCTATTTTCCGGAAGATACACCGGAAAATTCAGTTCTGCGTGTTCGTGATAAA
ACCATGCAGGGTATTCCGACCTATGATGAACTGAAATGGATTGATTGGCTGCCGAATGGTGCCCACCTGTTTTTT
AGCCCGATTGCAAAAGTTAGCGGTGAAGATGCAATGATGCAGTATGCAGTGACCAAAAAACGTTGTCAAGAAGCA
GGTCTGGATTTTATTGGCACCTTTACCGTTGGTATGCGTGAAATGCATCATATTGTGTGCATCGTGTTTAACAAA
AAAGATCTGATCCAGAAACGCAAAGTTCAGTGGCTGATGCGTACCCTGATTGATGATTGTGCAGCAAATGGTTGG
GGTGAATATCGTACCCATCTGGCATTTATGGACCAGATTATGGAAACCTATAACTGGAACAATAGCAGCTTTCTG
CGCTTTAATGAAGTGCTGAAAAATGCCGTTGATCCGAATGGTATTATTGCACCGGGTAAAAGCGGTGTTTGGCCG
AGCCAGTATAGCCATGTTACCTGGAAACTGTAA 
 
GenBank ID of not codon-optimized gene sequence (with introns): Y15627 
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7.1.2   Proteins 
 
Amino acid sequences of the wild type enzymes are shown below (without His-tags). 
 
MobA m-hydroxybenzoate hydroxylase from C. testosteroni GZ39 
GenBank: AAR25885 
MQFHLNGFRPGNPLIAPASPLAPAHTEAVPSQVDVLIVGCGPAGLTLAAQLAAFPDIRTCIVEQKEGPMELGQAD
GIACRTMEMFEAFEFADSILKEACWINDVTFWKPDPAQPGRIARHGRVQDTEDGLSEFPHVILNQARVHDHYLER
MRNSPSRLEPHYARRVLDVKIDHGAADYPVTVTLERCDAAHAGQIETVQARYVVGCDGARSNVRRAIGRQLVGDS
ANQAWGVMDVLAVTDFPDVRYKVAIQSEQGNVLIIPREGGHLVRFYVEMDKLDADERVASRNITVEQLIATAQRV
LHPYKLDVKNVPWWSVYEIGQRICAKYDDVADAVATPDSPLPRVFIAGDACHTHSPKAGQGMNFSMQDSFNLGWK
LAAVLRKQCAPELLHTYSSERQVVAQQLIDFDREWAKMFSDPAKEGGQGGVDPKEFQKYFEQHGRFTAGVGTHYA 
PSLLTGQASHQALASGFTVGMRFHSAPVVRVSDAKPLQLGHCGKADGRWRLYAFAGQNDLAQPESGLLALCRFLE
SDAASPLRRFTPSGQDIDSIFDLRAIFPQAYTEVALETLPALLLPPKGQLGMIDYEKVFSPDLKNAGQDIFELRG
IDRQQGALVVVRPDQYVAQVLPLGDHAALSAYFESFMRA 
 
CYP116B3 cytochrome P450 monooxygenase from R. ruber DSM 44319 
GenBank: AAY17950   
MSASVPASACPVDHAALAGGCPVSTNAAAFDPFGPAYQADPAESLRWSRDEEPVFYSPELGYWVVTRYEDVKAVF
RDNLVFSPAIALEKITPVSEEATATLARYDYAMARTLVNEDEPAHMPRRRALMDPFTPKELAHHEAMVRRLTREY
VDRFVESGKADLVDEMLWEVPLTVALHFLGVPEEDMATMRKYSIAHTVNTWGRPAPEEQVAVAEAVGRFWQYAGT
VLEKMRQDPSGHGWMPYGIRMQQQMPDVVTDSYLHSMMMAGIVAAHETTANASANAFKLLLENRPVWEEICADPS
LIPNAVEECLRHSGSVAAWRRVATTDTRIGDVDIPAGAKLLVVNASANHDERHFDRPDEFDIRRPNSSDHLTFGY
GSHQCMGKNLARMEMQIFLEELTTRLPHMELVPDQEFTYLPNTSFRGPDHVWVQWDPQANPERTDPAVLQRQHPV 
TIGEPSTRSVSRTVTVERLDRIVDDVLRVVLRAPAGNALPAWTPGAHIDVDLGALSRQYSLCGAPDAPTYEIAVL
LDPESRGGSRYVHEQLRVGGSLRIRGPRNHFALDPDAEHYVFVAGGIGITPVLAMADHARARGWSYELHYCGRNR
SGMAYLERVAGHGDRAALHVSAEGTRVDLAALLATPVSGTQIYACGPGRLLAGLEDASRHWPDGALHVEHFTSSL
TALDPDVEHAFDLDLRDSGLTVRVEPTQTVLDALRANNIDVPSDCEEGLCGSCEVTVLEGEVDHRDTVLTKAERA
ANRQMMTCCSRACGDRLTLRL 
 
CYP102A1 cytochrome P450 monooxygenase from B. megaterium ATCC 14581 
GenBank: AAA87602 
MTIKEMPQPKTFGELKNLPLLNTDKPVQALMKIADELGEIFKFEAPGRVTRYLSSQRLIKEACDESRFDKNLSQA
LKFVRDFAGDGLFTSWTHEKNWKKAHNILLPSFSQQAMKGYHAMMVDIAVQLVQKWERLNADEHIEVPEDMTRLT
LDTIGLCGFNYRFNSFYRDQPHPFITSMVRALDEAMNKLQRANPDDPAYDENKRQFQEDIKVMNDLVDKIIADRK
ASGEQSDDLLTHMLNGKDPETGEPLDDENIRYQIITFLIAGHETTSGLLSFALYFLVKNPHVLQKAAEEAARVLV  
DPVPSYKQVKQLKYVGMVLNEALRLWPTAPAFSLYAKEDTVLGGEYPLEKGDELMVLIPQLHRDKTIWGDDVEEF
RPERFENPSAIPQHAFKPFGNGQRACIGQQFALHEATLVLGMMLKHFDFEDHTNYELDIKETLTLKPEGFVVKAK
SKKIPLGGIPSPSTEQSAKKVRKKAENAHNTPLLVLYGSNMGTAEGTARDLADIAMSKGFAPQVATLDSHAGNLP
REGAVLIVTASYNGHPPDNAKQFVDWLDQASADEVKGVRYSVFGCGDKNWATTYQKVPAFIDETLAAKGAENIAD  
RGEADASDDFEGTYEEWREHMWSDVAAYFNLDIENSEDNKSTLSLQFVDSAADMPLAKMHGAFSTNVVASKELQQ
PGSARSTRHLEIELPKEASYQEGDHLGVIPRNYEGIVNRVTARFGLDASQQIRLEAEEEKLAHLPLAKTVSVEEL
LQYVELQDPVTRTQLRAMAAKTVCPPHKVELEALLEKQAYKEQVLAKRLTMLELLEKYPACEMKFSEFIALLPSI
RPRYYSISSSPRVDEKQASITVSVVSGEAWSGYGEYKGIASNYLAELQEGDTITCFISTPQSEFTLPKDPETPLI  
MVGPGTGVAPFRGFVQARKQLKEQGQSLGEAHLYFGCRSPHEDYLYQEELENAQSEGIITLHTAFSRMPNQPKTY
VQHVMEQDGKKLIELLDQGAHFYICGDGSQMAPAVEATLMKSYADVHQVSEADARLWLQQLEEKGRYAKDVWAG 
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VAO vanillyl alcohol oxidase from P. simplicissimum CBS 170.90 
GenBank: CAA75722 
MSKTQEFRPLTLPPKLSLSDFNEFIQDIIRIVGSENVEVISSKDQIVDGSYMKPTHTHDPHHVMDQDYFLASAIV
APRNVADVQSIVGLANKFSFPLWPISIGRNSGYGGAAPRVSGSVVLDMGKNMNRVLEVNVEGAYCVVEPGVTYHD
LHNYLEANNLRDKLWLDVPDLGGGSVLGNAVERGVGYTPYGDHWMMHSGMEVVLANGELLRTGMGALPDPKRPET
MGLKPEDQPWSKIAHLFPYGFGPYIDGLFSQSNMGIVTKIGIWLMPNPGGYQSYLITLPKDGDLKQAVDIIRPLR
LGMALQNVPTIRHILLDAAVLGDKRSYSSKTEPLSDEELDKIAKQLNLGRWNFYGALYGPEPIRRVLWETIKDAF
SAIPGVKFYFPEDTPENSVLRVRDKTMQGIPTYDELKWIDWLPNGAHLFFSPIAKVSGEDAMMQYAVTKKRCQEA
GLDFIGTFTVGMREMHHIVCIVFNKKDLIQKRKVQWLMRTLIDDCAANGWGEYRTHLAFMDQIMETYNWNNSSFL
RFNEVLKNAVDPNGIIAPGKSGVWPSQYSHVTWKL 
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7.1.3   Vectors 
 
Figure 7.1: Expression vectors (Novagen, Madison, WI, USA) used in this work. (A) pET-11a was 
used for expression of mobA. (B) pET-22b(+) was used for expression of cyp116B3, cyp102A1 and 
vao. (C) pET-24a(+) was used for expression of cyp116B3. (D) pET-28a(+) was used for expression of 
cyp102A1. 
 
 
 
 
 
 
A B 
C D 
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Table 7.1: List of expression vectors (Novagen, Madison, WI, USA) used in this work. 
Plasmid 
(Size) 
Sequence landmarks 
pET-11a T7 promoter 432-448 
(5677 bp) T7 transcription start 431 
 T7-Tag coding sequence 328-360 
 T7 terminator 213-259 
 lacI coding sequence 835-1914 
 pBR322 origin 3851 
 Amp
R
 
(bla) coding sequence 4612-5469 
pET-22b(+) T7 promoter 361-377 
(5493 bp) T7 transcription start 360 
 pelB coding sequence 224-289 
 Multiple cloning sites (NcoI – XhoI) 158-225 
 His-Tag coding sequence 140-157 
 T7 terminator 26-72 
 lacI coding sequence 764-1843 
 pBR322 origin 3277 
 Amp
R
 
(bla) coding sequence 4038-4895 
 f1 origin 5027-5482 
pET-24a(+) T7 promoter 311-327 
(5310 bp) T7 transcription start 310 
 T7-Tag coding sequence 207-239 
 Multiple cloning sites (BamHI – XhoI) 158-203 
 His-Tag coding sequence 140-157 
 T7 terminator 26-72 
 lacI coding sequence 714-1793 
 pBR322 origin 3227 
 Kan
R
 coding sequence 3936-4748 
 f1 origin 4844-5299 
pET-28a(+) T7 promoter 370-386 
(5369 bp) T7 transcription start 369 
 His-Tag coding sequence 270-287 
 T7-Tag coding sequence 207-239 
 Multiple cloning sites (BamHI – XhoI) 158-203 
 His-Tag coding sequence 140-157 
 T7 terminator 26-72 
 lacI coding sequence 773-1852 
 pBR322 origin 3286 
 Kan
R
 coding sequence 3995-4807 
 f1 origin 4903-5358 
Supplementary material 
142 
 
Table 7.2: Vector constructs used in this work. All plasmids are available at ITB. 
Name Gene insert / Application 
Point 
mutation 
ITB No. 
pET-11a - - pITB893 
pET-22b(+) - - pITB895 
pET-24a(+) - - pITB896 
pET-28a(+) - - pITB897 
pET-11a_MobA 
Codon-optimized m-hydroxybenzoate 
hydroxylase MobA from C. testosteroni 
GZ39 with C-terminal His6-tag 
- pITB899 
pET-11a_MobA_V257A 
Codon-optimized m-hydroxybenzoate 
hydroxylase MobA from C. testosteroni 
GZ39 with C-terminal His6-tag 
V257A pITB901 
pET-24a(+)_CYP116B3 
Codon-optimized cytochrome P450 
monooxygenase CYP116B3 from R. ruber 
DSM 44319 with N-terminal His6-tag 
- pITB903 
pET-24a(+)_CYP116B3_Var1 
Codon-optimized cytochrome P450 
monooxygenase CYP116B3 from R. ruber 
DSM 44319 with N-terminal MetGlySerSer 
(MGSS)-sequence prior to His6-tag 
- pITB905 
pET-24a(+)_CYP116B3_Var2 
Codon-optimized cytochrome P450 
monooxygenase CYP116B3 from R. ruber 
DSM 44319 with C-terminal His6-tag 
- pITB906 
pET-24a(+)_CYP116B3_Var3 
Codon-optimized cytochrome P450 
monooxygenase CYP116B3 from R. ruber 
DSM 44319 without His6-tag 
- pITB907 
pET-24a(+)_CYP116B3_Var1 
_A109F 
Focused mutant library of CYP116B3  
(N-terminal MGSS_His6-sequence) 
A109F pITB908 
pET-24a(+)_CYP116B3_Var1 
_A109I 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A109I pITB909 
pET-24a(+)_CYP116B3_Var1 
_A109L 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A109L pITB910 
pET-24a(+)_CYP116B3_Var1 
_A109V 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A109V pITB911 
pET-24a(+)_CYP116B3_Var1 
_V316A 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
V316A pITB912 
pET-24a(+)_CYP116B3_Var1 
_V316F 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
V316F pITB913 
pET-24a(+)_CYP116B3_Var1 
_V316I 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
V316I pITB914 
pET-24a(+)_CYP116B3_Var1 
_V316L 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
V316L pITB915 
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Table 7.2: Vector constructs used in this work (continued). 
Name Gene insert / Application 
Point 
mutation 
ITB No. 
pET-22b(+)_CYP116B3_Var1 
Codon-optimized cytochrome P450 
monooxygenase CYP116B3 from R. ruber 
DSM 44319 with N-terminal MetGlySerSer 
(MGSS)-sequence prior to His6-tag 
- pITB916 
pET-22b(+)_CYP116B3_Var1 
_A317F 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A317F pITB917 
pET-22b(+)_CYP116B3_Var1 
_A317I 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A317I pITB918 
pET-22b(+)_CYP116B3_Var1 
_A317L 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A317L pITB919 
pET-22b(+)_CYP116B3_Var1 
_A317V 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A317V pITB920 
pET-22b(+)_CYP116B3_Var1 
_A318F 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A318F pITB921 
pET-22b(+)_CYP116B3_Var1 
_A318I 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A318I pITB922 
pET-22b(+)_CYP116B3_Var1 
_A318L 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A318L pITB923 
pET-22b(+)_CYP116B3_Var1 
_A318V 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
A318V pITB924 
pET-22b(+)_CYP116B3_Var1 
_F420A 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
F420A pITB925 
pET-22b(+)_CYP116B3_Var1 
_F420I 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
F420I pITB926 
pET-22b(+)_CYP116B3_Var1 
_F420L 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
F420L pITB927 
pET-22b(+)_CYP116B3_Var1 
_F420V 
Focused mutant library of CYP116B3      
(N-terminal MGSS_His6-sequence) 
F420V pITB928 
pET-28a(+)_CYP102A1 
Cytochrome P450 monooxygenase 
CYP102A1 from B. megaterium ATCC 
14581 
- pITB930* 
pET-28a(+)_CYP102A1 
_A328F 
Focused mutant library of CYP102A1 A328F pITB931* 
pET-28a(+)_CYP102A1 
_A328I 
Focused mutant library of CYP102A1 A328I pITB932* 
pET-28a(+)_CYP102A1 
_A328L 
Focused mutant library of CYP102A1 A328L pITB933* 
pET-28a(+)_CYP102A1 
_A328V 
Focused mutant library of CYP102A1 A328V pITB934* 
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Table 7.2: Vector constructs used in this work (continued). 
Name Gene insert / Application 
Point 
mutation 
ITB No. 
pET-28a(+)_CYP102A1 
_F87A 
Focused mutant library of CYP102A1 F87A pITB935* 
pET-28a(+)_CYP102A1 
_F87A_A328F 
Focused mutant library of CYP102A1 
F87A, 
A328F 
pITB936* 
pET-28a(+)_CYP102A1 
_F87A_A328I 
Focused mutant library of CYP102A1 
F87A, 
A328I 
pITB937* 
pET-22b(+)_CYP102A1 
_F87A_A328L 
Focused mutant library of CYP102A1 
F87A, 
A328L 
pITB938* 
pET-28a(+)_CYP102A1 
_F87A_A328V 
Focused mutant library of CYP102A1 
F87A, 
A328V 
pITB939* 
pET-28a(+)_CYP102A1  
_F87I 
Focused mutant library of CYP102A1 F87I pITB940* 
pET-28a(+)_CYP102A1 
_F87I_A328F 
Focused mutant library of CYP102A1 
F87I, 
A328F 
pITB941* 
pET-28a(+)_CYP102A1 
_F87I_A328I 
Focused mutant library of CYP102A1 
F87I, 
A328I 
pITB942* 
pET-22b(+)_CYP102A1 
_F87I_A328L 
Focused mutant library of CYP102A1 
F87I, 
A328L 
pITB943* 
pET-28a(+)_CYP102A1 
_F87I_A328V 
Focused mutant library of CYP102A1 
F87I, 
A328V 
pITB944* 
pET-28a(+)_CYP102A1  
_F87L 
Focused mutant library of CYP102A1 F87L pITB945* 
pET-28a(+)_CYP102A1 
_F87L_A328F 
Focused mutant library of CYP102A1 
F87L, 
A328F 
pITB946* 
pET-28a(+)_CYP102A1 
_F87L_A328I 
Focused mutant library of CYP102A1 
F87L, 
A328I 
pITB947* 
pET-22b(+)_CYP102A1 
_F87L_A328L 
Focused mutant library of CYP102A1 
F87L, 
A328L 
pITB948* 
pET-28a(+)_CYP102A1 
_F87L_A328V 
Focused mutant library of CYP102A1 
F87L, 
A328V 
pITB949* 
pET-28a(+)_CYP102A1  
_F87V 
Focused mutant library of CYP102A1 F87V pITB950* 
pET-28a(+)_CYP102A1 
_F87V_A328F 
Focused mutant library of CYP102A1 
F87V, 
A328F 
pITB951* 
pET-28a(+)_CYP102A1 
_F87V_A328I 
Focused mutant library of CYP102A1 
F87V, 
A328I 
pITB952* 
pET-22b(+)_CYP102A1 
_F87V_A328L 
Focused mutant library of CYP102A1 
F87V, 
A328L 
pITB953* 
pET-22b(+)_CYP102A1 
_F87V_A328V 
Focused mutant library of CYP102A1 
F87V, 
A328V 
pITB954* 
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Table 7.2: Vector constructs used in this work (continued). 
Name Gene insert / Application 
Point 
mutation 
ITB No. 
pET-22b(+)_CYP102A1 
_F87V_A328L_L437A 
Triple mutant of CYP102A1 
F87V, 
A328L, 
L437A 
pITB955* 
pET-22b(+)_CYP102A1 
_F87V_A328L_L437F 
Triple mutant of CYP102A1 
F87V, 
A328L, 
L437F 
pITB956* 
pET-22b(+)_CYP102A1 
_F87V_A328L_L437I 
Triple mutant of CYP102A1 
F87V, 
A328L, 
L437I 
pITB957* 
pET-22b(+)_CYP102A1 
_F87V_A328L_L437V 
Triple mutant of CYP102A1 
F87V, 
A328L, 
L437V 
pITB958* 
pET-28a(+)_CYP102A1 
_R47L_Y51F 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F 
pITB959 
pET-28a(+)_CYP102A1 
_R47L_Y51F_F87V 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F, 
F87V 
pITB960 
pET-28a(+)_CYP102A1 
_R47L_Y51F_A328L 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F, 
A328L 
pITB961 
pET-28a(+)_CYP102A1 
_R47L_Y51F_F87V_A328F 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F, 
F87V, 
A328F 
pITB962* 
pET-28a(+)_CYP102A1 
_R47L_Y51F_F87V_A328I 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F, 
F87V, 
A328I 
pITB963* 
pET-28a(+)_CYP102A1 
_R47L_Y51F_F87V_A328L 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F, 
F87V, 
A328L 
pITB964* 
pET-28a(+)_CYP102A1 
_R47L_Y51F_F87V_A328V 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F, 
F87V, 
A328V 
pITB965* 
pET-22b(+)_CYP102A1 
_R47L_Y51F_F87V_A328L 
_L437I 
Substrate channel mutation variant of 
CYP102A1 
R47L, 
Y51F, 
F87V, 
A328L, 
L437I 
pITB966 
pMK-RQ_VAO 
Codon-optimized vanillyl alcohol oxidase 
VAO from P. simplicissimum CBS 170.90 in 
GeneArt cloning vector 
- pITB976 
pET-22b(+)_VAO 
Codon-optimized vanillyl alcohol oxidase 
VAO from P. simplicissimum CBS 170.90 
- pITB977 
pET-22b(+)_VAO_F454Y 
Codon-optimized vanillyl alcohol oxidase 
VAO from P. simplicissimum CBS 170.90 
F454Y pITB980 
pET-22b(+)_VAO_T505S 
Codon-optimized vanillyl alcohol oxidase 
VAO from P. simplicissimum CBS 170.90 
T505S pITB983 
* Provided by Dr. Alexander Seifert (ITB, University of Stuttgart, Stuttgart, Germany). 
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7.1.4   Primers 
 
Oligonucleotides were obtained from Metabion (Martinsried, Germany) in salt-free 
form. The lyophilized oligonucleotides were resuspended in TE buffer pH 8.0 and 
diluted 1:10 with deionized water prior to use. 
Table 7.3: Primers used in this work for PCR amplification of His-tag variants of CYP116B3. 
His-tag cloning based on pET-24a(+)_CYP116B3 
Application Primer Sequence (5’  3’) 
Cloning of 
CYP116B3  
_Var1 
F C CGC catatg GGC AGC AGC CAT CAT CAT CAT CAC CAT AGC 
R GGT gaattc TTA CAG ACG CAG GGT CAG ACG ATC ACC ACA TGC 
Cloning of 
CYP116B3  
_Var2 
F C CGC catatg AGC GCA AGC GTT CCG GCA AGC GC 
R 
GGT gaattc TTA ATG GTG ATG ATG ATG ATG  CAG ACG CAG GGT 
CAG ACG ATC 
Cloning of 
CYP116B3  
_Var3 
F C CGC catatg AGC GCA AGC GTT CCG GCA AGC GC 
R GGT gaattc TTA CAG ACG CAG GGT CAG ACG ATC ACC ACA TGC 
Underlined, His-tag; italic, MGSS-sequence; lower case, restriction sites (catatg, NdeI; gaattc, EcoRI); F, forward; R, reverse. 
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Table 7.4: Primers used in this work for site-directed mutagenesis. 
Site-directed mutagenesis of MobA from C. testosteroni GZ39 
Mutation Sequence (5’  3’) 
V257A 
F G AGC GAA CAG GGT AAT GCA CTG ATT ATT CCG CGT GAA GG 
R CC TTC ACG CGG AAT AAT CAG TGC ATT ACC CTG TTC GCT C 
Site-directed mutagenesis of CYP116B3 from R. ruber DSM 44319 
Mutation Sequence (5’  3’) 
A109F 
F CGT TAT GAT TAT GCA ATG TTT CGT ACC CTG GTG AAT GAA G 
R C TTC ATT CAC CAG GGT ACG AAA CAT TGC ATA ATC ATA ACG 
A109I 
F CGT TAT GAT TAT GCA ATG ATT CGT ACC CTG GTG AAT GAA G 
R C TTC ATT CAC CAG GGT ACG AAT CAT TGC ATA ATC ATA ACG 
A109L 
F CGT TAT GAT TAT GCA ATG CTG CGT ACC CTG GTG AAT GAA G 
R C TTC ATT CAC CAG GGT ACG CAG CAT TGC ATA ATC ATA ACG 
A109V 
F CGT TAT GAT TAT GCA ATG GTT CGT ACC CTG GTG AAT GAA G 
R C TTC ATT CAC CAG GGT ACG AAC CAT TGC ATA ATC ATA ACG 
V316A 
F CGT CAT AGC GGT AGC GCA GCA GCA TGG CGT CGT G 
R C ACG ACG CCA TGC TGC TGC GCT ACC GCT ATG ACG 
V316F 
F CGT CAT AGC GGT AGC TTT GCA GCA TGG CGT CGT G 
R C ACG ACG CCA TGC TGC AAA GCT ACC GCT ATG ACG 
V316I 
F CGT CAT AGC GGT AGC ATT GCA GCA TGG CGT CGT G 
R C ACG ACG CCA TGC TGC AAT GCT ACC GCT ATG ACG 
V316L 
F CGT CAT AGC GGT AGC CTG GCA GCA TGG CGT CGT G 
R C ACG ACG CCA TGC TGC CAG GCT ACC GCT ATG ACG 
A317F 
F CAT AGC GGT AGC GTT TTT GCA TGG CGT CGT GTT G 
R C AAC ACG ACG CCA TGC AAA AAC GCT ACC GCT ATG 
A317I 
F CAT AGC GGT AGC GTT ATT GCA TGG CGT CGT GTT G 
R C AAC ACG ACG CCA TGC AAT AAC GCT ACC GCT ATG 
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Table 7.4: Primers used in this work for site-directed mutagenesis (continued). 
Site-directed mutagenesis of CYP116B3 from R. ruber DSM 44319 
Mutation Sequence (5’  3’) 
A317L 
F CAT AGC GGT AGC GTT CTG GCA TGG CGT CGT GTT G 
R C AAC ACG ACG CCA TGC CAG AAC GCT ACC GCT ATG 
A317V 
F CAT AGC GGT AGC GTT GTT GCA TGG CGT CGT GTT G 
R C AAC ACG ACG CCA TGC AAC AAC GCT ACC GCT ATG 
A318F 
F CAT AGC GGT AGC GTT GCA TTT TGG CGT CGT GTT GCA ACC 
R GGT TGC AAC ACG ACG CCA AAA TGC AAC GCT ACC GCT ATG 
A318I 
F CAT AGC GGT AGC GTT GCA ATT TGG CGT CGT GTT GCA ACC 
R GGT TGC AAC ACG ACG CCA AAT TGC AAC GCT ACC GCT ATG 
A318L 
F CAT AGC GGT AGC GTT GCA CTG TGG CGT CGT GTT GCA ACC 
R GGT TGC AAC ACG ACG CCA CAG TGC AAC GCT ACC GCT ATG 
A318V 
F CAT AGC GGT AGC GTT GCA GTT TGG CGT CGT GTT GCA ACC 
R GGT TGC AAC ACG ACG CCA AAC TGC AAC GCT ACC GCT ATG 
F420A 
F CTG CCG AAT ACC AGC GCA CGT GGT CCG GAT CAT G 
R C ATG ATC CGG ACC ACG TGC GCT GGT ATT CGG CAG 
F420I 
F CTG CCG AAT ACC AGC ATT CGT GGT CCG GAT CAT G 
R C ATG ATC CGG ACC ACG AAT GCT GGT ATT CGG CAG 
F420L 
F CTG CCG AAT ACC AGC CTG CGT GGT CCG GAT CAT G 
R C ATG ATC CGG ACC ACG CAG GCT GGT ATT CGG CAG 
F420V 
F CTG CCG AAT ACC AGC GTT CGT GGT CCG GAT CAT G 
R C ATG ATC CGG ACC ACG AAC GCT GGT ATT CGG CAG 
Site-directed mutagenesis of CYP102A1 from B. megaterium ATCC 14581 
Mutation Sequence (5’  3’) 
R47L 
F C GAG GCG CCT GGT CTG GTA ACG CGC 
R GCG CGT TAC CAG ACC AGG CGC CTC G 
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Table 7.4: Primers used in this work for site-directed mutagenesis (continued). 
Site-directed mutagenesis of CYP102A1 from B. megaterium ATCC 14581 
Mutation Sequence (5’  3’) 
Y51F 
F CT GGT CGT GTA ACG CGC TTC TTA TCA AGT CAG 
R CTG ACT TGA TAA GAA GCG CGT TAC ACG ACC AG     
F87V 
F GCA GGA GAC GGG TTA GTA ACA AGC TGG ACG CAT G 
R C ATG CGT CCA GCT TGT TAC TAA CCC GTC TCC TGC 
A328L 
F CGC TTA TGG CCA ACT CTG CCT GCG TTT TC 
R GA AAA CGC AGG CAG AGT TGG CCA TAA GCG 
Site-directed mutagenesis of VAO from P. simplicissimum CBS 170.90 
Mutation Sequence (5’  3’) 
F454Y 
F GAA GCA GGT CTG GAT TAT ATT GGC ACC TTT ACC 
R GGT AAA GGT GCC AAT ATA ATC CAG ACC TGC TTC 
T505S 
F GG GGT GAA TAT CGT AGC CAT CTG GCA TTT ATG 
R CAT AAA TGC CAG ATG GCT ACG ATA TTC ACC CC 
Bold, codon of exchanged amino acid; F, forward; R, reverse. 
 
7.1.5   Strains 
 
E. coli strain DH5α (formerly Invitrogen now Life Technologies, Darmstadt, Germany) 
was employed for cloning and plasmid amplification. As host for recombinant gene 
expression the E. coli strain BL21(DE3) (Novagen, Madison, WI, USA) was used. 
 
Table 7.5: Bacterial strains. 
Strain Genotype description 
Manufacturer 
(Country) 
Escherichia coli 
DH5α 
F
-
 supE44 ΔlacU169 (φ80lacZΔM15) hsdR17 
recA1 endA1 gyrA96 thi-1relA1 
Invitrogen (now Life 
Technologies, 
Darmstadt, Germany)  
Escherichia coli 
BL21(DE3) 
F
-
 ompT hsdSB(rB
-
mB
-
) gal dcm (DE3) 
 
Novagen (Madison, WI, 
USA) 
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7.2   Supplementary tables 
 
7.2.1   Media, buffers and solutions 
 
Table 7.6: Culture media. 
Medium Component Amount 
LB broth 
 
 
 
 
LB agar 
Yeast extract 
NaCl 
Tryptone 
dH2O 
pH 7 
Agar 
5 g 
5 g 
10 g 
to 1 l 
 
15 g 
SOC 
 
 
 
 
 
Yeast extract 
NaCl 
Tryptone 
250 mM KCl 
Glucose 
dH2O 
5 g 
0.5 g 
20 g 
10 ml 
20 mM 
to 1 l 
 
Culture media were autoclaved at 121°C for 20 min. For the preparation of media 
supplemented with antibiotics, stock solutions of ampicillin or kanamycin were 
prepared, sterilized by filtration using a 0.2 µm sterile filter and added to the medium 
after autoclaving and cooling to ca. 45°C to yield a final concentration of 100 µg/ml or 
30 µg/ml, respectively. 
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Table 7.7: Buffers for preparation of competent cells. 
Buffer Component Amount 
Tfb I 
 
 
 
 
 
 
Potassium acetate 
RbCl 
CaCl2 
MnCl2 · 4 H2O 
Glycerol (87%) 
adjust to pH 5.8 with acetic acid 
dH2O 
0.59 g 
2.42 g 
0.29 g 
2.00 g 
30 ml 
 
to 200 ml 
Tfb II 
 
 
 
 
 
MOPS 
CaCl2 
RbCl 
Glycerol (87%) 
adjust to pH 6.5 with NaOH 
dH2O 
0.21 g 
1.10 g 
0.12 g 
15 ml 
 
to 100 ml 
 
Tfb I and Tfb II buffers were sterilized by filtration using a 0.2 µm sterile filter. 
 
Table 7.8: Buffers for DNA reconstitution. 
Buffer Component Amount 
TE, pH 8.0 
 
 
1 M Tris-HCl, pH 8.0 
EDTA 
dH2O 
1 ml 
37.22 mg 
to 100 ml 
 
Table 7.9: Buffers and solutions for agarose gel electrophoresis. 
Buffer Component Amount 
1% Agarose gel  
solution 
Agarose  
1x TAE  
5 g  
to 500 ml  
TAE buffer (50x) 
 
 
 
Tris  
Glacial acetic acid  
0.5 M EDTA (pH 8.0)  
dH2O  
242 g  
57 ml  
100 ml  
to 1 l  
DNA sample loading 
buffer  
 
 
 
Urea  
EDTA  
Glycerol (87%)  
Bromophenol blue  
dH2O  
12.01 g  
0.21 g  
25 ml  
50 mg  
to 1 l  
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Table 7.10: Buffers and solutions for SDS-PAGE. 
Buffer Component Amount 
SDS sample loading 
buffer (2x) 
 
 
 
 
 
MgCl2 
SDS  
Glycerol (87%) 
Bromophenol blue  
2-Mercaptoethanol  
1 M Tris-HCl (adjust to pH 6.8 with HCl)  
dH2O  
190 mg  
0.8 g  
2 ml  
2 mg  
1 ml  
2 ml  
to 20 ml  
4x Lower Tris  
 
 
 
Tris  
SDS  
adjust to pH 8.8 with HCl  
dH2O  
36.34 g 
0.8 g 
 
to 200 ml 
4x Upper Tris  
 
 
 
Tris  
SDS  
adjust to pH=6.8 with HCl  
dH2O  
12.11 g 
0.8 g 
 
to 200 ml 
10% APS  
 
APS  
dH2O  
100 mg 
to 1 m 
Resolving gel  
(12.5% Acrylamide)  
 
 
 
Acrylamide (30%)  
4x Lower Tris  
dH2O  
10% APS  
TEMED  
3.33 ml 
2.00 ml 
2.67 ml 
40 μl 
4 μl 
Stacking gel  
(4% Acrylamide) 
 
 
 
Acrylamide (30%)  
4x Upper Tris  
dH2O  
10% APS  
TEMED 
0.52 ml 
1.00 ml 
2.47 ml 
40 μl 
4 μl 
Running buffer  
 
 
 
Tris  
SDS  
Glycine  
dH2O  
30 g 
10 g 
144 g 
to 2 l 
Staining solution  
 
 
 
Coomassie
®
 
Brilliant Blue  
Methanol  
Glacial acetic acid  
dH2O  
500 mg 
150 ml 
50 ml 
to 500 ml 
Destaining solution  
 
 
Methanol  
Glacial acetic acid  
dH2O  
300 ml 
100 ml 
to 1000 ml  
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Table 7.11: Buffers for IMAC purification. 
Medium Component Amount 
1 M Tris-HCl, pH 7.5 
 
 
Tris 
dH2O 
adjust to pH 7.5 with 37% HCl 
121.14 g 
to 1 l 
 
50 mM Tris-HCl, pH 7.5 
 
1 M Tris-HCl, pH 7.5 
dH2O 
25 ml 
to 500 ml 
Equilibration buffer  
 50 mM Tris-HCl, pH 7.5 
 500 mM NaCl 
 5% Glycerol 
 0.1 mM PMSF 
1 M Tris-HCl, pH 7.5 
NaCl 
Glycerol (87%) 
100 mM PMSF 
dH2O 
50 ml 
29.22 g   
57.5 ml 
1 ml 
to 1 l 
Elution buffers 
 
Imidazol 
Buffer B 
20-200 mM 
to 100 ml 
 
Table 7.12: Buffer for dialysis. 
Medium Component Amount 
Dialysis buffer 
 50 mM Tris-HCl, pH 7.5 
 5% Glycerol 
 0.1 mM PMSF 
1 M Tris-HCl, pH 7.5 
Glycerol (87%) 
100 mM PMSF 
dH2O 
75 ml 
86 ml 
1.5 ml 
to 1.5 l 
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7.2.2   In vitro biotransformations 
 
Table 7.13: Primary screening for the conversion of 3-methylanisole by all members of the CYP102A1 
minimal mutant library. 
Amino acid position 
87 
A F I L V 
328 
A ++ + + + +++ 
F ++ ++ ++ + +++ 
I ++ ++ ++ ++ +++ 
L + +++ ++ - +++ 
V + ++ ++ - +++ 
a
CYP102A1 wild type          -, no conversion          +, conversion < 5%          ++, conversion < 25%          +++, conversion > 25% 
Samples were analyzed by HPLC. Negative controls showed no conversion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 a
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7.3   Supplementary figures 
 
7.3.1   Protein expression 
 
 
Figure 7.2: SDS-PAGE analysis of the MobA expression study samples. Expression was investigated 
after induction with 0.1, 0.5 or 1 mM IPTG and incubation at 20, 25 and 30°C with shaking at 180 rpm. 
M, marker; pI, prior to induction; numbers 1 to 96 indicate the total expression time in hours of 
samples taken after induction. 
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Figure 7.3: SDS-PAGE analysis of the CYP116B3 expression study samples. Expression was 
investigated after induction with 0.1, 0.5 or 1 mM IPTG and incubation at 20, 25 and 30°C with shaking 
at 180 rpm. M, marker; pI, prior to induction; numbers 1 to 48 indicate the total expression time in 
hours of samples taken after induction. 
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Figure 7.4: SDS-PAGE analysis of the expression of the CYP116B3 focused mutant library variants 
(A109F/I/L/V, V316A/F/I/L, A317F/I/L/V, A318F/I/L/V, F420A/I/L/V). Expression was investigated after 
induction with 0.1 mM IPTG and incubation at 20°C with shaking at 140 rpm for 18 h. Whole cell 
samples (pI and aI) were adjusted to an OD600 value of 0.25 and an equal volume of 7.5 µl was loaded 
onto the gel. For soluble protein fractions, 7.5 µg of protein was loaded in the respective lanes. 
 
7.3.2   Molecular dynamics simulations 
 
  
Figure 7.5: Distance of 4-methylguaiacol carbon atoms from the activated oxygen of the CYP102A1 
heme in a 100 ns MD run. The molecule approaches the heme oxygen to a distance <4 Å (C7) where 
it stays stable for 90 ns. Lines show a moving average of 20 data points. 
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Figure 7.6: Distance between all possible hydrogen bond donors and acceptors of 4-methylguaiacol 
and the side chain of Y51 (green, red and magenta lines) and R47 (all remaining lines) in 4 out of 15 
MD simulations. A hydrogen bond is considered present at a hydrogen bond donor to acceptor 
distance ≤3.5 Å. Lines show a moving average of 20 data points. 
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7.3.3   GC-MS analysis 
 
 
 
 
Figure 7.7: Chromatogram (A) and fragmentation pattern (B) of GC-MS analysis of the in vivo 
biotransformation sample after 12 h conversion time. (C) Fragmentation pattern of the GC-MS analysis 
of a vanillin reference (0.05 mM vanillin). 
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